For participants who receive therapeutic anticoagulation: stable anticoagulant regimenXx_NEWLINE_xXParticipants must have histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; participants with uncontrolled Kaposi sarcoma are permitted (KS must be increasing despite HAART and HIV suppression for greater than or equal to 2 months, or stable KS despite HAART for greater than or equal to 3 months)\r\n* For participants in the 24 participant solid tumor cohort, only those histologies not known to respond to single agent nivolumab (such as pancreas, prostate, and microsatellite stable [MSS] colorectal cancer) will be excluded\r\n* For participants in the relapsed refractory HIV-cHL expansion cohort, participants must have histologically confirmed, relapsed/refractory (defined as relapsed/refractory to one or greater lines of therapy) HIV-associated classical Hodgkin lymphomaXx_NEWLINE_xXPARTICIPANTS ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Creatinine: < 1.5 x upper normal limit (UNL) or CrCl > 50ml/min, within 2 weeks prior to enrollmentXx_NEWLINE_xXParticipants must be purified protein derivative (PPD) negative; alternatively, the QuantiFERON-TB Gold In-Tube (QFT-GIT) assay can be used; an individual is considered positive for M. tuberculosis infection if the IFN-gamma response to tuberculosis (TB) antigens is above the test cut-off (after subtracting the background IFN-gamma response in the negative control); the result must be obtained within 12 weeks prior to enrollment; PPD positive (or Quantiferon assay positive) participants are permitted if prophylaxis has been completed prior to enrollmentXx_NEWLINE_xXParticipants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications when clinically indicated, and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 12 weeks following enrollmentXx_NEWLINE_xXParticipants with clinical or radiographic evidence of pancreatitis are excludedXx_NEWLINE_xXParticipant has >= grade 2 diarrhea (participants with grade 1 diarrhea are eligible provided stool for ova/parasites and stool cryptosporidium studies are negative)Xx_NEWLINE_xXCriteria for Solid Tumor Expansion and Lymphoma Cohorts:\r\n* Inclusion and exclusion criteria for this cohort are the same as above, with the following rule for CD4 count based on tolerability in Phase I; if, participants with lymphocyte T CD4 count between 100-200/mm^3 (Stratum 2) are shown to tolerate treatment in the Phase I dose de-escalation portion at the same dose level as those with CD4 counts > 200/mm^3 (Stratum 1), participants in the expansion cohort with CD4 counts >= 100/mm^3 are permitted; otherwise, the expansion is open to all solid tumor patients except those whose tumors are known not to respond to nivolumab (pancreas, prostate and MSS colon cancer); for the relapsed refractory HIV-cHL cohort, participants with CD4 count >= 100/mm^3 are permittedXx_NEWLINE_xXParticipants must have previously untreated HIV-classical HL (cHL), with the exception of up to 14 consecutive days of steroids, emergency radiation, or 1 prior cycle of cyclophosphamide to reduce tumor burden and improve hyperbilirubinemia in the setting of lymphoma related liver involvementXx_NEWLINE_xXFemale participants must have a negative pregnancy test within 1 week of enrollment and all participants must agree to use two reliable methods of contraception simultaneously if conception is possible during the study and for 6 months after stopping treatment; should a woman subject become pregnant or suspect she is pregnant while the subject is participating in this study, she should inform her treating physician immediately; the participant will then be removed from protocol therapy; participants who father a child while participating in the study will be permitted to continue with the protocol; the participant, however, is required to notify the investigator if he fathers a childXx_NEWLINE_xXParticipants are required to be on antiretroviral regimens that are in accordance with the current International Acquired Immune Deficiency Syndrome (AIDS) Society guidelines concurrently with chemotherapy; the specific agents are at the discretion of the investigator and the use of investigational agents currently available on an expanded access basis is allowed; use of experimental antiretroviral agents or those containing zidovudine (including Combivir and Trizivir) or ritonavir (includes Norvir or Kaletra), cobicistat, didanosine (Videx or Videx EC), or similar potent cytochrome P450 (CYP)3 inhibitors are prohibited; in order to be eligible, participants taking zidovudine or ritonavir, or cobicistat, didanosine, or other CYP3 inhibitors must change to a different regimen 7 days prior to therapy initiation; changes to HAART therapy during the study may be made if medically necessary (toxicity, failure of regimen, etc.); participants must be on HAART at least 7 days prior to therapyXx_NEWLINE_xXParticipants with evidence of relapsed primary disease, or participants who have been treated for relapse after the allo-HSCT was performed.Xx_NEWLINE_xXRadical or partial nephrectomy with lymphadenectomy in select participantsXx_NEWLINE_xXParticipants may not have had any prior history of hypertensive crisis or hypertensive encephalopathyXx_NEWLINE_xXParticipants may not have current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months prior to starting study drugsXx_NEWLINE_xXParticipants may not have a dependency on IV hydration or total parenteral nutrition (TPN)Xx_NEWLINE_xXEligible participants will be asked to sign a separate consent form for this optional study at the time they are enrolling on SJMB12; participants will then be randomly assigned to either the standard-of-care control group or the exercise intervention groupXx_NEWLINE_xXEligible participants will be asked to sign a separate consent form for this optional study; participants will then be randomly assigned to either the standard-of-care control group or the Cogmed computerized intervention groupXx_NEWLINE_xXParticipants must be Stratum S (SHH)Xx_NEWLINE_xXParticipants who are less than 10 years of age at start of maintenance chemotherapyXx_NEWLINE_xXParticipants may not have received any prior treatment with therapies targeting PDL1, PD1 or CTLA4Xx_NEWLINE_xXOne prior line of therapy which must include sorafenib or participant must have progressed or been intolerant to sorafenib for participants not eligible for transarterial chemoembolization. Participants who had sorafenib for locally advanced disease or are intolerant to sorafenib are eligible. Participants may have had clinical progression only following sorafenib or local therapy.Xx_NEWLINE_xXFor hepatitis B participants, must be on a nucleoside analog reverse transcriptase inhibitor (lamivudine, telbivudine, adefovir, tenofovir, or entecavir).Xx_NEWLINE_xXParticipants who have had prior anti-EGF or anti-HER2 therapy or cancer-directed chemotherapyXx_NEWLINE_xXParticipants must have a lumbar puncture with negative cerebral spinal fluid cytology within 4 weeks prior to enrollmentXx_NEWLINE_xXParticipants must have a CD4 count performed within 30 days of enrollmentXx_NEWLINE_xXParticipants with active infection(s) for which they are receiving drug treatment unless the clinical status is judged to be stable and survival is estimated to be at least 6 weeksXx_NEWLINE_xXParticipants with known metastasesXx_NEWLINE_xXPARTICIPANTS FROM ST. JUDE AND COLLABORATING SITES PARTICIPATING IN THERAPEUTIC AND BIOLOGICAL OBJECTIVES:Xx_NEWLINE_xXAll participants must have screening prior to enrollment; participants whose results indicate that they are carrier of hepatitis B can still be treated per group B and C but will NOT receive rituximabXx_NEWLINE_xXPARTICIPANTS FROM COLLABORATING SITES PARTICIPATING IN BIOLOGICAL OBJECTIVES ONLY: Participant must be previously untreated, (no more than 72 hours of steroids, one intrathecal chemotherapy treatment, and/or emergency radiation)Xx_NEWLINE_xXPARTICIPANTS FROM COLLABORATING SITES PARTICIPATING IN THERAPEUTIC AND BIOLOGICAL OBJECTIVES:Xx_NEWLINE_xXPARTICIPANTS FROM COLLABORATING SITES PARTICIPATING IN BIOLOGICAL OBJECTIVES ONLY:Xx_NEWLINE_xXParticipants with a first diagnosis of HCC who have undergone a curative resection or ablationXx_NEWLINE_xXParticipants are eligible to enroll if they have non-viral related-HCC, or if they have HBV-HCC, or HCV-HCCXx_NEWLINE_xXParticipants previously receiving any prior therapy for HCC, including loco-regional therapiesXx_NEWLINE_xXFor participants in Part 2:Xx_NEWLINE_xXParticipants cannot have received more than two prior regimens Specifically for participants in Arm B:Xx_NEWLINE_xXTreatment-naive participants with AML who are >/=75 years oldXx_NEWLINE_xXTreatment-naive participants unfit for induction chemotherapy for AML due to comorbidities who are >/=65 years oldXx_NEWLINE_xXCohort A Dose Expansion (Ribociclib + PDR001): Participants with accessible tumor lesion(s) must be willing to undergo two research biopsies: one prior to treatment initiation and one after 7 weeks of protocol therapy; participants who undergo an attempted on-treatment research biopsy and in whom inadequate tissue is obtained are still eligible to receive protocol therapy; they will not be required to undergo a repeat research biopsy attemptXx_NEWLINE_xXExpansion Cohort B (Ribociclib + PDR001 + Fulvestrant): Participants with accessible tumor lesion(s) must be willing to undergo two research biopsies: one prior to treatment initiation and one after 7 weeks of protocol therapy; participants who undergo an attempted on-treatment research biopsy and in whom inadequate tissue is obtained are still eligible to receive protocol therapy; they will not be required to undergo a repeat research biopsy attemptXx_NEWLINE_xXParticipants cannot receive treatment with any other investigational agents during protocol therapyXx_NEWLINE_xXParticipants with brainstem lesionsXx_NEWLINE_xXParticipants who have a diagnosis of an immunodeficiencyXx_NEWLINE_xXPrior treatment with appropriate tyrosine kinase inhibitors (TKIs) as follows:\r\n* ALK-positive NSCLC (Cohorts B and D): Participants must have progressed on or after 1 or more next-generation ALK-TKI(s)\r\n* EGFR-mutant NSCLC (Cohorts A and C): Participants must have progressed on or after 1 or more third-generation, T790M mutant-selective EGFR-TKI(s)Xx_NEWLINE_xXParticipants must have PD-L1 IHC testing with results performed by a central laboratory during the screening periodXx_NEWLINE_xXParticipants eligible for taxane monotherapyXx_NEWLINE_xXParticipants are permitted to have any number of prior therapies prior to enrollmentXx_NEWLINE_xXParticipants may not be receiving any other study agents concurrently with the study drugsXx_NEWLINE_xXParticipants in all monotherapy arms must have an advanced solid tumor that has progressed on standard therapies known to provide clinical benefit or the participants are intolerant to such therapies.Xx_NEWLINE_xXParticipants in all combination therapy arms must have recurrent or metastatic NSCLC and previously received platinum-based therapy and progressed either during or after anti-programmed death ligand 1 (PDL1)-based therapy. In addition, participants must have received only one prior immunotherapy.Xx_NEWLINE_xXParticipants in all combination therapy arms must not have a history of exposure to an immunotherapy experiencing an immune-mediated adverse event that required permanent discontinuation of the immunotherapy.Xx_NEWLINE_xXFemale participants must not be pregnant, breastfeeding or considering becoming pregnant during the study or for at least 5 or 6 months (for monotherapy and combination therapy participants, respectively) after the last dose of study drug.Xx_NEWLINE_xXMale participants must not be considering fathering a child or donating sperm during the study or for at least 3 or 6 months (for monotherapy and combination therapy participants, respectively) after the last dose of study drug.Xx_NEWLINE_xXParticipants must have an advanced solid tumor that has progressed on standard therapies known to provide clinical benefit or the participants are intolerant to such therapies.Xx_NEWLINE_xXMale participants who are considering fathering a child or donating sperm during the study or for at least 3 or 5 months (for monotherapy and combination therapy participants, respectively) after the last dose of study drug.Xx_NEWLINE_xXParticipants who are receiving other concurrent chemotherapies or immunotherapies for their cancer (except for patients who will receive letrozole, anastrozole, exemestane, tamoxifen, fulvestrant, trastuzumab, bisphosphonates, or ovarian suppression therapy)Xx_NEWLINE_xXParticipants who are receiving or will receive other concurrent chemotherapies or immunotherapies for their cancer (except for patients who will receive letrozole, anastrozole, exemestane, tamoxifen, fulvestrant, trastuzumab, bisphosphonates, denosumab or ovarian suppression therapy)Xx_NEWLINE_xXParticipants who have demonstrated intolerance to 125 mg of palbociclib are ineligible for the phase I portionXx_NEWLINE_xXParticipants with bilateral diffuse lymphangitic carcinomatosisXx_NEWLINE_xXParticipants with CD4 counts > 50/microL are eligible for this study if their viral load is < 50 copies/mL by reverse transcription polymerase chain reaction (RT-PCR) since majority of the participants have received aggressive chemotherapy that can potentially decrease the CD4 counts despite the ART therapy; timeline: within 3 weeks prior to start of trialXx_NEWLINE_xXParticipants with hepatitis B should be on appropriate anti-viral therapy at the time of the transplant, and their viral load should be negative; timeline: within 3 weeks prior to enrollmentXx_NEWLINE_xXParticipants with unexplained anemia, and/or thrombocytopeniaXx_NEWLINE_xXParticipants with clear evidence of myeloproliferative disorders, or myelodysplastic disorders in the marrowXx_NEWLINE_xXParticipants with persistently low CD4 counts less than 200 and a history of any acquired immune deficiency syndrome (AIDS)-defining infection in the last 6 months before screening are excluded from the studyXx_NEWLINE_xXFor Part B dose confirmation: All participants must have histological evidence of advanced or metastatic colon cancer or soft tissue sarcoma. Colon cancer participants must have prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway.Xx_NEWLINE_xXFor Part C dose confirmation: All participants must have histological evidence of advanced or metastatic breast cancer and prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway.Xx_NEWLINE_xXFor Part D dose confirmation: All participants must have histological evidence of cholangiocarcinoma and prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway. Participants must not have received >1 line of prior systemic therapy for metastatic or resectable disease (that is, participants may have received adjuvant gemcitabine and then later gemcitabine/cisplatin for recurrent metastatic disease).Xx_NEWLINE_xXInclusion Criteria:\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Histologically or cytologically confirmed, Stage IV non-squamous NSCLC. Participants\n             with tumors of mixed non-small cell histology (i.e., squamous and non-squamous) are\n             eligible if the major histological component appears to be non-squamous\n\n          -  No prior treatment for Stage IV non-squamous NSCLC. Participants with a sensitizing\n             mutation in the epidermal growth factor receptor (EGFR) gene or with an anaplastic\n             lymphoma kinase (ALK) fusion oncogene are excluded. Participants with unknown EGFR and\n             ALK status require test results at screening from a local or central laboratory\n\n          -  Participants who have received prior neo-adjuvant, radiotherapy, adjuvant\n             chemotherapy, or chemoradiotherapy with curative intent for non-metastatic disease\n             must have experienced a treatment-free interval of at least 6 months from\n             randomization since the last dose of chemotherapy and/or radiotherapy\n\n          -  Participants should submit a pre-treatment tumor tissue sample if available before or\n             within 4 weeks after enrollment. If tumor tissue is not available, participants are\n             still eligible\n\n          -  For participants enrolled in the extended China enrollment phase: current resident of\n             mainland China, Hong Kong, or Taiwan and of Chinese ancestry\n\n          -  Measurable disease, as defined by RECIST v1.1\n\n          -  Adequate hematologic and end organ function\n\n          -  For women of childbearing potential: agreement to remain abstinent or use\n             contraceptive methods that result in a failure rate of less than (<) 1 percent (%) per\n             year during the treatment period and for at least 5 months after the last dose of\n             atezolizumab or 6 months after the last dose of cisplatin\n\n          -  For men: agreement to remain abstinent or use contraceptive measures and agreement to\n             refrain from donating sperm\n\n        Exclusion Criteria:\n\n        Cancer-Specific Exclusions\n\n          -  Participants with a sensitizing mutation in the EGFR gene or an ALK fusion oncogene\n\n          -  Active or untreated central nervous system (CNS) metastases as determined by computed\n             tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and\n             prior radiographic assessments\n\n          -  Spinal cord compression not definitively treated with surgery and/or radiation or\n             previously diagnosed and treated spinal cord compression without evidence that disease\n             has been clinically stable for greater than or equal to (>= 2) weeks prior to\n             randomization\n\n          -  Leptomeningeal disease\n\n          -  Uncontrolled tumor-related pain\n\n          -  Uncontrolled or symptomatic hypercalcemia (greater than [>] 1.5 millimole/Liter\n             ionized calcium or calcium >12 milligrams/deciliter or corrected serum calcium >upper\n             limit of normal)\n\n          -  Malignancies other than NSCLC within 5 years prior to randomization\n\n          -  Known tumor programmed death-ligand 1 (PD-L1) expression status from other clinical\n             studies (e.g., participants whose PD-L1 expression status was determined during\n             screening for entry into a study with anti-PD-1 or anti-PD L1 antibodies but were not\n             eligible are excluded)\n\n        General Medical Exclusions:\n\n          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to\n             chimeric or humanized antibodies or fusion proteins\n\n          -  History of certain autoimmune disease\n\n          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced\n             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis\n\n          -  All participants will be tested for human immunodeficiency virus (HIV) prior to the\n             inclusion into the study and HIV-positive participants will be excluded from the\n             clinical study\n\n          -  Severe infections within 4 weeks prior to randomization\n\n          -  Significant cardiovascular disease, such as New York Heart Association cardiac disease\n             (Class II or greater), myocardial infarction or cerebrovascular accident within 3\n             months prior to randomization, unstable arrhythmias, or unstable angina\n\n          -  Illness or condition that may interfere with a participant's capacity to understand,\n             follow, and/or comply with study procedures\n\n        Exclusion Criteria Related to Medications and Chemotherapy:\n\n          -  Prior treatment with EGFR inhibitors or ALK inhibitors\n\n          -  Any approved anti-cancer therapy, including hormonal therapy within 21 days prior to\n             initiation of study treatment\n\n          -  Prior treatment with cluster of differentiation 137 (CD137) agonists or immune\n             checkpoint blockade therapies, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n\n          -  Treatment with systemic immunostimulatory agents within 4 weeks prior to randomization\n\n          -  Treatment with systemic immunosuppressive medications\n\n        Exclusion Criteria Related to Chemotherapy:\n\n          -  History of allergic reactions to cisplatin, carboplatin, or other platinum-containing\n             compounds\n\n          -  Participants with hearing impairment (cisplatin)\n\n          -  Grade >=2 peripheral neuropathy as defined by National Cancer Institute Common\n             Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria (cisplatin)\n\n          -  Creatinine clearance (CRCL) <60 milliliters/minute (mL/min) for cisplatin or <45\n             mL/min for carboplatinXx_NEWLINE_xXParticipants who have a history of non-compliance to medical therapiesXx_NEWLINE_xXPrisoners or participants who are involuntarily incarceratedXx_NEWLINE_xXFemale research participants of childbearing age must not be pregnant as confirmed by a serum or urine pregnancy test within 1 week of start of treatment; participants must not be breast-feedingXx_NEWLINE_xXParticipants may not have been treated intratumorally with polyICLC.Xx_NEWLINE_xXFor Parts A, B, and C, eligibility of participants who require blood transfusion before and after the start of the study treatment should be discussed by the Sponsor and investigatorXx_NEWLINE_xXFor Part 2: Cohort A and B: Participants disease must have most recently progressed following treatment with a marketed EGFR inhibitor. Exception: In participants diagnosed with mutations associated with de novo EGFR inhibitor resistance (for example, exon 20 insertions), only previous treatment with combination platinum-based chemotherapy is required. Cohort C: Participants must have been previously treated with a third generation EGFR TKI (eg, osimertinib). Cohort D: Participants must have been previously diagnosed with an EGFR Exon 20 insertionXx_NEWLINE_xXParticipants with prior Hepatitis B or C are eligible on the condition that participants have adequate liver function as defined by Inclusion Criterion number 16 and Exclusion Criterion number 5Xx_NEWLINE_xXParticipants must have bi-dimensionally measurable disease with a minimum measurement of 1 cm per dimension on MRI performed within 14 days prior to registration; if receiving corticosteroids, participants must be on a stable or decreasing dose of corticosteroids for at least 5 days prior to baseline MRIXx_NEWLINE_xXParticipants who have received prior treatment with interstitial brachytherapy, stereotactic radiosurgery, or implanted chemotherapy sources, such as wafers of polifeprosan 20 with carmustineXx_NEWLINE_xXParticipants taking medications that are known to be associated with torsades de pointes or QT prolongation within 14 days of starting treatmentXx_NEWLINE_xXParticipants must be fully postmenopausalXx_NEWLINE_xXParticipants who achieve either a partial response or stable disease >= 4 months must agree to undergo a tumor biopsy, if safe and feasible, at the time of progressive disease while on study drug everolimusXx_NEWLINE_xXParticipants may not be receiving any other research study agentsXx_NEWLINE_xXParticipants may not be receiving any other study agents for at least 7 days prior to enrollmentXx_NEWLINE_xXParticipants must be at least 100 days after the transplantation or a donor lymphocyte infusionXx_NEWLINE_xXParticipants must have cGVHD (as defined by the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease)Xx_NEWLINE_xXParticipants may have either extensive or limited cGVHD requiring systemic treatmentXx_NEWLINE_xXParticipants who have received systemic chemotherapy within 3 weeks of starting study drugXx_NEWLINE_xXParticipants must have disease that is not amenable to curative resectionXx_NEWLINE_xXParticipants must have evidence of disease progression within 12 months prior to study entryXx_NEWLINE_xXTreatment with a somatostatin analog (e.g., octreotide acetate) is required for all participants; octreotide naive patients may initiate this during the screening period or at start of studyXx_NEWLINE_xXParticipants with an Inventory of Depressive Symptomatology (IDS) score > 32 or IDS #18 score 2 >= will be referred to Dr. Andrew MillerXx_NEWLINE_xXParticipants with uncontrolled or chronic pain, a score greater than 4 on the standard pain scale, will be excluded unless otherwise approved by the principal investigator or PI’s designeeXx_NEWLINE_xXParticipants taking drugs known to affect the immune system (e.g. glucocorticoids, methotrexate, sulfasalazine and nonsteroidal anti-inflammatory agents) will also be excluded, unless otherwise approved by the principal investigator or PI’s designeeXx_NEWLINE_xXParticipants must have a lung cancer harboring an EGFR mutationXx_NEWLINE_xXParticipants in the control arm from Study BO21976/TDM4450g whose disease progression has occurred during the transition interval between the parent study and this extension study may initiate trastuzumab emtansine treatment at the time of enrollment into study TDM4529g (NCT00781612)Xx_NEWLINE_xXMale participants whose partners are pregnant should use condoms for the duration of the pregnancyXx_NEWLINE_xXKnown human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with prexasertib and LY3300054. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy such as prexasertib.Xx_NEWLINE_xXParticipants must be willing to undergo a research biopsy at baseline and at cycle 2 day 1 if extracranial metastases are safely accessible. Participants for whom biopsies cannot be safely performed must be willing to submit an archival primary and/or metastatic specimen. The biopsies may be waived with prior principal investigator (PI) approval for the first 6 participants enrolled to the safety run in phaseXx_NEWLINE_xXParticipants with a known history of human immunodeficiency virus (HIV) are ineligible because of the potential for pharmacokinetic interactions with MCS110, dabrafenib, and trametinib with antiretroviral agents. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapyXx_NEWLINE_xXParticipants with a history of or current evidence of retinal vein occlusion or retinal pigment epithelial detachmentXx_NEWLINE_xXUnequivocal evidence of new and/or progressive brain metastases, and at least one of the following scenarios:\r\n* Treated with stereotactic radiosurgery (SRS) or surgery with residual un-treated lesions remaining; such participants are eligible for immediate enrollment on this study providing that at least one untreated lesion is measurable\r\n* Participants who have had prior whole- brain radiation therapy and/or SRS and then whose lesions have subsequently progressed are also eligible; in this case, lesions which have been treated with SRS may be considered as target lesions if there is unequivocal evidence, in the opinion of the treating physician, of progression following SRS \r\n* Participants who have not previously been treated with cranial radiation (e.g., WBRT or SRS) are eligible to enter the study, but such participants must be asymptomatic from their CNS metastases and not requiring corticosteroids for symptom control\r\n* Both participants who present with systemic stable/absent or progressive disease are eligible to this trial, as long as they fulfill one of the above criteriaXx_NEWLINE_xXParticipants must be >= 2 weeks since any major surgery (excluding vascular access placement, mediastinoscopy, or biopsies performed by an interventional service)Xx_NEWLINE_xXParticipants who cannot receive gadoliniumXx_NEWLINE_xXParticipants with inadequate mental capacity to complete quality of life questionnairesXx_NEWLINE_xXFor enrollment to arm 2: participants must have a confirmed CDK4 or CDK6 high-level amplification, identified via DFCI/BWH OncoPanel or any CLIA-certified methodXx_NEWLINE_xXParticipants receiving an enzyme-inducing antiepileptic drug (EIAED) who cannot be transferred to a non-EIAED (e.g., levetiracetam, lacosamide, lamotrigine, etc.) prior to the initiation of protocol therapyXx_NEWLINE_xXParticipants =< 12-15 years Lansky 100-70%Xx_NEWLINE_xXUncontrolled cancer pain. Participants requiring pain medication must be on a stable regimen at study entry. Symptomatic lesions amenable to palliative radiotherapy should be treated prior to enrollment.Xx_NEWLINE_xXHistory of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies (for participants receiving regimen including rituximab).Xx_NEWLINE_xXInclusion Criteria:\n\n        Arms 1 and 2 Participants:\n\n          -  Has any histologically or cytologically confirmed advanced/metastatic solid tumor by\n             pathology report and has received, or have been intolerant to all treatment known to\n             confer clinical benefit. Solid tumors and lymphomas of any type are eligible for\n             enrollment. For cutaneous T-cell lymphoma (CTCL), histopathological diagnosis should\n             be confirmed in a skin biopsy representative of disease.\n\n          -  Have Stage III or Stage IV disease that is not surgically resectable. Stage IIB\n             (T3N0M0B0-1) CTCL participants are eligible.\n\n        Arm 3 Participants:\n\n        -Has metastatic liver and/or liver lesion involvement that does not exceed one third of the\n        total liver volume in participants to be treated by liver IT injection. Hepatocellular\n        carcinoma participants are excluded from eligibility of IT liver injection.\n\n        All Participants:\n\n          -  Stage III or Stage IV disease that is not surgically resectable.\n\n          -  Has ?1 injectable lesion that is amenable to injection and biopsy via visual\n             inspection for a cutaneous lesion, or via ultrasound guidance for a subcutaneous\n             lesion.\n\n          -  Has ?1 discrete, distant noninjected lesion that is amenable to biopsy via visual\n             inspection or amenable to biopsy via image guidance.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n\n          -  Demonstrates adequate organ function.\n\n          -  If of childbearing potential, must agree to use adequate contraception during the\n             treatment period and for at least 120 days after the last dose of study treatment.\n\n        Exclusion Criteria:\n\n          -  History of a second malignancy, unless potentially curative treatment has been\n             completed, with no evidence of malignancy for 2 years (except for successful\n             definitive resection of basal cell carcinoma of the skin, superficial bladder cancer,\n             or in situ cervical cancer).\n\n          -  Clinically active central nervous system metastases and/or carcinomatous meningitis.\n\n          -  Severe hypersensitivity reaction to treatment with a monoclonal antibody (mAb).\n\n          -  Active autoimmune disease that has required systemic treatment in the past 2 years.\n\n          -  History of vasculitis.\n\n          -  Active infection requiring therapy.\n\n          -  History of (noninfectious) pneumonitis that required steroids or current pneumonitis.\n\n          -  Undergone prior allogeneic hematopoietic stem cell transplantation within the last 5\n             years.\n\n          -  Known human immunodeficiency virus (HIV) and/or Hepatitis B or C infection.\n\n          -  Pregnant or breastfeeding, or expecting to conceive or father children within the\n             projected duration of the study.\n\n          -  Not fully recovered from any effects of major surgery, and is free of significant\n             detectable infection.\n\n          -  Had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2\n             weeks for palliative radiation) prior to the first dose of study treatment, or has not\n             recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) Grade\n             1 from the AEs due to cancer therapeutics administered >4 weeks earlier.\n\n          -  Been treated within 2 weeks of Cycle 1 Day1 with any of the following: strong/moderate\n             Cytochrome P450 2C9 (CYP2C9) inhibitors, such as: amiodarone, felbamate, fluconazole,\n             miconazole, piperine, oxandrolone, fluorouracil and its derivatives (combination drug\n             tegafur/gimeracil/oteracil [TS-1], Uftoral [UFT], tegafur, carmofur, doxifluridine,\n             capecitabine), sulfaphenazole, cyclosporine, bucurol, tienilic acid; UGT1A3 inhibitors\n             (including ritonavir, quinidine, probenecid, and valproic acid); or strong carbonyl\n             reductase (CBR) inhibitors (including quercetin, menadione, glycyrrhetinic acid, and\n             flufenamic acid).\n\n          -  Currently participating and receiving study therapy or has participated in a study of\n             an investigational agent and has received study therapy or has used an investigational\n             device within 28 days of administration of MK 2118.\n\n          -  Expected to require any other form of antineoplastic therapy while on study.\n\n          -  On chronic systemic steroid therapy in excess of replacement doses (prednisone ?10\n             mg/day is acceptable), or on any other form of immunosuppressive medication. For CTCL,\n             continued use of either prednisone ?10 mg/day or continued use of topical steroids is\n             acceptable.\n\n          -  Received a live vaccine within 28 days prior to first dose.\n\n          -  Been treated with a stimulator of interferon genes (STING) agonist (eg, MK-1454,\n             ADU-S100 [synthetic cyclic dinucleotide (CDN)]).\n\n          -  Has a history of re-irradiation for SCCHN at the projected injection site.\n\n          -  Has a tumor(s) in direct contact or encases a major blood vessel and has ulceration\n             and/or fungation onto the skin surface at the projected injection site.Xx_NEWLINE_xXFor participants in MTD/OBD cohort expansion and Phase 2 only: participant has measurable disease.Xx_NEWLINE_xXParticipants with symptomatic hyperviscosity or serum IgM > 5,000 mg/dL to undergo plasmapheresis prior to treatment initiationXx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Part I dose escalation: Participants are required to have measurable disease per RECIST 1.1 within 4 weeks of study entryXx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Participants are permitted to have any number of prior therapies prior to enrollmentXx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Participants receiving any other study agents concurrently with the study drugsXx_NEWLINE_xXEXPANDED ACCESS COHORT: Participants must be currently enrolled to DFCI protocol number 13-506 or discontinued from protocol 13-506 solely because the study agents were no longer available via protocol 13-506Xx_NEWLINE_xXEXPANDED ACCESS COHORT: Participants must be experiencing clinical benefit from the 13-506 study drug combination as judged by the treating investigatorXx_NEWLINE_xXParticipants with progressive systemic malignancyXx_NEWLINE_xXConcurrent therapy with drugs active against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir); participants must be off treatment with these agents for at least 7 days prior to surgeryXx_NEWLINE_xXParticipants must be >= 4 weeks since any major surgery (excluding vascular access placement, mediastinoscopy, or biopsies performed by an interventional service)Xx_NEWLINE_xXParticipants with previously untreated T1/T2 N0 squamous cell carcinoma of the oral cavity with or without extension to the oropharynxXx_NEWLINE_xXParticipants must have documentation of a new or progressive lesion on a radiologic imaging study performed within 12 months prior to study enrollment (progression of disease over any interval is allowed) and/or new/worsening disease related symptoms within 12 months prior to study enrollment; this assessment is performed by the treating investigator; evidence of progression by RECIST criteria is not requiredXx_NEWLINE_xXParticipants must be willing and able to undergo a biopsy at the start of this study and an on-treatment biopsy if safe and feasibleXx_NEWLINE_xXParticipants who have undergone a pneumonectomy due to known potential for pulmonary toxicities and heightened risk for complicationsXx_NEWLINE_xXParticipants must have a biopsy proven solid malignancy with untreated (by radiation) intracranial lesions radiographically consistent with or pathologically proven to be brain metastases; patients who have undergone prior systemic therapy are eligibleXx_NEWLINE_xXParticipants who cannot receive gadoliniumXx_NEWLINE_xXParticipants with evidence of pneumonitis on scans at screening will be excludedXx_NEWLINE_xXParticipants with bone lesions requiring surgical fixation to provide mechanical stability are ineligible; participants with previously fixed lesions are allowedXx_NEWLINE_xXFor participants treated with prior neoadjuvant chemotherapy: tumor stage of ypT2-4a or ypN+ (ypT2-4 or ypN+ for participants with upper urinary tract UC) and M0Xx_NEWLINE_xXFor participants who have not received prior neoadjuvant chemotherapy: tumor stage of pT3-4a or pN+ (pT3-4 or pN+ for participants with upper urinary tract UC) and M0Xx_NEWLINE_xXMolecular testing results from clinical laboratory improvement amendments (CLIA)-certified laboratories (using tissue and/or blood) demonstrating HER2 overexpression or amplification. Participants must have one of the following tumor types: biliary cancer, salivary cancer, or bladder cancer. a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)Xx_NEWLINE_xXParticipants with hematologic malignanciesXx_NEWLINE_xXParticipants with symptomatic bradycardiaXx_NEWLINE_xXParticipating participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications, when clinically indicated and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 8 weeks following study entry; as study-specific (antiretroviral-based) strata fill, however, only participants who are receiving the therapies eligible for the remaining open strata will be accruedXx_NEWLINE_xXParticipants with clinically diagnosed moderate to severe cGvHD according to NIH Consensus Criteria prior to randomization:Xx_NEWLINE_xXParticipants currently receiving systemic or topical corticosteroids for the treatment of cGvHD for a duration of < 12 months prior to Cycle 1 Day 1 (if applicable), and have a confirmed diagnosis of steroid-refractory cGvHD defined per 2014 NIH consensus criteria irrespective of the concomitant use of a calcineurin inhibitor (CNI), as follows:Xx_NEWLINE_xXParticipants who have received 2 or more systemic treatment for cGvHD in addition to corticosteroids ± CNI for cGvHDXx_NEWLINE_xXParticipants with relapsed primary malignancy, or who have been treated for relapse after the alloSCT was performedXx_NEWLINE_xXParticipants with known history of pancreatitis or progressive multifocal leukoencephalopathy (PML)Xx_NEWLINE_xXParticipants with neuroblastoma with only metaiodobenzylguanidine (MIBG)-positive evaluable disease may be enrolledXx_NEWLINE_xXParticipants must have a complete history and physical examination within 45 days of study entry\r\n* Participants must have a digital rectal examination (confirming clinical stage T1c to T2c) of prostate within 180 days of study entryXx_NEWLINE_xXFemale participants must agree not to breastfeed or donate ova throughout the study drug treatment period and for 6 months after the final study drug administration.Xx_NEWLINE_xXTBL < 2.5 mg/dL, except for participants with Gilbert's syndrome.Xx_NEWLINE_xXParticipants must have operable breast cancer, with tumors greater than or equal to 2 cm in size; participants must not have any evidence of metastatic diseaseXx_NEWLINE_xXNot compliant with anti-retroviral therapy (HIV infected participants)Xx_NEWLINE_xXCD4 count < 200 cells/ml and detectable viral load within the least 3 months (HIV infected participantsXx_NEWLINE_xXParticipants with known addiction to any drugsXx_NEWLINE_xXParticipants enrolling into the MET cohort must have a MET exon 14 mutation as confirmed by targeted next generation (NextGen) sequencing using the Dana-Farber Cancer Institute (DFCI)/Brigham and Women’s Hospital (BWH) OncoPanel or another Clinical Laboratory Improvement Act (CLIA)-certified method; participants whose NSCLC specimens contain actionable genetic mutations/alterations (e.g. ALK/EGFR) should receive appropriate targeted therapies prior to enrollment in the trialXx_NEWLINE_xXParticipants enrolling to the NTRK cohort who have received treatment with a prior NTRK inhibitor must be able and willing to undergo a baseline tumor biopsyXx_NEWLINE_xXParticipants enrolling to the MET cohort who have received a prior MET inhibitor may not be on anticoagulant therapy unless the investigator has deemed it safe to temporarily hold to facilitate the baseline tumor biopsyXx_NEWLINE_xXParticipants enrolling to the NTRK cohort who have received a prior NTRK inhibitor may not be on anticoagulant therapy unless the investigator has deemed it safe to temporarily hold to facilitate the baseline tumor biopsyXx_NEWLINE_xXFor participants receiving therapeutic anticoagulation: stable anticoagulant regimen and stable INR during the 28 days immediately preceding initiation of study treatmentXx_NEWLINE_xXParticipants must agree to discontinue all vitamin supplements while taking study medication and for thirty days past the last dose of study medicationXx_NEWLINE_xXFor biopsy cohort, participants must be bevacizumab naive or received the last bevacizumab treatment at least 12 months prior to Cycle 1 Day 1 and according to the investigator's judgment the planned biopsies would not expose participants to substantially increased risk of complicationsXx_NEWLINE_xXParticipants with known microsatellite (MSI)-high statusXx_NEWLINE_xXHave prior malignancies. Participants with carcinoma in situ of any origin and participants with prior malignancies who are in remission and whose likelihood of recurrence is very low, as judged by the Lilly clinical research physician, are eligible for this study.Xx_NEWLINE_xXParticipants must be in first recurrence or have disease that is primarily refractory to conventional therapyXx_NEWLINE_xXParticipants who have had prior exposure to ibrutinibXx_NEWLINE_xXParticipants may have received prior cranial irradiationXx_NEWLINE_xXParticipants may receive either a myeloablative or a non-myeloablative (reduced-intensity) conditioning regimenXx_NEWLINE_xXAge >= 4 years old and toilet-trained; participants must be able to deposit stool samples directly into stool collection containersXx_NEWLINE_xXParticipants receiving GVHD prophylaxis with drugs other than calcineurin inhibitor, short-course methotrexate, steroids, mycophenolate mofetil, or sirolimusXx_NEWLINE_xXParticipants undergoing active therapy for immune-mediated or infectious colitis upon admission for allogeneic HSCTXx_NEWLINE_xXParticipants with known addiction to any drugsXx_NEWLINE_xXStudy participants will be women who have gone through a bi-lateral oophorectomy procedureXx_NEWLINE_xXParticipants who have already received anti-VEGF or experimental antiangiogenic therapy for glioblastomaXx_NEWLINE_xXNewly diagnosed, previously untreated participants with rhabdomyosarcoma (RMS)Xx_NEWLINE_xXParts A, A2 & B1: Participants must have pathological evidence of a diagnosis of advanced and/or metastatic cancer and must be, in the judgment of the investigator, an appropriate candidate for experimental therapyXx_NEWLINE_xXPart B3 only: Participants must have malignant pleural or peritoneal mesotheliomaXx_NEWLINE_xXPart B4 only: Participants must have malignant pleural or peritoneal mesothelioma and appropriate candidate for treatment with cisplatin/pemetrexed; no prior systemic chemotherapyXx_NEWLINE_xXPart B6 only: Participants must have squamous NSCLC; documented evidence of an activating molecular aberration of the PI3K/mTOR pathwayXx_NEWLINE_xXParticipants with active alcohol abuse, as determined by the investigatorXx_NEWLINE_xXActive or prior documented autoimmune disease within the past 2 years (NOTE: The following are exceptions to this criterion: Participants with vitiligo or alopecia; Participants with hypothyroidism (e.g. following Hashimoto syndrome) who are stable on hormone replacement; Participants with celiac disease controlled by diet alone: Participants with Grave’s disease, or any chronic skin condition not requiring systemic treatment. Participants without active disease in the last 5 years may be included but only after consultation with the study physician.Xx_NEWLINE_xXParticipants must not have ocular melanomaXx_NEWLINE_xXNot currently pregnant during the study; participants will be informed that the use of contraceptive pills is contraindicated because it may interfere with the study drug and it may be harmful to the woman who has been diagnosed with breast cancerXx_NEWLINE_xXParticipants with recurrent, progressive, or refractory brain tumorsXx_NEWLINE_xXParticipants with a diagnosis of recurrent, progressive, or refractory low grade glioma (LGG)Xx_NEWLINE_xXSTRATUM A: Participants with recurrent, progressive, or refractory non-WNT non-SHH (NWNS) medulloblastoma or ependymoma as confirmed through central pathology reviewXx_NEWLINE_xXSTRATUM A: Participants who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to study enrollment with no plans for escalationXx_NEWLINE_xXSTRATUM A: Participants must discontinue herbal preparations, herbal medication, and dietary supplements, with the exception of multivitamins, at least 7 days prior to study enrollmentXx_NEWLINE_xXSTRATUM A: Participants with subependymoma or myxopapillary ependymomaXx_NEWLINE_xXSTRATUM A: Participants with a pathogenic somatic or known germline retinoblastoma (RB1) gene mutationXx_NEWLINE_xXSTRATUM B: Participants with recurrent, progressive, or refractory CNS tumors as confirmed through central pathology reviewXx_NEWLINE_xXSTRATUM B: Participants who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to study enrollment with no plans for escalationXx_NEWLINE_xXSTRATUM B: Participants must discontinue herbal preparations, herbal medication, and dietary supplements, with the exception of multivitamins, at least 7 days prior to study enrollmentXx_NEWLINE_xXSTRATUM B: Participants with low grade glioma (LGG) or diffuse intrinsic pontine glioma (DIPG)Xx_NEWLINE_xXSTRATUM B: Participants with a pathogenic somatic or known germline retinoblastoma (RB1) gene mutationXx_NEWLINE_xXSTRATUM B: Participants with retinal vein occlusion (RVO)Xx_NEWLINE_xXSTRATUM C: Participants who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to study enrollment with no plans for escalationXx_NEWLINE_xXSTRATUM C: Participants must discontinue herbal preparations, herbal medication, and dietary supplements, with the exception of multivitamins, at least 7 days prior to study enrollmentXx_NEWLINE_xXSTRATUM C: Participants with a pathogenic somatic or known germline retinoblastoma (RB1) gene mutationXx_NEWLINE_xXParticipants who are WOCBP who are continuously not heterosexually active are exempted from contraceptive requirements but still must undergo pregnancy testingXx_NEWLINE_xXParticipants who are azoospermic males are exempt from contraceptive requirementsXx_NEWLINE_xXParticipants must not have a known additional malignancy that could confuse analysis of on-study treatment; inclusion of all study participants with more than one malignancy must be discussed and approved by the principal investigator (PI)Xx_NEWLINE_xXParticipants may not concomitantly use statins while on study; however, a patient using statins for over 3 months prior to study drug administration and in stable status without CK rise may be permitted to enrollXx_NEWLINE_xXParticipants must not have a history of any significant drug allergy (such as anaphylaxis or hepatotoxicity) to prior anti-cancer immune-modulating therapies (eg, checkpoint inhibitors and T-cell co-stimulatory antibodies)Xx_NEWLINE_xXParticipants must not be prisoners or be involuntarily incarceratedXx_NEWLINE_xXCOHORT II ONLY: Participants are ineligible for ruxolitinib – do not have splenomegaly or symptoms of myelofibrosis as defined by the MPN-SAF. Or participants failed ruxolitinib as defined by loss of response to therapy and no allergy to ruxolitinib in the pastXx_NEWLINE_xXResearch participants with new symptoms of CHF, cardiomyopathy, myocarditis, MI, or exposure to cardiotoxic medications must have a cardiac consultation, creatinine phosphokinase (CPK), and troponin testing at pre -study and as clinically indicatedXx_NEWLINE_xXResearch participants with any non-malignant intercurrent illness which is either poorly controlled with currently available treatment, or which is of such severity that the investigators deem it unwise to enter the research participant on protocol shall be ineligibleXx_NEWLINE_xXResearch participants with any other active malignanciesXx_NEWLINE_xXResearch participants being treated for severe infection or who are recovering from major surgery are ineligible until recovery is deemed complete by the investigatorXx_NEWLINE_xXIf the research participants has new symptoms of CHF, cardiomyopathy, myocarditis, MI, or exposure to cardiotoxic medications they already had a cardiac consultation, creatinine phosphokinase (CPK), and troponin testing at pre study deeming them fit for study participationXx_NEWLINE_xXResearch participants must not require more than 2 mg TID of dexamethasone during CAR T cell therapyXx_NEWLINE_xXParticipants, who completed at least 2 cycles of combination olaratumab/doxorubicin therapy then discontinued doxorubicin due to toxicity or maximum dosing and proceeded to olaratumab monotherapy, are eligible.Xx_NEWLINE_xXHas had major surgery, other than nephrectomy and/or resection of pre-existing metastases for M1 NED participants, within 12 weeks prior to randomization.Xx_NEWLINE_xXParticipants that have received prior anthracycline therapy if the participant is to be enrolled in the doxorubicin combination arm.Xx_NEWLINE_xXParticipants with biopsy-proven adenocarcinoma of the pancreas that is determined to be potentially or borderline resectable by National Comprehensive Cancer Network (NCCN) criteriaXx_NEWLINE_xXParticipants must have had prior therapyXx_NEWLINE_xXParticipants must agree to undergo a research biopsy, if tumor is safely accessible, at baseline and within 14 days prior to course 3 day 1 (C3D1); participants for whom newly-obtained samples cannot be provided (e.g. inaccessible or participant safety concern) may submit an archived specimen\r\n* Note: After the first 6 participants undergo biopsy on cabozantinib, we will review their adverse event profiles to ensure no more than a 20% rate of grade 3 or higher bleeding or wound healing complications occur; if more than 2 patients (> 20%) have safety concerns, we will reassess the safety of collecting the research biopsies; full review of all grade (including grade 1 and 2) may also prompt changes and will be reviewed by the study team; Exelixis may be consulted if necessaryXx_NEWLINE_xXParticipants may have received 0-3 prior chemotherapeutic regimens for metastatic breast cancer and must have been off treatment with chemotherapy for at least 14 days prior to registration; participants should also be adequately recovered from acute toxicities of prior treatmentXx_NEWLINE_xXParticipants that cannot take alternate medications will be excluded from this studyXx_NEWLINE_xXParticipants may have had any extent of prior surgery and/or chemotherapyXx_NEWLINE_xXParticipants who require continuous use of proton pump inhibitors (PPIs) or histamine-2 (H2) receptor antagonists and participants who are taking PPIs within 5 days before the first dose of study drug.Xx_NEWLINE_xXParticipants with known microsatellite instability-high (MSI-H) genotype or known wild type tumor protein 53 (TP53) per local testing.Xx_NEWLINE_xXWestern Safety Cohort Only: Participants with Japanese heredity.Xx_NEWLINE_xXPhase 2: Participants must be diagnosed with histologically confirmed rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) or ewing sarcoma (EWS) which is relapsed or refractory having received at least 1 prior therapy, including primary treatment.Xx_NEWLINE_xXParticipants must have disease that has progressed on prior treatment and is not amenable to surgical resection or other approved therapeutic options with curative intent. Participants must not be eligible for further therapy that is likely to provide a survival benefitXx_NEWLINE_xXParticipants must have discontinued EGFR targeted therapy prior to the first dose of study drug.Xx_NEWLINE_xXParticipants must have liver metastases deemed unresectable due to anatomy, medical fitness, or presence of extrahepatic diseaseXx_NEWLINE_xXParticipants with local conditions or systemic illnesses that would reduce the local tolerance to radiation treatment, such as serious local injuries, active collagen vascular disease, etcXx_NEWLINE_xXParticipants who have previously received TAS-102Xx_NEWLINE_xXParticipants who have received prior sorafenib or anti-PD1 therapy for HCCXx_NEWLINE_xXParticipants with a history of variceal bleed within 6 months prior to enrollmentXx_NEWLINE_xXNo preexisting condition that would deter radiotherapy, eg, fistulas, severe ulcerative colitis (particularly participants currently taking sulphasalazine), Crohn's disease, prior adhesionsXx_NEWLINE_xXParticipants with interstitial pneumonia or extensive and symptomatic fibrosis of the lungsXx_NEWLINE_xXParticipants are not permitted to receive enzyme inducing anti-epileptic drugsXx_NEWLINE_xXFOR ALL PHASES (Ib AND II): Participants receiving anticoagulation therapy are not allowedXx_NEWLINE_xXParticipants must have a complete history and physical examination within 60 days of study entryXx_NEWLINE_xXEastern Cooperative Oncology Group (ECOG) performance status =< 1 for MSS participants or < 2 for microsatellite instability (MSI) participantsXx_NEWLINE_xXParticipants have had at least 1 episode of vaso-occlusive crisis (VOC) in the past 12 months.Xx_NEWLINE_xXFor participants taking hydroxyurea (HU), the dose of HU (mg/kg) must be stable for at least 3 months prior to signing the ICF.Xx_NEWLINE_xXParticipants with a history of progressive multifocal leukoencephalopathyXx_NEWLINE_xXParticipants who have previously received ibrutinib for another indicationXx_NEWLINE_xXParticipants with a history of sustained ventricular tachycardia or aborted ventricular fibrillation or with a history of atrioventricular (AV) nodal or sinoatrial (SA) nodal dysfunction for which a pacemaker/implantable cardioverter-defibrillators [ICD] is indicated but not placed (participants who do have a pacemaker/ICD are allowed on study)Xx_NEWLINE_xXInclusion Criteria:\n\n        For both portions of the study, participants must satisfy all of the following inclusion\n        criteria to be enrolled in the study:\n\n          -  Written Institutional Review Board/Ethics Committee-approved informed consent form\n             (ICF), signed by participant or legally authorized representative.\n\n          -  Participants must be determined to have histologically confirmed unresectable, locally\n             advanced or metastatic adenocarcinoma of the intra- and/or extra-hepatic bile ducts\n             and/or gallbladder. Participants must have sufficient tissue with architectural\n             integrity, including tumor and associated stroma, available for retrospective\n             biomarker testing.\n\n          -  One or more lesions measurable on computed tomography (CT) scan/magnetic resonance\n             imaging (MRI) scan per Response Evaluation Criteria in Solid Tumors (RECIST) version\n             1.1 (v1.1).\n\n          -  Participants having Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\n             to 1.\n\n          -  Life expectancy ?3 months.\n\n          -  Males and females aged ?18 years.\n\n          -  Screening clinical laboratory values within pre-determined parameters\n\n          -  Female participants of childbearing potential (WOCBP) must have a negative urine or\n             serum pregnancy test within 7 days before Day 1 (first dose of study medication).\n\n          -  For WOCBP and for men, agreement to use a highly effective contraceptive method from\n             the time of screening throughout the study until 5 months (WOCBP) or 6 months (men)\n             after administration of the last dose of any study medication. Highly effective\n             contraceptive methods consist of prior sterilization, intrauterine device (IUD),\n             intrauterine hormone releasing system (IUS), oral or injectable contraceptives,\n             barrier methods, and/or true sexual abstinence.\n\n        Exclusion Criteria:\n\n        Participants are ineligible for enrollment if they meet any of the following exclusion\n        criteria:\n\n          -  Clinical evidence of deep vein thrombosis or pulmonary embolism present during the\n             screening period\n\n          -  New York Heart Association Class III or IV cardiac disease, atrial fibrillation,\n             unstable angina, or myocardial infarction within the past 12 months before screening.\n\n          -  Participants with known brain metastases\n\n          -  History of cerebrovascular accident or transient ischemic attack\n\n          -  History of active bleeding within the last 3 months prior to screening requiring\n             transfusion.\n\n          -  Participants must have received no previous radiotherapy, surgery, chemotherapy or\n             investigational therapy for treatment of metastatic or locally advanced disease.\n\n          -  Active hepatitis B virus (HBV) infection, defined as having a positive hepatitis B\n             surface antigen (HBsAg) test at screening\n\n          -  Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody\n             test at screening\n\n          -  History of:\n\n               1. Idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis\n                  obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of\n                  active pneumonitis on screening chest CT scan. History of radiation pneumonitis\n                  in the radiation field (fibrosis) is permitted.\n\n               2. Or known cases of hepatobiliary diseases (e.g., primary biliary cholangitis,\n                  primary sclerosing cholangitis, history of immune-mediated cholangitis);\n\n                  Participants with cholangitis attributed to infectious etiology (e.g., ascending\n                  cholangitis, bacterial cholangitis) are eligible if the infection has been fully\n                  resolved prior to the screening visit.\n\n               3. Or known cases of drug-induced hepatobiliary toxicities.\n\n          -  Active or history of autoimmune diseases\n\n          -  Uncontrolled hypercalcemiaXx_NEWLINE_xXParticipants in cohort C must have completed systemic therapy (4-6 cycles cisplatin or carboplatin + etoposides) and NOT be a candidate for consolidation thoracic radiotherapy or prophylactic cranial irradiation (PCI); participants in cohort C must initiate therapy with pembrolizumab within 6 weeks of the last dose of chemotherapy (therapy must not start within 2 weeks from the last dose); participants in cohort C must not have had progression of disease prior to the start of therapyXx_NEWLINE_xXParticipants with treated brain metastases are allowed; radiation must be completed at least 2 weeks prior to pembrolizumab dosing and participants must not require ongoing steroids; participants with untreated brain metastases that are all < 5 mm with no clinical symptoms or vasogenic edema may be allowed on study on a case-by-case basis on discussion with sponsor; these participants will require MRI monitoring every 6 weeks to ensure stabilityXx_NEWLINE_xXParticipants in cohort A may not have had prior therapy for their disease; participants in cohort B may not have had more than 1 cycle of systemic therapy (cisplatin or carboplatin + etoposide); participants in cohort C and D should not have had more than one prior regimen of chemotherapyXx_NEWLINE_xXParticipants who have had a complete response (CR) after pre-study therapy are not eligible for studyXx_NEWLINE_xXPreviously treated with ixazomib (excluding comparator or placebo participants not on current treatment with ixazomib) in a Millennium-sponsored study. Participants will be eligible to enter the rollover study when:Xx_NEWLINE_xXParticipants are required to stop receiving myeloid growth factors at least 1 week (Neupogen) or 2 weeks (Neulasta) before starting treatment on the studyXx_NEWLINE_xXParticipants who are not considered candidates for pertuzumab + trastuzumab + chemotherapyXx_NEWLINE_xXFOR PARTICIPANTS WHO WILL BE RECEIVING NAB-PACLITAXEL (ALL ARMS EXCEPT ARM B1 SINGLE AGENT LEAD-IN)Xx_NEWLINE_xXFOR PARTICIPANTS WHO WILL NOT RECEIVE NAB-PACLITAXEL (ARM B1 SINGLE AGENT LEAD-IN ONLY)Xx_NEWLINE_xXParticipants must not have an invasive infection at time of protocol entryXx_NEWLINE_xXFor LY3300054 + abemaciclib only: No participants with liver metastases. Participants must have normal aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, gamma-glutamyl transferase (GGT) and alkaline phosphatase (AP).Xx_NEWLINE_xXAll participants and/or their parents or legally authorized representatives must sign a written informed consent; assent will be obtained for all participants under the age of 18 yearsXx_NEWLINE_xXNewly diagnosed or relapsed participants are eligible to participate; this protocol is intended to enroll both previously treated and untreated patientsXx_NEWLINE_xXFor Part 2 and Part 3 of the study, participants must have histopathologically and clinically confirmed diagnosis of relapsed DLBCL. Participants will be considered to have a relapsed disease if they showed a duration of response of at least 24 weeks after their first line of therapy. The following participants with relapsed DLBCL will be enrolled:Xx_NEWLINE_xXFor Part 2 and Part 3 of the study, participants that are eligible to undergo first time HD-ASCT.Xx_NEWLINE_xXFor Part 2 and Part 3 of the study, participants with R/R FL, MZL/MALT, MCL, or any other NHL subtypes according to the WHO classification.Xx_NEWLINE_xXFirst relapsed participants aged less than (<) 60 years with first CR duration greater than (>) 1 yearXx_NEWLINE_xXParticipants who have received allogeneic HSCT within 90 days prior to randomizationXx_NEWLINE_xXParticipants who have received immunosuppressive therapy for graft versus host disease within 2 weeks prior to randomizationXx_NEWLINE_xXParticipants receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within 30 days from first receipt of study drugXx_NEWLINE_xXParticipants who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the studyXx_NEWLINE_xXParticipants with extramedullary AML with no evidence of systemic involvementXx_NEWLINE_xXPatients previously treated with alectinib (Note: this only applies to the phase II portion of the study; participants entering the phase I portion of the study will still be eligible if previously treated with alectinib)Xx_NEWLINE_xXParticipants with non-secretory or oligo-secretory myeloma, plasma cell leukemia or Waldenström's macroglobulinemiaXx_NEWLINE_xXParticipants must have metastatic colorectal or pancreatic cancerXx_NEWLINE_xXAll participants will be required to undergo mandatory pre and on-treatment biopsiesXx_NEWLINE_xXParticipants with ALL with Philadelphia chromosome or with an ABL class targetable fusion are eligible.Xx_NEWLINE_xXParticipants with LL must have radiographic evidence of diseaseXx_NEWLINE_xXParticipants who have received any of the following prior to the first dose of study drug:Xx_NEWLINE_xXParticipants with malabsorption syndrome or any other condition that precludes enteral administration.Xx_NEWLINE_xXParticipants with preoperatively staged T3, N1, or N2 tumors who return > 12 weeks following completion of neoadjuvant chemoradiation therapy (CRT)Xx_NEWLINE_xXRelapsed or refractory solid tumor malignancy that has progressed on standard anticancer therapy with no available curative options. (Note: Osteosarcoma participants must be in first or subsequent relapse [greater than or equal to first relapse]). Only the osteosarcoma participants enrolled to Cohorts 3A and 3B must be deemed candidates for ifosfamide and etoposide chemotherapy).Xx_NEWLINE_xXDTC participants must be 131 iodine-refractory/ relapsed as defined by at least one of the following:Xx_NEWLINE_xXOsteosarcoma participants receiving combination therapy of lenvatinib with ifosfamide and etoposide should meet only Inclusion Criteria Numbers 6 through 17 (after progression in Cohort 2B).Xx_NEWLINE_xXPrevious treatment with lenvatinib (except for participants previously enrolled into Cohorts 1 or 2B of this study).Xx_NEWLINE_xXOsteosarcoma participants receiving combination therapy of lenvatinib with ifosfamide and etoposide should meet all the exclusion criteria, with the exception of Criterion Number 6.Xx_NEWLINE_xXFor Part B participants: SGPT (ALT) concentration < 2.5 x institutional ULNXx_NEWLINE_xXIn the absence of rapid progressive disease, the interval from prior systemic anticancer treatment to time of TAK-659 administration should be at least 2 weeks for cytotoxic agents (other than hydroxyurea), or at least 5 half-lives for noncytotoxic agents, and participants have to have recovered from acute toxicities of these therapies. Participants who are on hydroxyurea may be included in the study and may continue on hydroxyurea for the first 28 days while participating in this study.Xx_NEWLINE_xXResearch participants must not require more than 2 mg TID of dexamethasone during T cell therapyXx_NEWLINE_xXResearch participants with any non-malignant intercurrent illness which is either poorly controlled with currently available treatment, or which is of such severity that the investigators deem it unwise to enter the research participant on protocol shall be ineligibleXx_NEWLINE_xXResearch participants with any other active malignanciesXx_NEWLINE_xXResearch participants being treated for severe infection or who are recovering from major surgery are ineligible until recovery is deemed complete by the investigatorXx_NEWLINE_xXResearch participants' last dose of prior chemotherapy or radiation must be >= 2 weeks before leukapheresis; Note: this criterion is not applicable if the research participant's donor is undergoing leukapheresisXx_NEWLINE_xXResearch participants who received memory-enriched CD19R(EQ):CD28:zeta/EGFRt+ on IRB#13277Xx_NEWLINE_xXResearch participants with known active hepatitis B or C infection; research participants who are human immunodeficiency virus (HIV) seropositive based on testing performed within 4 weeks of screening; research participants with any signs of symptoms of active infection, positive blood cultures or radiological evidence of infectionsXx_NEWLINE_xXResearch participants with confirmed 1st or higher relapse of disease by morphology, cytogenetics or molecular, or research participants with refractory or residual diseaseXx_NEWLINE_xXResearch participants with known active hepatitis B or C infection; research participants who are human immunodeficiency virus (HIV) positive based on testing performed within 4 weeks of enrollment; research participants with any signs or symptoms of active infection, positive blood cultures or radiological evidence of infectionsXx_NEWLINE_xXResearch participants receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy\r\n* Note: Please note that the above criterion is not applicable at the time of enrollment if the research participant's donor is undergoing leukapheresisXx_NEWLINE_xXParticipants in the study must permit targeted prostate biopsy prior to initiation of study treatment and at the time of fiducial marker placementXx_NEWLINE_xXIf taking immunosuppressants, retinoids or anti-neutrophil therapy, participants must maintain stable doses of these medications during the 2 weeks prior to study initiationXx_NEWLINE_xXPreviously treated participantsXx_NEWLINE_xXParticipants must not have an invasive infection at time of protocol entryXx_NEWLINE_xXParticipants with cervical cancer may undergo chemotherapy in conjunction with adjuvant proton therapy; the agents, doses, routes and schedule of administration will be determined by their attending gynecologic oncologist or medical oncologistXx_NEWLINE_xXParticipants will not be eligible if the original diagnosis was a lower grade glioma and a subsequent histologic diagnosis revealed glioblastomaXx_NEWLINE_xXParticipants in Part D must have NSCLC of any subtype.Xx_NEWLINE_xXParticipants in Part E must have melanoma of any subtype.Xx_NEWLINE_xXFor HER2+ breast cancer participants in parts A, C, and F: participants may receive concurrent treatment (ongoing or initiated simultaneously with abemaciclib) with IV trastuzumab.Xx_NEWLINE_xXParticipants must have classical histology posterior fossa medulloblastoma as determined by institutional neuro-pathological evaluationXx_NEWLINE_xXAre planning to undergo SCT prior to PD on this study (ie, these participants should not be enrolled in order to reduce disease burden prior to transplant).Xx_NEWLINE_xXParticipants willing to undergo all protocol-specified biopsiesXx_NEWLINE_xXParticipants must have completed 3 cycles of a bortezomib-based induction regimen (as defined by current NCCN guidelines) and have no evidence of disease progression as defined by IMWG criteria.Xx_NEWLINE_xXParticipants must be considered by their physician eligible to receiving the IRD regimen.Xx_NEWLINE_xXInclusion Criteria:\n\n        Each participant must meet all of the following inclusion criteria to be enrolled in the\n        study:\n\n          1. Male or female participants 18 years or older.\n\n          2. To be enrolled to the dose escalation (Part A), participants must have\n\n               1. histologically or cytologically confirmed diagnosis of metastatic and/or advanced\n                  solid tumor malignancy or lymphoma, for which no effective standard treatment is\n                  available. However, participants with primary brain tumors or WM will be\n                  excluded.\n\n               2. Radiographically or clinically measurable or nonmeasurable (but evaluable)\n                  disease. Radiographically measurable disease is determined by RECIST (version\n                  1.1) for solid tumors or by International Working Group (IWG) criteria for\n                  malignant lymphoma (2007 IWG).\n\n          3. To be enrolled to the dose expansion cohorts (Part B), participants must meet the\n             following criteria:\n\n               1. Diagnosis of CLL that meets International Workshop on Chronic Lymphocytic\n                  Leukemia (IWCLL) 2008 criteria for Cohort 1; pathologically confirmed diagnosis\n                  of DLBCL for Cohort 2; histologically confirmed diagnosis of B-cell NHL\n                  (follicular lymphoma [FL] [Grade 1, 2, or 3a], small lymphocytic lymphoma (SLL),\n                  lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM), marginal zone\n                  lymphoma (MZL) [splenic, nodal, or extra-nodal]) for Cohort 3; histologically\n                  confirmed diagnosis of MCL for Cohort 4; and histologically confirmed diagnosis\n                  of PTLD (early lesion, polymorphic, monomorphic, classical Hodgkin lymphoma-type,\n                  Epstein-Barr virus (EBV) -positive DLBCL of the elderly, DLBCL associated with\n                  chronic inflammation; along with documented or documentable Epstein-Barr\n                  virus-encoded small RNA (EBER) status by tissue in situ hybridization [ISH]) for\n                  Cohort 5; histologically confirmed DLBCL (de novo or transformed disease from\n                  iNHL) for Cohort 6.\n\n               2. Must have received greater than or equal to (>=) 1 prior therapy (excluding\n                  radiation); documented PD (MCL); either treatment naïve to, relapsed/refractory\n                  to, or treatment failure due to other reasons with ibrutinib, idelalisib, or any\n                  other investigational B-cell receptor (BCR) in pathway inhibitors not directly\n                  targeting Spleen tyrosine kinase (SYK); considered not appropriate for treatment\n                  or retreatment with purine analog-based therapy (CLL); or considered ineligible\n                  for at least 1 prior therapy (PTLD); or relapsed or refractory to >= 2 prior\n                  lines of chemotherapy (including standard first line therapy including Rituximab\n                  and an anthracycline [or equivalent if contraindicated] and one additional\n                  systemic multiagent chemotherapy as second-line salvage therapy that may have\n                  included autologous stem cell transplant (ASCT) [unless ineligible for salvage\n                  therapy and ASCT]) and should not have failed more than 4 prior lines of therapy\n                  (DLBCL Cohort 6).\n\n               3. Radiographically or clinically measurable and/or evaluable disease as specified\n                  in the protocol.\n\n          4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n\n          5. Participants must have adequate organ function, including bone marrow reserve,\n             hepatic, renal, pancreatic function and controlled blood pressure as described in the\n             protocol.\n\n          6. Female participants who are postmenopausal for at least 1 year, are surgically\n             sterile, or if of childbearing potential who agree to use 2 effective method(s) of\n             contraception during the study treatment period through 6 months after the last dose\n             of study drug or practice true abstinence.\n\n             Male participants, even if surgically sterilized, who agree to practice effective\n             barrier contraception during the study treatment period through 6 months after the\n             last dose of study drug or practice true abstinence.\n\n          7. Voluntary written consent must be given before performance of any study related\n             procedure not part of standard medical care, with the understanding that consent may\n             be withdrawn by the participant at any time without prejudice to future medical care.\n\n          8. Participants must have recovered from the reversible effects of prior anticancer\n             therapy (to Grade less than or equal to (<=) 1).\n\n        Exclusion Criteria:\n\n        Participants meeting any of the following exclusion criteria are not to be enrolled in the\n        study.\n\n          1. Participants with brain metastasis, or participants with central nervous system (CNS)\n             lymphoma or participants with another malignancy within two years of study start, with\n             exceptions as described in the protocol.\n\n          2. Any serious medical or psychiatric illness, including drug or alcohol abuse, that\n             could, in the investigator's opinion, potentially interfere with the completion of\n             treatment according to this protocol.\n\n          3. Life-threatening illness unrelated to cancer; major surgery within 14 days before the\n             first dose of study drug; systemic infection requiring intravenous (IV) antibiotic\n             therapy or other serious infection (bacterial, fungal, or viral) within 21 days before\n             the first dose of study drug.\n\n          4. Female participants who are pregnant or lactating.\n\n          5. Any immunotherapy, chemotherapy, radiotherapy, or investigational therapy within 3-4\n             weeks before the first dose of study treatment, as detailed in the protocol.\n\n          6. For escalation cohort or expansion cohorts excluding PTLD, ASCT within 6 months before\n             Day 1 of Cycle 1, or prior ASCT at any time without full hematopoietic recovery before\n             Day 1 of Cycle 1, or prior allogeneic stem cell transplant at any time.\n\n          7. Treatment with high dose corticosteroids (> daily dose equivalent to 10 milligram (mg)\n             oral prednisone) for anticancer purposes within 7 days before the first dose of\n             TAK-659.\n\n          8. Known human immunodeficiency virus (HIV) positive; known hepatitis B surface\n             antigen-positive; or known or suspected active hepatitis C infection (testing not\n             required).\n\n          9. Evidence of currently uncontrolled cardiovascular conditions as listed in the\n             protocol.\n\n         10. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral\n             absorption or tolerance of TAK-659 including difficulty swallowing tablets; diarrhea >\n             Grade 1 despite supportive therapy.\n\n         11. Lack of suitable venous access for required blood sampling.\n\n         12. Use or consumption of P-glycoprotein (P-gp) inducers/inhibitors and/or strong CYP3A\n             inducers/inhibitors as described in the protocol, and grapefruit-containing food or\n             beverages as described in the protocol.Xx_NEWLINE_xXParticipants with history of brain metastases or of leptomeningeal involvement should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse eventsXx_NEWLINE_xXInclusion Criteria:\n\n          -  Study Participants must be 18 years or older.\n\n          -  Study Participants must have 2 sites of cutaneous metastatic melanoma that can not be\n             removed with surgery.\n\n          -  Study Participants may have been previously treated with chemotherapy or immunotherapy\n             but not with in 4 weeks of first dose of study treatment.Xx_NEWLINE_xXParticipants must be currently participating in a PCI-32765 clinical study considered completed and have received at least 6 months of treatment with PCI-32765.Xx_NEWLINE_xXAt study entry, participants must be actively receiving treatment with single-agent PCI-32765 or participants must have participated in a PCI-32765 randomized clinical study in which they initially received comparator treatment and now cross-over to ibrutinib. Note: A minimum of 6 months requirement for prior PCI-32765 treatment will not be mandatory in this case and participants with less than 6 months will be required to have more frequent initial safety assessmentsXx_NEWLINE_xXInvestigator-determined radiographic disease progression per RECIST 1.1 after treatment with an EGFR TKI therapy: a) Participants previously treated with 1st or 2nd generation EGFR TKI (e.g. erlotinib/afatinib/gefitinib) are required to have confirmed documented absence of EGFR T790M mutation; b) Participants with confirmed acquired T790M mutation after 1st or 2nd generation EGFR TKI (e.g. erlotinib/afatinib/gefitinib) are required to have osimertinib TKI treatment failure prior to enrollment; c) Participants previously failed osimertinib TKI treatment as 1st line therapy are eligible regardless of their EGFR T790M mutation status.Xx_NEWLINE_xXParticipants must have a negative human immunodeficiency virus (HIV) antibody/antigen test and negative Chlamydia (C.) trachomatis/Neisseria (N.) gonorrhea nucleic acid amplification test (NAAT)Xx_NEWLINE_xXParticipants requiring the use of anti-tumor necrosis factor (anti-TNF) therapies, such as infliximab, or has received treatment with anti-TNF therapies within 5 half-lives of the drugXx_NEWLINE_xXParticipants with a history of cranial nerve palsyXx_NEWLINE_xXHistological confirmation of RCC with a clear-cell component, including participants who may also have sarcomatoid featuresXx_NEWLINE_xXInclusion Criteria:\n\n        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please\n        visit www.BMSStudyConnect.com\n\n          -  Children and adolescents diagnosed with either:\n\n          -  Diffuse Intrinsic Pontine Glioma (DIPG), in first-line, after completion of standard\n             radiotherapy\n\n          -  High Grade Glioma (HGG), recurrent or progressive\n\n          -  Medulloblastoma, recurrent or progressive\n\n          -  Ependymoma, recurrent or progressive\n\n          -  Other high-grade tumors of the central nervous system, recurrent or progressive\n\n          -  Lansky play score (LPS) for =< 16 years of age or Karnofsky performance scale (KPS)\n             for > 16 years of age assessed within two weeks of enrollment must be >= 60\n\n          -  A tumor sample must be available for submission to central laboratory [not required\n             for DIPG]\n\n        Exclusion Criteria:\n\n          -  Participants with active, known or suspected autoimmune disease\n\n          -  Participants unable to taper steroids due to ongoing mass effect\n\n          -  Participants with low-grade gliomas or tumors of unknown malignant potential\n\n          -  Prior treatment with any drug that targets T cell co-stimulation pathways (such as\n             checkpoint inhibitors)\n\n        Other protocol defined inclusion/exclusion criteria could applyXx_NEWLINE_xXHIV seropositive participants must be on antiretroviral therapy (ART) with the following criteria:\r\n* A complete ART regimen that does not include the study drug as one of a minimum of 3 active drugs, which may include an integrase inhibitor or efavirenz in combination with nucleoside reverse-transcriptase inhibitors (NRTIs)\r\n* The ART regimen must not include protease inhibitor (PIs); participants must not have received a PI-based regimen for at least 4 weeks prior to enrollment\r\n* Participants must either have an undetectable HIV plasma ribonucleic acid (RNA), or if plasma RNA detectable, must be on the same stable regimen for a minimum of 12 weeks prior to study enrollment\r\n* No minimum cluster of differentiation (CD)4 count, but maximum HIV plasma RNA of 1,000 copies/mLXx_NEWLINE_xXParticipants who have ever previously received any anti-neoplastic agent, including methotrexate, 6-mercaptopurine, 6-thioguanine, vincristine cyclophosphamide, cytarabine (except for IT cytarabine), or any anthracycline, for any reason (e.g., rheumatologic or autoimmune condition) are not eligibleXx_NEWLINE_xXParticipants must be able to adhere to the dosing and visit schedules, and agree to record medication times accurately and consistently in a daily diaryXx_NEWLINE_xXParticipants must undergo central pathology review to histologically confirm the diagnosis of glioblastoma or variants (1 unstained slide or 1 haematoxylin and eosin [H&E] slide must be submitted to and reviewed by a pathologist at the Dana Farber Cancer Institute [DFCI] Coordinating Center prior to enrollment of the participant for central pathology review); participants will not be eligible if the prior diagnosis was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants was made (e.g. secondary GBM)Xx_NEWLINE_xXParticipants with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of progressive disease based upon nuclear imaging, magnetic resonance (MR) spectroscopy, perfusion imaging or histopathologyXx_NEWLINE_xXParticipants who have received anti-VEGF targeted agents (e.g. bevacizumab, cediranib, aflibercept, vandetanib, XL184, sunitinib etc)Xx_NEWLINE_xXParticipants taking an enzyme-inducing anti-epileptic drug (EIAED): phenobarbital, phenytoin, fosphenytoin, primidone, carbamazepine, oxcarbazepine, eslicarbazepine, rufinamide, and felbamate; participants must be off any EIAEDs for at least 14 days prior to starting study drugXx_NEWLINE_xXSpecifically, for participants in Cohorts A1 and A2: Age greater than or equal to (>=) 18 years, disease progression or failure to achieve complete or partial response after intensive cytotoxic therapy, participants cannot have received more than two prior intensive regimens (e.g., induction + consolidation and one salvage therapy + consolidation)Xx_NEWLINE_xXSpecifically, for participants in Cohorts A3 and A4: Treatment naïve participants unfit for induction chemotherapy for AML as defined by the following: Age >= 70 or age 65 to 69 years with at least one of the following: ECOG performance status of 2, Intermediate I/II or adverse risk cytogenetic and molecular alterations per ELN 2010 guidelines or secondary AML, or other comorbidity judged incompatible with intensive chemotherapyXx_NEWLINE_xXIn Cohorts A3 and A4 only, participants with AML eligible for standard intensive induction therapy with an anthracycline and cytarabineXx_NEWLINE_xXParticipants who have received prior chest radiation are excludedXx_NEWLINE_xXDiagnosis of MDS (participants with therapy-related MDS are eligible)Xx_NEWLINE_xXParticipants with a history of allergic reactions attributed to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)Xx_NEWLINE_xXParticipants unwilling or unable to discontinue use of prohibited therapies, including any cytotoxic chemotherapy, radiotherapy, immunotherapy or biologic agent (approved or investigational) for the treatment of TCC are ineligibleXx_NEWLINE_xXParticipants who weigh > 110 kg will be ineligible due to study drug limitationsXx_NEWLINE_xXParticipants are allowed to receive, but are not required to receive, biologic/targeted (noncytotoxic) therapy as part of their primary treatment regimenXx_NEWLINE_xXParticipants must be able and willing to follow protocol instructions and schedulesXx_NEWLINE_xXParticipants may have received prior treatment with weekly paclitaxel; however, participants who have had progression on or within 8 weeks of their last dose of weekly paclitaxel will not be eligibleXx_NEWLINE_xXADDITIONAL CRITERIA FOR COHORTS 1A AND 1B PARTICIPANTS ONLY: No corticosteroid dosing within 5 days of study therapy initiationXx_NEWLINE_xXADDITIONAL CRITERIA FOR COHORTS 1A AND 1B PARTICIPANTS ONLY: Cohort 1a: MGMT promoter unmethylatedXx_NEWLINE_xXParticipants who have received or plan to receive any additional treatment for glioblastoma aside from surgical resection and conventional radiotherapy (cohort 1), pembrolizumab (cohorts 1a and 1b) and temozolomide (cohort 1b) including but not limited to temozolomide (cohort 1 & 1a participants), stereotactic radiosurgery, placement of Gliadel (carmustine; BCNU) wafers, any other intratumoral or intracavitary treatment, brachytherapy, novo-tumor treating fields (Optune), or investigational therapeutic agentsXx_NEWLINE_xXCOHORT 1A & 1B PARTICIPANTS ONLY:Xx_NEWLINE_xXParticipants who have received any chemotherapy or radiotherapy for previous malignancy are not eligible; participants who have ever previously received any anti-neoplastic agent, including methotrexate, 6-mercaptopurine, 6-thioguanine, vincristine cyclophosphamide, cytarabine (except for IT cytarabine), or any anthracycline, for any reason (e.g., rheumatologic or autoimmune condition) are not eligibleXx_NEWLINE_xXParticipants may or may not be receiving hormonal therapy at the time of study entryXx_NEWLINE_xXParticipants with known or suspected allergies to any component of the vaccineXx_NEWLINE_xXParticipants may not have been vaccinated previously with any of the synthetic peptides included in this protocolXx_NEWLINE_xXFor the purpose of obtaining a RECIST v1.1 baseline scan, participants must have a\n             radiological evaluation conducted no more than 28 days prior to beginning study\n             therapy (PLD).  NOTE: For participants with a history of CNS metastasis, baseline\n             radiological imaging must include an evaluation of the head.Xx_NEWLINE_xXParticipants must have had prior debulking surgery.Xx_NEWLINE_xXParticipants are allowed to have received, but are not required to have received, one\n             additional non-cytotoxic antitumor agent (eg, biologic or cytostatic) for the\n             management of ovarian cancer.Xx_NEWLINE_xXParticipants must have recovered (to baseline/stabilization) from prior cytotoxic\n             therapy-associated acute toxicities.Xx_NEWLINE_xXParticipants must have adequate organ function including:\n\n               1. Bone Marrow Reserve:\n\n                    1. Absolute neutrophil count (ANC) ? 1.5x10^9/L prior to treatment.\n                       Participants on maintenance doses of granulocyte colony stimulating factor\n                       (G-CSF) are eligible.\n\n                    2. Platelets ? 100x10^9/L\n\n                    3. Hemoglobin ? 9 g/dL\n\n                    4. Use of supportive care measures (eg, use of white blood cell [WBC] growth\n                       factors, antiemetics, epoetin) should follow the ASCO guidelines as listed\n                       at www.asco.org.  Participants should receive full supportive care,\n                       including transfusion of blood as mandated by clinical need; however,\n                       transfusions administered for the sole purpose of meeting the study\n                       inclusion criteria between the time informed consent is signed and first\n                       dose of EC145/placebo/PLD is administered are not allowed.\n\n               2. Hepatic: Total bilirubin level < 1.5 x ULN and ALT, AST, GGT, and alkaline\n                  phosphatase levels < 2.5 x ULN.\n\n               3. Renal: Serum creatinine level ? 1.5 x ULN or for participants with serum\n                  creatinine levels above 1.5 x ULN, creatinine clearance ? 50 mL/min/1.73m^2\n\n               4. Cardiac: Left ventricular ejection fraction (LVEF) equal to or greater than the\n                  institutional lower limit of normal.Xx_NEWLINE_xXParticipants who are receiving any other study or off protocol anti-cancer agentsXx_NEWLINE_xXParticipants must have tumors with anticipated transurethral resection time =< 1 hourXx_NEWLINE_xXFor stage 2 GBM participants, no prior treatment with bevacizumab/vascular endothelial growth factor receptor (VEGFR) inhibitors; prior treatment with bevacizumab/VEGFR inhibitors is allowed in stage 1 for all participants, as well as stage 2 endometrial and ovarian cancer participantsXx_NEWLINE_xXStudy participants with a history of prior treatment with BRAF or MEK inhibitorsXx_NEWLINE_xXParticipants must be hepatitis C negative =< 6 months prior to screeningXx_NEWLINE_xXParticipants on an antiretroviral regimen should be receiving treatment that is in accordance with the current International acquired immune deficiency syndrome (AIDS) Society guidelines; the specific agents are at the discretion of the investigator and use of agents currently available on an expanded access basis is allowed but use of experimental antiretroviral agents or those containing zidovudine (including Combivir and Trizivir) are prohibited; changes to highly active anti-retroviral therapy (HAART) therapy may be made if medically necessary (toxicity, failure of regimen, etc.); antiretroviral naïve participants: participants who are not on HAART at study entry MUST begin therapy (utilizing the above guidelines) AFTER one cycle of chemotherapy has been completed under protocol; changes to HAART therapy may be made if medically necessary (toxicity, failure of regimen, etc.); concurrent therapy with zidovudine or a zidovudine-containing regimen (including Combivir and Trizivir) will be prohibited until 2 months following the participant’s completion of chemotherapy as part of this protocol; the use of cobicistat (e.g., Tybost), or cobicistat containing single tablet regimens (e.g., Stribild) is prohibited during concurrent chemotherapy under this protocol; participants taking cobicistat or cobicistat-containing single table regimens must switch to a different agent or regimen prior to enrollment, and will remain on the regimen until at least 2 months following treatment discontinuation; Cobicistat is a pure and potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitor and has the potential to increase the area under the curve (AUC) of CYP3A4 substrates; therefore, both vincristine and doxorubicin would have the potential for drug drug interaction (DDI) with cobicistat since they are CYP3A4 substratesXx_NEWLINE_xXParticipants who have received more than one (1) prior cycle of chemotherapy similar to cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (CHOP) or EPOCH with or without rituximabXx_NEWLINE_xXRituximab therapy within the 12 months prior to study entry; participants treated with rituximab within 12 months prior to study registration are eligible only if it was given for indications other than the treatment of aggressive lymphomaXx_NEWLINE_xXParticipants who undergo primary cytoreductive surgery must be entered between 1 and 12 weeks after surgery. Participants undergoing interval surgery must have a tumor sample confirming the histological diagnosis prior to enrollment.Xx_NEWLINE_xXParticipants must have V20 (volume of lung to receive 20 Gy radiotherapy according to simulation) < 35%.Xx_NEWLINE_xXParticipants with prior chemotherapy or radiotherapy (RT) for current NSCLC. Participants curatively treated for past early stage NSCLC greater than 3 years ago may be included.Xx_NEWLINE_xXParticipants with prior exposure to poly-ADP-ribose polymerase (PARP) inhibitors.Xx_NEWLINE_xXParticipants with chronic infection by Hepatitis C Virus (HCV) who are treated (successfully or treatment failure) or untreated are allowed on study. In addition, participants with successful HCV treatment are allowed as long as there are >4 weeks between achieving sustained viral response (SVR12) and start of study drug.Xx_NEWLINE_xXParticipants must have shown unequivocal evidence of tumor progression.Xx_NEWLINE_xXFemale participants of childbearing potential must have 2 negative urine pregnancy tests (with a sensitivity of at least 25 Milli-international units/Milliliter) within 10 to 14 days and within 24 hours prior to receiving study medication.Xx_NEWLINE_xXAll Participants:Xx_NEWLINE_xXParticipants who plan to proceed with ASCT as part of first line therapyXx_NEWLINE_xXParticipants who are newly diagnosed and not considered for high-dose chemotherapy due to: being age >=65 years; or participants less than (<) 65 years with presence of important comorbid condition(s) likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation. Sponsor review and approval of participants below 65 years of age is required before randomizationXx_NEWLINE_xXParticipants with known or suspected COPD must have a FEV1 test during ScreeningXx_NEWLINE_xXParticipants in Stage 1 (Safety Evaluation) receiving erlotinib: No limit to the number of prior therapies (except for EGFR TKIs).Xx_NEWLINE_xXFor participants receiving erlotinib group: prior treatment with any EGFR mutant-targeting TKIXx_NEWLINE_xXParticipants who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication are elgible for study after discussion and approval by the Medical Monitor.Xx_NEWLINE_xXParticipants with paraspinal, paratracheal and mediastinal pathologic lesions larger than 2 centimeters unless they are previously irradiatedXx_NEWLINE_xXParticipants requiring any daily supplemental oxygenXx_NEWLINE_xXParticipants on bisphosphonates or receptor activator of nuclear factor kappa B (RANK) ligand inhibitors may continue receiving therapy during study treatmentXx_NEWLINE_xXFor female participants of childbearing potential and male participants, willingness to use acceptable methods of contraceptionXx_NEWLINE_xXT-ALL or T-LBL participants with relapsed/refractory disease.Xx_NEWLINE_xXInclusion Criteria:\n\n        All Treatment Arms:\n\n          1. Male or female participants 18 years or older.\n\n          2. Participants who, in the opinion of the treating physician, have failed standard\n             therapies and for whom a phase 1 trial is an appropriate option.\n\n          3. Radiographically or clinically evaluable tumor. For expansion phase: Tumors must be\n             measurable and of the protocol specified genetic mutational status, where applicable.\n\n          4. Recovered (ie, less than or equal to [<=] Grade 1 toxicity) from adverse effects\n             (except alopecia) of prior therapy.\n\n          5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n\n          6. Expected survival time of at least 3 months in the opinion of the investigator.\n\n          7. Block of banked tumor tissue and/or greater than or equal to (>=) 10 unstained slides.\n             Participants who satisfy all other eligibility criteria but do not have banked\n             tissue/slides may be asked to consent to baseline biopsy.\n\n          8. Suitable vein access for the study-required blood sampling.\n\n          9. Thyroid function tests consistent with stable thyroid function. Note: Participants on\n             a stable dose of thyroid replacement therapy for a suggested minimum of 12 weeks\n             before Cycle 1, Day 1 are eligible.\n\n         10. Left ventricular ejection fraction (LVEF) of 50 percent (%) or greater, as measured by\n             echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA), within 28 days before\n             the first dose of MLN2480\n\n         11. Female participants who are post menopausal for at least 1 year, surgically sterile,\n             or agree to practice 2 effective methods of contraception through 120 days (4 months)\n             after the last dose of study drug for participants in Arms 1, 2, and 5, and through 6\n             months for participants in Arms 3 and 4, or agree to practice true abstinence.\n\n         12. Male participants who, even if surgically sterilized, agree to practice effective\n             barrier contraception through 120 days (4 months) after the last dose of study drug\n             for participants in Arms 1, 2, and 5, and through 6 months for participants in Arms 3,\n             and 4, or agree to practice true abstinence.\n\n         13. Additional inclusion criteria for arm 3 expansion only (MLN2480 + paclitaxel):\n\n             a. Participants with KRAS exon 2 or BRAF non-V600 mutation-positive non small cell\n             lung cancer (NSCLC) who have received a minimum of 1 but not more than 2 prior\n             cytotoxic-approved regimens.\n\n         14. Additional inclusion criteria for arms 4 and 5 expansion only (MLN2480 + cetuximab;\n             MLN2480 + irinotecan):\n\n               1. Participants with CRC who have received a minimum of 1 but not more than 2 prior\n                  cytotoxic-approved regimens.\n\n        Exclusion Criteria:\n\n        All treatment arms:\n\n          1. Female participants who are pregnant or currently breastfeeding.\n\n          2. History of any serious medical or psychiatric illness that could, in the\n             investigator's opinion, potentially interfere with safe protocol completion.\n\n          3. History of uncontrolled brain metastasis unless: previously treated with surgery,\n             whole-brain radiation, or stereotactic radiosurgery; stable disease for >= 60 days\n             without steroid use (or stable steroid dose established for >= 28 days before the\n             first dose of MLN2480).\n\n          4. Ongoing seizure disorder or a requirement for antieplieptics.\n\n          5. Recent prior therapies, including: chemotherapy and hormonal therapy <= 4 weeks or 4\n             half lives, whichever occurs first, before administration of study drug;\n             immunotherapy/monoclonal antibody use <= 4 weeks before administration of MLN2480; or\n             radiation therapy <= 3 weeks before administration of study drug.\n\n          6. Chronic therapeutic corticosteroid use with the exception of replacement therapy for\n             adrenal insufficiency or corticosteroid inhalers.\n\n          7. Known history of human immunodeficiency virus infection, hepatitis B, or hepatitis C;\n             Prior allogeneic bone marrow or organ transplantation, or active condition of chronic\n             immune suppression is not allowed.\n\n          8. Concomitant use, or administration <= 14 days before first dose of study drug(s), of\n             clinically significant enzyme inducers.\n\n          9. Treatment with gemfibrozil (strong Cytochrome P4502C8 [CYP2C8] inhibitor) within 14\n             days before the first dose of MLN2480.\n\n         10. History of or current illicit drug use, drug abuse, or alcohol abuse.\n\n         11. Major surgery within 14 days before the first dose of study drug.\n\n         12. Inability to comply with study requirements.\n\n         13. Other unspecified reasons that, in the opinion of the investigator or Millennium, make\n             the participant unsuitable for enrollment.\n\n         14. Additional exclusion criteria for arms 3, 5, and 6 expansion only (MLN2480 +\n             paclitaxel; MLN2480 + irinotecan; MLN2480 monotherapy):\n\n             a. Prior treatment with rapidly accelerated fibrosarcoma (RAF), extracellular\n             signal-regulated kinases (MEK), or other inhibitors of the mitogen-activated protein\n             kinase (MAPK) pathway.\n\n         15. Additional exclusion criteria for arm 2 only (MLN2480 + alisertib):\n\n             a. History of uncontrolled sleep apnea syndrome and other conditions that could result\n             in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease.\n\n         16. Additional exclusion criteria for arm 3 only (MLN2480 + paclitaxel):\n\n             a. Known hypersensitivity to paclitaxel or its components or other drugs formulated in\n             Cremophor® EL (polyoxyethylated castor oil).\n\n         17. Additional exclusion criteria for arm 5 only (MLN2480 + irinotecan):\n\n               1. Use of strong or moderate Cytochrome P4503A (CYP3A) inhibitors <= days of the\n                  first dose of irinotecan.Xx_NEWLINE_xXParticipants no longer need to be able to receive intravenous (IV) dexamethasone or an equivalent IV corticosteroidXx_NEWLINE_xXHave a known BRCA 1/2 mutation status (for participants who do not have a known BRCA 1/2 status at screening, a blood sample will be collected to determine the status with the results available prior to randomizationXx_NEWLINE_xXParticipants unwilling or unable to have a central venous catheter placed will not be excluded from receiving single-agent DoxilXx_NEWLINE_xXParticipants previously treated in the recurrent/metastatic setting with any 1 of the 3 SOC therapies in this study (i.e., docetaxel, capecitabine, or gemcitabine) may not receive the same therapy if randomized to the SOC arm. Additionally, participants previously treated in the recurrent/metastatic setting with all 3 SOC therapies are excluded from this study.Xx_NEWLINE_xXParticipants with history of confirmed progressive multifocal leukoencephalopathy (PML)Xx_NEWLINE_xXInclusion Criteria:\n\n          -  Histologically or cytologically documented locally advanced or metastatic solid tumors\n             meeting the following study drug-specific criteria:\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n\n          -  Life expectancy greater than or equal to (>/=) 12 weeks\n\n          -  Measurable disease, as defined by RECIST v1.1\n\n          -  Adequate hematologic and end organ function as confirmed by laboratory results within\n             14 days prior to the first study treatment\n\n        Inclusion criteria specific to Arm A: Atezolizumab+ Ipilimumab\n\n          -  Escalation stage: NSCLC participants\n\n          -  Mandatory biopsy cohort: NSCLC or melanoma atezolizumab\n\n          -  Prior atezolizumab-treated cohort: participants with NSCLC or melanoma previously\n             treated with atezolizumab\n\n        Inclusion criteria specific to Arm B: Atezolizumab+ Interferon alfa-2b\n\n          -  Escalation stage: RCC or melanoma participants\n\n          -  Expansion stage: RCC or melanoma participants\n\n          -  Mandatory biopsy cohort: RCC or melanoma participants\n\n          -  Prior immunotherapy-treated cohort: participants with RCC, NSCLC, or melanoma\n             previously treated with programmed death-ligand 1 (PD-L1)/ Programmed death 1 (PD-1)\n\n        Inclusion Criteria Specific to Arm C (Atezolizumab plus PEG-Interferon Alafa-2a):\n\n          -  Cohort 1: participants with RCC\n\n          -  Cohort 2: participants who were previously treated with anti-PD-L1/PD-1 with locally\n             advanced or metastatic solid tumor (e.g., NSCLC, RCC, or melanoma)\n\n        Inclusion Criteria Specific to Arm D (Atezolizumab plus PEG?Interferon Alfa-2a\n        +Bevacizumab)\n\n          -  Cohort 1: participants with metastatic RCC with no prior line of systemic therapy for\n             metastatic disease\n\n          -  Cohorts 2-3: disease progression during or after at least one previous systemic,\n             anti-cancer treatment for locally advanced or metastatic solid tumors; participants\n             with sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic\n             lymphoma kinase (ALK) rearrangements must have failed or are intolerant to prior\n             treatment with EGFR or ALK inhibitors; participants with melanoma with actionable BRAF\n             mutations (e.g., V600) must have failed or are intolerant to prior treatment with BRAF\n             inhibitors\n\n        Inclusion Criteria Specific to Arm E (Atezolizumab +Obinutuzumab)\n\n        - R/M HNSCC participants with at least one prior line of systemic therapy\n\n        Inclusion Criteria Specific to prior Anti?PD-L1/PD-1 Treated Cohorts:\n\n          -  No permanent discontinuation of atezolizumab or other immunotherapies due to a\n             treatment-related adverse event\n\n          -  Recovery from all immunotherapy-related adverse events to Grade less than or equal to\n             (?) 1 or baseline at the time of consent\n\n        Exclusion Criteria:\n\n        General Medical Exclusions:\n\n          -  Pregnant and lactating women\n\n          -  Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3\n             weeks prior to initiation of study treatment, with the following exception: (1)\n             hormone-replacement therapy or oral contraceptives; (2) tyrosine kinase inhibitors\n             (TKIs) that have been discontinued greater than (>) 7 days prior to Cycle 1, Day 1,\n             baseline scans must be obtained after discontinuation of prior TKIs\n\n          -  Investigational therapy within 28 days prior to initiation of study treatment\n\n          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to\n             chimeric or humanized antibodies or fusion proteins\n\n          -  Known hypersensitivity or allergy to Chinese hamster ovary cell products or any\n             component of the atezolizumab formulation\n\n          -  History of or active autoimmune disease\n\n          -  History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced\n             pneumonitis, organizing pneumonia, risk of pulmonary toxicity, or evidence of active\n             pneumonitis on screening chest computed tomography (CT) scan\n\n          -  Prior allogeneic bone marrow transplantation or prior solid organ transplantation\n\n          -  History of human immunodeficiency virus (HIV)\n\n          -  Participants with active hepatitis B\n\n          -  Participants with active hepatitis C\n\n          -  Participants with active tuberculosis\n\n          -  Participants with a history of confirmed progressive multifocal leukoencephalopathy\n\n          -  Any serious medical condition, physical examination finding, or abnormality in\n             clinical laboratory tests that, in the investigator's judgment, precludes the\n             participant's safe participation in and completion of the study\n\n        Cancer-Specific Exclusions:\n\n          -  Active or untreated central nervous system (CNS) metastases, as determined by CT or\n             magnetic resonance imaging (MRI) evaluation during screening and prior radiographic\n             assessments\n\n          -  Spinal cord compression not definitively treated with surgery and/or radiation or\n             previously diagnosed and treated spinal cord compression without evidence that disease\n             has been clinically stable for >/= 2 weeks prior to screening\n\n          -  Leptomeningeal disease\n\n          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent\n             drainage procedures (once monthly or more frequently); participants with indwelling\n             catheters are allowed.\n\n          -  Uncontrolled tumor-related pain\n\n          -  Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of\n             bisphosphonate therapy or denosumab\n\n          -  History of other malignancy within 2 years prior to screening, except for\n             appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma,\n             Stage I uterine cancer, localized prostate cancer treated with curative intent, ductal\n             carcinoma in situ treated surgically with curative intent, or other cancers with a\n             similar outcome\n\n        Exclusion Criteria Related to Medications:\n\n          -  Prior treatment with cluster of differentiation 137 (CD137) agonists or immune\n             checkpoint blockade therapies (Note: Participants enrolled in the prior\n             anti?PD-L1/PD-1 treated cohorts with melanoma may have received prior anti-cytotoxic\n             T-lymphocyte-associated protein 4 treatment or other immunotherapies)\n\n          -  Treatment with systemic immunostimulatory agents within four weeks or five half-lives\n             of the drug, whichever is shorter, prior to Cycle 1, Day 1\n\n          -  Treatment with systemic immunosuppressive medications within 2 weeks prior to Cycle 1,\n             Day 1 (the use of inhaled corticosteroids and mineralocorticoids is allowed)\n\n        Exclusion Criteria Specific to Interferon Alpha Therapy (Arms B?D):\n\n          -  History of depression, suicidal ideation or behavior, bipolar disorder, or psychosis\n\n          -  Hypersensitivity to interferon alpha or any component of the product\n\n        Exclusion Criteria Specific to Bevacizumab (Arm D)\n\n          -  Inadequately controlled hypertension\n\n          -  Prior history of hypertensive crisis or hypertensive encephalopathy\n\n          -  Significant vascular disease within 6 months prior to Day 1\n\n          -  History of hemoptysis\n\n          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of\n             therapeutic anticoagulation)\n\n          -  History of tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal\n             abscess within 6 months prior to Day 1\n\n          -  Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine\n             parenteral hydration, parenteral nutrition, or tube feeding\n\n          -  Evidence of abdominal free air that is not explained by paracentesis or recent\n             surgical procedure\n\n          -  Proteinuria, as demonstrated by urine dipstick or > 1.0 gram of protein in a 24-hour\n             urine collection\n\n          -  Metastatic disease that involves major airways or blood vessels, or centrally located\n             mediastinal tumor masses of large volume\n\n        Exclusion Criteria Specific Obinutuzumab (Arm E)\n\n          -  Hypersensitivity to obinutuzumab\n\n          -  Prior treatment with obinutuzumabXx_NEWLINE_xXFor Part B: All participants must have a histological evidence of their advanced or metastatic cancer and prescreened alterations in a defined pathway.Xx_NEWLINE_xXFor Part C: All participants must have histological evidence of advanced or metastatic specific subtypes of soft tissue sarcoma.Xx_NEWLINE_xXFor Part D: All participants must have histological evidence of advanced or metastatic cancer and prescreened alterations in a defined pathway.Xx_NEWLINE_xXCohort 2: Participants must have hepatocellular carcinoma (HCC). These participants should have Child-Pugh stage A.Xx_NEWLINE_xXCohort 3: Participants must have cholangiocarcinoma.Xx_NEWLINE_xXCohort 5: Participants must have a mature T cell, B cell, or natural killer (NK) cell neoplasm.Xx_NEWLINE_xXFor Part E: Participants must have adenoid cystic carcinoma (ACC).Xx_NEWLINE_xXFor Part F dose confirmation: Participants must have leiomyosarcoma and prescreened alterations in a defined pathway.Xx_NEWLINE_xXParticipants with HCC that:Xx_NEWLINE_xXEligibility for autologous SCT (participants with r/r DLBCL)Xx_NEWLINE_xXParticipants who are 16 to 17 years old would be enrolled after consultation with the Medical MonitorXx_NEWLINE_xXMeasurable disease per RECIST v1.1 for participants with solid malignancies. Disease-specific criteria for participants with prostate cancer, glioblastoma multiforme (GBM), malignant lymphoma, or multiple myelomaXx_NEWLINE_xXHave a histologically confirmed diagnosis of STS for which olaratumab and doxorubicin would be appropriate therapy. Participants with a diagnosis of Grade 1 liposarcoma are eligible if there is histological or radiographic evidence of evolution to more aggressive disease. Participants with Kaposi's sarcoma and gastrointestinal stromal tumors (GIST) will be excluded. Participants must have potentially resectable disease (as assessed by the study investigator) and have a primary tumor lesion deemed amenable to serial biopsy.Xx_NEWLINE_xXParticipants for whom endocrine therapy (example [e.g.], fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the studyXx_NEWLINE_xXParticipants with any programmed death-ligand 1 (PD-L1) test result by immunohistochemistry (IHC) are eligible for the studyXx_NEWLINE_xXParticipants requiring daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI within 7 days before receiving the first dose of study drug.Xx_NEWLINE_xXHas had encephalopathy in the last 6 months. Participants on rifaximin or lactulose to control their encephalopathy are not allowedXx_NEWLINE_xXParticipants with diagnosis of HCC.Xx_NEWLINE_xXImmunocompromised participants, including participants known to be infected with human immunodeficiency virus (HIV).Xx_NEWLINE_xXFor MDS and CMML participants, prognostic risk category, based on the Revised International Prognostic Scoring System (IPSS R), of:Xx_NEWLINE_xXFor CMML participants: WBC count <20,000/mcL before administration of the first dose of study drug on Cycle 1 Day 1; participants must have been off hydroxyurea for at least 1 week prior to WBC count assessment.Xx_NEWLINE_xXFemale participants who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s).Xx_NEWLINE_xXMale participants who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s).Xx_NEWLINE_xXFor participants enrolled in the expansion phase: lymphoma classified as either previously untreated Grade 1, 2, or 3a FL that requires treatment or previously untreated advanced DLBCLXx_NEWLINE_xXFor participants with DLBCL: preplanned consolidative radiotherapyXx_NEWLINE_xXParticipants requiring anti-diabetic medications must be on a stable dose and regimen for >=4 weeksXx_NEWLINE_xXParticipants with adenocarcinoma of the esophagus are excluded.Xx_NEWLINE_xXParticipants receiving chronic therapy with nonsteroidal anti-inflammatory agents.Xx_NEWLINE_xXParticipants with intracardiac defibrillators.Xx_NEWLINE_xXParticipants receiving daily treatment with aspirin >325mg/day or other known inhibitors of platelet function.Xx_NEWLINE_xXParticipants with baseline QTc greater than (>) 470 milliseconds or symptomatic bradycardiaXx_NEWLINE_xXRecipient of any drug with potential QT interval prolonging effects within 14 days prior to the first dose for all participants and while on treatment through the end of the study for crizotinib-treated participants onlyXx_NEWLINE_xXParticipants must have never received previous R-CHOP treatmentXx_NEWLINE_xXAny relapsed/refractory participants that are enrolled during the dose escalation should have received only a single previous treatment regimen Expansion Portion of the Study:Xx_NEWLINE_xXParticipants must have agreed to and signed an authorization for the release of their protected health informationXx_NEWLINE_xXFor arms A and B, participants must have relapsed after or been refractory to first-line chemotherapy, i.e., they must have failed to achieve CR after first-line therapy or must have relapsed subsequently if they achieved CR; for arm C, participants will be eligible if transplant is performed as consolidation of first remission (partial or complete)Xx_NEWLINE_xXParticipants must be planning to receive or have received autologous stem cell transplantation; participants may enroll prior to ASCT, but will not be eligible to begin treatment until after ASCT, and must fulfill all inclusion and exclusion criteria at that time; ASCT will be performed according to institutional standards and is not a part of this studyXx_NEWLINE_xXParticipants must have chemosensitive disease prior to ASCT, defined as achieving at least a partial remission (as determined with PET imaging) to salvage treatment using International Harmonization Project (IHP) criteria; participants with cHL or DLBCL (arms A and B) transplanted in first (1st) remission after only one line of treatment are not eligible; participants with PTCL (arm C) transplanted beyond 1st remission are also not eligibleXx_NEWLINE_xXParticipants must begin study treatment no later than 21 days from the post-ASCT discharge; additionally, they must have recovered from ASCT toxicities at the time of first study treatment; recovery from ASCT toxicity is defined using the eligibility criteria in this section, as well as outpatient status, ability to drink and eat normally, without the need for intravenous hydration; participants must be no later than 60 days from stem cell reinfusion; exceptions to these time frames may be made in discussion with the overall principal investigator (PI) and will not constitute study violationsXx_NEWLINE_xXParticipants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1Xx_NEWLINE_xXParticipants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over. If not clinically feasible, discussion with Sponsor is requiredXx_NEWLINE_xXParticipants who have received prior bevacizumab are eligible unless there is evidence of unacceptable toxicity due to prior bevacizumab exposureXx_NEWLINE_xXParticipants must have stopped any hormonal therapy at least 1 week prior to treatment with nivolumab and bevacizumab; participants may continue on hormone replacement therapy administered for post-menopausal symptomsXx_NEWLINE_xXParticipants must agree not to use natural herbal products or other “folk remedies” while participating in this studyXx_NEWLINE_xXInclusion Criteria:\n\n        Disease-specific inclusion criteria:\n\n          -  Histologically confirmed adenocarcinoma originating from the colon or rectum (Stage 4\n             American Joint Committee on Cancer [AJCC] 7th edition)\n\n          -  Experienced disease progression or was intolerant to at least two systemic\n             chemotherapy regimens for metastatic colorectal cancer that must have included\n             fluroropyrimidines, irinotecan, and oxaliplatin; adjuvant regimen can be considered as\n             one chemotherapy regimen for metastatic disease if the participant had disease\n             recurrence within 6 months of completion; disease progression must have occurred\n             within 3 months of the last systemic therapy administration\n\n        General inclusion criteria:\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Anticipated life expectancy greater than or equal to (>=) 3 months\n\n          -  Adequate hematologic and end organ function\n\n          -  Women of childbearing potential must agree to appropriately use an effective form of\n             contraception (failure rate of less than [<] 1 percent [%] per year) during the\n             treatment period, within 5 months after the last dose of atezolizumab, and within 3\n             months after the last dose of cobimetinib and regorafenib\n\n          -  Men must agree not to donate sperm or have intercourse with a female partner without\n             using appropriate barrier contraception during the treatment period and for 3 months\n             after the last dose of either cobimetinib or regorafenib\n\n          -  Provide an archival or newly obtained tumor tissue sample\n\n        Exclusion Criteria:\n\n          -  After the approximate 5% cap for microsatellite (MSI)-high participants is reached,\n             only MSI-stable participants will be eligible\n\n          -  Once the 50% cap for wild-type RAS has been reached, only extended RAS-mutant\n             participants will be eligible\n\n          -  Major surgery or radiotherapy within 21 days prior to Cycle 1 Day 1 or anticipation of\n             needing such procedure while receiving study treatment\n\n          -  Treatment with any anti-cancer agent within 14 days prior to Cycle 1 Day 1\n\n          -  Uncontrolled tumor-related pain. Participants requiring narcotic pain medication must\n             be on a stable regimen at study entry\n\n          -  Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated\n             drainage more than once every 28 days. Indwelling drainage catheters (e.g., PleurX®)\n             are allowed\n\n          -  Active or untreated central nervous system (CNS) metastases are excluded\n\n          -  Prior therapy with any cancer immunotherapy, MEK inhibitor, or regorafenib\n\n          -  Participants with active malignancy (other than CRC) or a prior malignancy within the\n             past 3 years are excluded. Participants with completely resected cutaneous melanoma\n             (early stage), basal cell carcinoma, cutaneous squamous cell carcinoma, cervical\n             carcinoma in-situ, breast carcinoma in-situ, and localized prostate cancer are\n             eligible\n\n          -  Unstable angina, new onset angina within last 3 months, myocardial infarction within\n             last 6 months and current congestive heart failure New York Heart Association Class II\n             or higher\n\n          -  Left ventricular ejection fraction (LVEF) below institutional lower limit of normal or\n             below 50%, whichever is lower\n\n          -  Poorly controlled hypertension, defined as a blood pressure consistently above 150/90\n             millimeters of Mercury (mmHg) despite optimal medical management\n\n          -  Human immunodeficiency virus (HIV) infection\n\n          -  Active tuberculosis infection\n\n          -  Severe infections within 2 weeks prior to Cycle 1 Day 1\n\n          -  Active or chronic viral hepatitis B or C infection\n\n          -  History of or evidence of retinal pathology on ophthalmologic examination that is\n             considered a risk factor for central serous retinopathy, retinal vein occlusion, or\n             neovascular macular degeneration\n\n          -  Participants will be excluded if they currently have any of the risk factors as\n             defined in the study protocol for retinal vein occlusion\n\n          -  History of autoimmune disease\n\n          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, bronchiolitis\n             obliterans, drug-induced pneumonitis, or idiopathic pneumonitis\n\n          -  History of organ transplantation including allogeneic bone marrow transplantation\n\n          -  Inability to swallow medications\n\n          -  Malabsorption condition that would alter the absorption of orally administered\n             medications\n\n          -  Pregnant, lactating, breastfeeding, or intending to become pregnant during the study\n\n          -  Administration of a live, attenuated vaccine within 4 weeks before randomization or\n             anticipation of a live attenuated vaccine will be required during the studyXx_NEWLINE_xXFor the ibrutinib arm only: participants must not currently require ongoing anticoagulation for any reason, or have had any major bleeding events within 6 months of enrollmentXx_NEWLINE_xXParticipants with a history of poor tolerance to either ibrutinib or idelalisib should not be enrolled on the arm containing that drug, but may be enrolled to the other arm; must agree not to share study medication with another personXx_NEWLINE_xXAML participants must have the following malignancy criteria: measurable and evaluable disease per tumor response criteria; ? 5% bone marrow blasts without alternate causality; and > 90 days since allogeneic stem cell transplantation relapse in participants relapsing after transplantXx_NEWLINE_xXParticipants for whom endocrine therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the studyXx_NEWLINE_xXHistologically confirmed diagnosis of advanced unresectable or metastatic soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy. Participants with Kaposi's sarcoma and gastrointestinal stromal tumors (GIST) will be excluded. Note: Evidence of disease progression is required for participants that are not newly diagnosed.Xx_NEWLINE_xXHER-2/neu status known and participants with HER2/neu positive tumors show documentation of disease progression on treatment containing trastuzumabXx_NEWLINE_xXParticipants may not have had any prior history of hypertensive crisis or hypertensive encephalopathyXx_NEWLINE_xXParticipants may not have current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months prior to starting study drugsXx_NEWLINE_xXParticipants may not have a dependency on intravenous (IV) hydration or total parenteral nutrition (TPN)Xx_NEWLINE_xXWilling to use acceptable contraceptive measures as defined by the protocol during and at least for 6 months (male participants) or 12 months (female participants) after the last dose of study drugXx_NEWLINE_xXParticipants with new immunosuppressive medication, extra-corporeal photopheresis or rituximab therapy initiated in the 4 weeks priorXx_NEWLINE_xXPatient is currently using herbal preparations or medications; participants should stop using herbal medications 7 days prior to the first dose of the study drugXx_NEWLINE_xXParticipants may not be receiving any other investigational agents for 30 days prior to baseline evaluation and during the study intervention (which will be captured on the Concomitant Medications CRFs)Xx_NEWLINE_xXAny omega-3 fatty acids should not be taken for 30 days prior to baseline evaluation and during the study intervention; if participants are consuming any of these items and would like to participate in this study, then a 30-day washout period will be required; participants will be encouraged to limit their use of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase 2 (COX-2) inhibitors (which will be captured on the Concomitant Medications CRFs) in favor of alternatives, such as acetaminophen; for those who take these medications on a regular basis, they will be suggested to maintain a constant doseXx_NEWLINE_xXParticipants must be candidates for RP and considered surgically resectable by urologic evaluationXx_NEWLINE_xXParticipants with a history of confirmed progressive multifocal leukoencephalopathy (PML)Xx_NEWLINE_xXParticipants with uncontrolled autoimmune hemolytic anemia or immune thrombocytopeniaXx_NEWLINE_xXMale participants, even if surgically sterilized (ie, status postvasectomy), who:Xx_NEWLINE_xXParticipants with known or suspected COPD must have a FEV1 test during screeningXx_NEWLINE_xXHigh-risk participants who have received chemopreventive drugs in the past are not allowed to enter the studyXx_NEWLINE_xXResearch participants with any uncontrolled illness including ongoing or active infections; research participants with known active hepatitis B or C infection; research participants who are human immunodeficiency virus (HIV) positive based on testing performed within 4 weeks of enrollment; research participants with any signs or symptoms of active infection, positive blood cultures or radiological evidence of infectionsXx_NEWLINE_xXInclusion Criteria:\n\n        Each participant with newly diagnosed multiple myeloma (NDMM) must meet all of the\n        following inclusion criteria to be enrolled in the study:\n\n          1. Adult male or female participants 18 years of age or older with a confirmed diagnosis\n             of symptomatic multiple myeloma (MM) according to standard criteria.\n\n          2. Participants for whom cyclophosphamide and dexamethasone treatment is appropriate and\n             who are considered not eligible for high-dose therapy (HDT)-stem cell transplantation\n             (SCT) for 1 or more of the following reasons:\n\n               -  The participant is 65 years of age or older.\n\n               -  The participant is less than 65 years of age but has significant comorbid\n                  condition(s) that are, in the opinion of the investigator, likely to have a\n                  negative impact on tolerability of HDT-SCT.\n\n        Each participant with relapsed and/or refractory multiple myeloma (RRMM) must meet all of\n        the following inclusion criteria to be enrolled in the study:\n\n          1. Adult male or female participants 18 years or older with a confirmed diagnosis of\n             symptomatic MM either currently or at the time of initial diagnosis, according to\n             standard criteria, and relapsed and/or refractory disease after 1 to 3 lines of prior\n             therapy. A participant is considered to have refractory disease if disease progression\n             occurred during the treatment period or within 60 days of receiving the last dose of a\n             given therapy. A line of therapy is defined as 1 or more cycles of a single-agent or\n             combination therapy or a sequence of planned treatments such as induction therapy\n             followed by autologous stem cell transplantation (ASCT) and then maintenance therapy.\n\n          2. No evidence of graft-versus-host disease for participants who have undergone prior\n             allogeneic stem cell transplantation.\n\n        In addition, all participants (NDMM and RRMM) must meet all of the remaining criteria:\n\n          1. Participants must have measurable disease defined by at least 1 of the following 3\n             measurements:\n\n               -  Serum M-protein ? 1 g/dL (? 10 g/L).\n\n               -  Urine M-protein ? 200 mg/24 hours.\n\n               -  Serum free light chain assay: involved free light chain level ? 10 mg/dL (? 100\n                  mg/L), provided that the serum free light chain ratio is abnormal.\n\n          2. Participants must meet all of the following clinical laboratory criteria:\n\n               -  Absolute neutrophil count (ANC) ? 1000/mm^3 and platelet count ? 75,000/mm^3.\n                  Platelet transfusions to help participants meet eligibility criteria are not\n                  allowed within 3 days prior to administration of the study drug.\n\n               -  Total bilirubin ? 1.5 x the upper limit of the normal range (ULN).\n\n               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 x ULN.\n\n               -  Calculated creatinine clearance (CrCL) ? 30 mL/min.\n\n          3. Eastern Cooperative Oncology Group performance status of 0, 1, or 2.\n\n          4. Female participants who:\n\n               -  are postmenopausal for at least 1 year before the screening visit, or\n\n               -  are surgically sterile, or\n\n               -  If they are of childbearing potential, agree to practice 2 effective methods of\n                  contraception, at the same time, from the time of signing the informed consent\n                  through 90 days after the last dose of study drug, or\n\n               -  agree to practice true abstinence over the period previously described, when this\n                  is in line with the preferred and usual lifestyle of the participant. (Periodic\n                  abstinence [ie, calendar, ovulation, symptothermal, postovulation methods] and\n                  withdrawal are not acceptable methods of contraception.), and\n\n               -  adhere to any treatment-specific pregnancy prevention guidelines for\n                  cyclophosphamide and dexamethasone.\n\n          5. Male participants, even if surgically sterilized (ie, status post-vasectomy), who:\n\n               -  agree to practice effective barrier contraception during the entire study\n                  treatment period and through 90 days after the last dose of study drug, or\n\n               -  agree to practice true abstinence over the period previously described, when this\n                  is in line with the preferred and usual lifestyle of the participant. (Periodic\n                  abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the\n                  female partner] and withdrawal are not acceptable methods of contraception.), and\n\n               -  adhere to any treatment-specific pregnancy prevention guidelines for\n                  cyclophosphamide and dexamethasone.\n\n          6. Voluntary written consent must be given before performance of any study-related\n             procedure not part of standard medical care, with the understanding that consent may\n             be withdrawn by the participant at any time without prejudice to future medical care.\n\n          7. Suitable venous access for the study-required blood sampling.\n\n          8. Is willing and able to adhere to the study visit schedule and other protocol\n             requirements.\n\n        Exclusion Criteria:\n\n          1. Prior treatment for multiple myeloma with either standard of care treatment or\n             investigational regimen (for participants with NDMM only).\n\n             NOTE: Prior treatment with corticosteroids (maximum dose of corticosteroids should not\n             exceed the equivalent of 160 mg of dexamethasone over 14 days. Localized radiation is\n             permitted as long as it is below a therapeutic level and administered at least 14 days\n             prior to the first dose of study treatment.\n\n          2. Diagnosis of smoldering MM, Waldenström's macroglobulinemia, POEMS (polyneuropathy,\n             organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome,\n             plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or\n             myeloproliferative syndrome.\n\n          3. Central nervous system involvement.\n\n          4. Diagnosed or treated for another malignancy within 2 years before the first dose or\n             previously diagnosed with another malignancy and have any evidence of residual\n             disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type\n             are not excluded if they have undergone complete resection.\n\n          5. Peripheral neuropathy Grade 1 with pain or Grade 2 or higher peripheral neuropathy of\n             any cause on clinical examination during the Screening period.\n\n          6. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral\n             absorption or tolerance of study drug, including difficulty swallowing.\n\n          7. Infection requiring intravenous (IV) antibiotic therapy or other serious infection\n             within 14 days before the first dose of study drug.\n\n          8. Ongoing or active infection, known human immunodeficiency virus (HIV) positive, active\n             hepatitis B or C infection.\n\n          9. Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin,\n             ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin,\n             itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A\n             inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital),\n             or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of\n             study treatment.\n\n         10. Known allergy to any of the study medications, their analogues, or excipients in the\n             various formulations.\n\n         11. Major surgery within 14 days before the first dose of study drug. (Note: kyphoplasty\n             or vertebroplasty is not considered major surgery.)\n\n         12. Female participants who are lactating and breastfeeding or have a positive serum\n             pregnancy test during the Screening period.\n\n         13. Any serious medical or psychiatric illness that could, in the investigator's opinion,\n             potentially interfere with the completion of treatment according to this protocol.\n\n         14. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment\n             of the investigator, would make the participant inappropriate for entry into this\n             study or interfere significantly with the proper assessment of safety and toxicity of\n             the prescribed regimens.\n\n         15. Treatment with any investigational products for reasons other than MM within 30 days\n             before the first dose of study drug.Xx_NEWLINE_xXPHASE I: Participants may not be receiving any other study agents within 2 weeks of initiating treatmentXx_NEWLINE_xXInclusion Criteria\n\n        Each participant must meet all the following inclusion criteria to be enrolled in the\n        study:\n\n          1. Male or female participants ? 18 years old.\n\n          2. Have a pathologically (histology or cytology) confirmed diagnosis of SCLC.\n\n          3. Have received and progressed after a platinum-based standard chemotherapy regimen for\n             first line treatment of SCLC, either limited stage (LS) or extensive stage (ES).\n\n          4. Have measurable disease within ? 2 weeks before randomization. Clear radiographic\n             evidence of disease progression after initial therapy should have been documented.\n\n          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (PS 0-1).\n\n          6. Participants with treated brain metastases (surgery, whole or stereotactic brain\n             radiation) are allowed provided the lesions have been stable for at least 2 weeks and\n             the participant is off steroids or is on a stable dose of steroids. Participants\n             should be without neurologic dysfunction that would confound the evaluation of\n             neurological and/or other AEs.\n\n        Exclusion Criteria\n\n        Participants meeting any of the following exclusion criteria are not to be randomized to\n        treatment:\n\n          1. Any prior therapy for second-line treatment of SCLC.\n\n          2. Participants who relapsed ? 180 days after their response to first-line treatment.\n\n          3. Prior treatment with an Aurora A specific-targeted or pan-Aurora-targeted agent,\n             including alisertib, or any other investigational agent.\n\n          4. Prior treatment with paclitaxel or any other taxane agent.\n\n          5. Known hypersensitivity to Cremophor® EL, paclitaxel, or its components.\n\n          6. Any comorbid condition or unresolved toxicity that would preclude administration of\n             alisertib or weekly paclitaxel.\n\n          7. Prior history of ? Grade 2 neurotoxicity that is not resolved to ? Grade 1.\n\n          8. Participants with symptomatic and/or progressive brain metastases or with\n             carcinomatous meningitis.\n\n          9. Treatment with clinically significant enzyme inducers within 14 days prior to the\n             first dose of alisertib and during study conduct. Major prohibited enzyme inducers\n             include: phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine,\n             and St. John's wort.\n\n         10. Inability to swallow alisertib or other orally administered medications.\n\n         11. Requirement for administration of proton pump inhibitor (PPI), H2 antagonist, or\n             pancreatic enzymes.\n\n         12. Diagnosed with or treated for another malignancy within 2 years before the first dose\n             of study drug, or previously diagnosed with another malignancy and have any evidence\n             of residual disease.\n\n         13. Other severe acute or chronic medical or psychiatric condition(s) per protocol.\n\n         14. History of myocardial infarction, unstable symptomatic ischemic heart disease,\n             uncontrolled hypertension despite appropriate medical therapy, any ongoing cardiac\n             arrhythmias of Grade > 2, thromboembolic events (eg, deep vein thrombosis, pulmonary\n             embolism, or symptomatic cerebrovascular events), or any other cardiac condition (eg,\n             pericardial effusion or restrictive cardiomyopathy) within 6 months before receiving\n             the first dose of study drug.\n\n         15. Known history of human immunodeficiency virus (HIV) infection, hepatitis B or\n             hepatitis C.\n\n         16. Surgery within 3 weeks (or 2 weeks for a minor surgery) before study enrollment and\n             not fully recovered to baseline or to a stable clinical status.\n\n         17. Participants who are pregnant, lactating, or do not agree to use effective methods of\n             contraception during the study treatment period through 6 months after the last dose\n             of study drug per protocol.Xx_NEWLINE_xXParticipants without orchiectomy must be maintained on luteinizing-hormone-releasing hormone (LHRH) agonist/antagonist therapyXx_NEWLINE_xXParticipants may have had up to two previous cytotoxic therapeutic regimens provided these were discontinued >= 4 weeks before starting the trialXx_NEWLINE_xXParticipants receiving bisphosphonates therapy or denosumab can be maintained on this therapy; if participants have not started bisphosphonates, it is recommended that they start treatment after the first (optional) biopsyXx_NEWLINE_xXParticipants are permitted to have any number of prior therapies prior to enrollmentXx_NEWLINE_xXParticipants may not be receiving any other study agents concurrently with the study drugsXx_NEWLINE_xXWarfarin use is excluded; other anticoagulants are permitted, but for participants enrolled in the RP2D cohort, the investigator must deem it safe to temporarily hold to facilitate pre and on-treatment tumor biopsies; participants where this is not feasible are excluded from participationXx_NEWLINE_xXPreviously untreated participants are eligible if their tumor(s) are measurableXx_NEWLINE_xXParticipants should have normal blood pressure according to age; participants 18 years of age and younger should have a blood pressure =< 95th percentile for age, height and gender, and should not be receiving medication for treatment of hypertension; preexisting hypertension in adults should be controlled (either with pharmacological or non-pharmacological methods) at the time of enrollmentXx_NEWLINE_xXParticipants who are >= 18 years of age or Legally Authorized Representative (LAR) of participants who are younger than 18 years must sign an informed consent for the Pediatric Oncology Branch (POB) Screening Protocol (01-C-0157: Eligibility Screening and Tissue Procurement for the National Cancer Institute [NCI], Pediatric Oncology Branch [POB] Clinical Research Protocols) prior to participating in studies required to determine eligibility for this trial; after confirmation of eligibility, participants who are >= 18 years of age or LAR of minor participants must sign an informed consent document for this trial, indicating that they are aware of the investigational nature of the proposed treatment, the risks and benefits of participating and the alternatives to participating, prior to the conduct of any study proceduresXx_NEWLINE_xXParticipants previously treated with bendamustine only if their duration of response was >/= 24 monthsXx_NEWLINE_xXParticipants must use effective birth control throughout study until at least 30 days after study treatment or 1 year after rituximab treatment, whichever is later; female participants must not be pregnant or breast-feedingXx_NEWLINE_xXInclusion Criteria:\n\n        All Participants:\n\n          -  At least one bi-dimensionally measurable lesion, defined as greater than (>) 1.5\n             centimeters (cm) in its longest dimension\n\n          -  Life expectancy of at least 24 weeks\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n\n          -  Adequate hematologic function (unless inadequate function is due to underlying\n             disease, as established by extensive bone marrow involvement or is due to\n             hypersplenism secondary to the involvement of the spleen by lymphoma per the\n             investigator)\n\n          -  Agreement to use highly effective contraception measures. Women of childbearing\n             potential must agree to remain abstinent or use contraceptive measures that result in\n             a failure rate of <1 percent (%) per year during the treatment period and for at least\n             12 months for R-CHP arm or for at least 18 months for G-CHP arm after the last dose of\n             study drug. Men must agree to remain abstinent or to use a condom plus an additional\n             contraceptive method that together result in a failure rate of <1% per year during the\n             treatment period and for at least 5 months after the last dose of study drug\n\n        Dose-Escalation Portion of the Study:\n\n          -  Histologically confirmed B-cell NHL: Participants with newly diagnosed B-cell NHL or\n             relapsed/refractory B-cell NHL are eligible\n\n          -  No more than one prior systemic treatment regimen for B-cell NHL (single agent\n             anti-cluster of differentiation [CD] 20 monoclonal antibody therapy will not be\n             counted as a prior treatment regimen)\n\n          -  No prior treatment with anthracyclines\n\n        Expansion Portion of the Study:\n\n          -  Previously untreated participants with diffuse large B-cell lymphoma (DLBCL)\n\n          -  International Prognostic Index score of 2-5\n\n        Exclusion Criteria:\n\n        Dose-Escalation Portion of the Study:\n\n          -  Diagnosis of primary mediastinal DLBCL\n\n        Expansion Portion of the Study:\n\n          -  Participants with transformed lymphoma\n\n          -  Prior therapy for NHL\n\n        All Participants:\n\n          -  Prior stem cell transplant\n\n          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal\n             antibodies or known sensitivity or allergy to murine products\n\n          -  Contraindication to receive any of the individual components of R-CHP or G-CHP\n\n          -  Current Grade greater than (>) 1 peripheral neuropathy\n\n          -  Ongoing corticosteroid use of >30 milligrams per day (mg/day) of\n             prednisone/prednisolone or equivalent. Participants receiving corticosteroid treatment\n             with less than or equal to (</=) 30 mg/day of prednisone//prednisolone or equivalent\n             must be documented to be on a stable dose of at least 4 weeks' duration before Cycle 1\n             Day 1\n\n          -  Primary central nervous system (CNS) lymphoma\n\n          -  Vaccination with live vaccines within 6 months before Cycle 1 Day 1\n\n          -  History of other malignancy that could affect compliance with the protocol or\n             interpretation of results. Participants with a history of curatively treated basal or\n             squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix are\n             eligible. Participants with a malignancy that has been treated with surgery alone with\n             curative intent will also be excluded unless the malignancy has been in documented\n             remission without treatment for greater than or equal to (</=) 5 years before\n             enrollment\n\n          -  Evidence of significant, uncontrolled concomitant diseases, including renal disease\n             that would preclude chemotherapy administration, or pulmonary disease (including\n             obstructive pulmonary disease and history of bronchospasm)\n\n          -  Significant cardiovascular disease (such as New York Heart Association Class III or IV\n             cardiac disease, congestive heart failure, myocardial infarction within the previous 6\n             months, unstable arrhythmias, or unstable angina) or significant pulmonary disease\n\n          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection\n             (excluding fungal infections of nail beds) at study enrollment or any major episode of\n             infection requiring treatment with IV antibiotics or hospitalization (relating to the\n             completion of the course of antibiotics) within 4 weeks before Cycle 1 Day 1\n\n          -  Clinically significant history of liver disease, including viral or other hepatitis,\n             current alcohol abuse, or cirrhosis\n\n          -  Positive for hepatitis B or hepatitis C infection\n\n          -  Prior radiotherapy to the mediastinal/pericardial region\n\n          -  Pregnant or lactating women\n\n          -  Recent major surgery within 6 weeks before the start of Cycle 1 Day 1\n\n          -  Abnormal laboratory valuesXx_NEWLINE_xXParticipants enrolling in the indication-specific expansion cohorts in Stage 2 must consent to tumor biopsies and must have one of the following types of cancer:Xx_NEWLINE_xXAdequately excised: participants must have undergone either breast-conserving surgery or mastectomy/nipple- or skin-sparing mastectomyXx_NEWLINE_xXParticipants with synchronous bilateral invasive disease are eligible only if both lesions are HER2-positiveXx_NEWLINE_xXParticipants with contraindication to RT while adjuvant RT is clinically indicatedXx_NEWLINE_xXParticipants with primary refractory diseaseXx_NEWLINE_xXParticipants may not use natural herbal products or remedies not approved by the Food and Drug Administration (FDA) while participating in this studyXx_NEWLINE_xXFor those participants who do not require radiation, registration must be within 84 days of surgery.Xx_NEWLINE_xXParticipants for Cohort A:Xx_NEWLINE_xXParticipants for Cohorts B and C:Xx_NEWLINE_xXParticipants for Cohorts D and E:Xx_NEWLINE_xXParticipants for Cohorts A, C, and E:Xx_NEWLINE_xXPotential Participants for Cohorts A, C or E who are to Receive Binimetinib:Xx_NEWLINE_xXPotential Participants for Cohorts A, C, D or E:Xx_NEWLINE_xXPotential Participants for Cohorts D or E:Xx_NEWLINE_xXPhase 1b: Participants with AML who are refractory to or have relapsed after initial treatment for their disease, with no more than three prior lines of therapy. Participants who have received prior treatment with cytarabine or decitabine are not excluded.Xx_NEWLINE_xXPhase 2: i. Participants with AML who are refractory to, or have relapsed after, initial treatment for their disease, with no more than one prior line of therapy, and are judged not to be candidates for re-induction therapy that includes hematopoietic cell transplantation. Participants who have received prior cytarabine or decitabine are not excluded. OR ii. Participants with newly diagnosed, untreated AML ineligible for, or who have refused, standard intensive induction therapyXx_NEWLINE_xXParticipants who have received previous therapy with neratinib or fulvestrantXx_NEWLINE_xXParticipants must have a minimum body surface area (BSA) of 0.6 m^2 at study entry, with the exception of one study arm which requires a minimum BSA of 1.33 m^2.Xx_NEWLINE_xXParticipants who have had or are planning to have the following invasive proceduresXx_NEWLINE_xXEvidence of new intracranial hemorrhage of more than punctate size on MRI assessment obtained within 28 days prior to study enrollment for Participants with HGGXx_NEWLINE_xXParticipants without orchiectomy must be maintained on luteinizing hormone-releasing hormone (LHRH) agonist/antagonist therapyXx_NEWLINE_xXParticipants may have had any number of previous hormonal therapies (antiandrogens, steroids, estrogens, finasteride, dutasteride, ketoconazole, abiraterone) provided these were discontinued >= 4 weeks before enrollment; participants on prednisone 10 mg daily or another equivalent steroid dose are eligible; participants on inhaled steroid are eligibleXx_NEWLINE_xXParticipants may have had up to two previous cytotoxic therapeutic regimens provided these were discontinued >= 4 weeks before enrollment; the use of antineoplastic agents for non-cancer therapy (i.e. colitis, rheumatoid arthritis) may be allowed provided the patient has been on a stable dose without toxicities greater than grade 1Xx_NEWLINE_xXParticipants receiving bisphosphonates therapy or denosumab can be maintained on this therapy; if participants have not started bisphosphonates or denosumab, it is recommended that they start treatment after the first biopsyXx_NEWLINE_xXNew or progressive CNS lesions, as assessed by the patient’s treating physician, with at least one of the following clinical scenarios:\r\n* It is anticipated that some participants may have multiple progressive CNS lesions, one or several of which are treated with stereotactic radiosurgery (SRS) or surgery with residual un-treated lesions remaining; such participants are eligible for immediate enrollment on this study providing that at least one untreated lesion is measurable; the location of the measurable lesion should be documented in the patient chart and case report form\r\n* Participants who have had prior cranial surgery are eligible, provided that there is evidence of measurable residual or progressive lesions; if a patient has surgical resection followed by whole brain radiation therapy (WBRT) and/or SRS, then there must be evidence of progressive CNS disease after the completion of WBRT and/or SRS\r\n* Participants who have had prior WBRT and/or SRS and then whose lesions have progressed thereafter are also eligible; in this case, lesions which have been treated with SRS may be considered as target lesions if there is unequivocal evidence, in the opinion of the treating physician, of progression following SRS\r\n* Participants who have not previously been treated with cranial radiation (e.g. WBRT or SRS) are eligible to enter the study, but such participants must be asymptomatic from their CNS metastases and not requiring corticosteroidsXx_NEWLINE_xXParticipants must be at least 2 weeks out from prior chemotherapy, or other cancer-directed therapy (including novel agents), with adequate recovery of toxicity to baseline, or grade =< 1, with the exception of alopecia and hot flashes; washout from hormonal therapy and radiation is not required as long as participants have adequately recovered from any significant toxicities that occurred as a result from these treatments (grade 1 or less); participants may have initiated bisphosphonate/denosumab therapy prior to start of protocol therapy; bisphosphonate/denosumab therapy may continue during protocol treatment; such participants will have bone lesions considered evaluable for progression; washout for trastuzumab or pertuzumab is not necessaryXx_NEWLINE_xXParticipants who previously received eribulin mesylate are not eligible for enrollment on the phase II portionXx_NEWLINE_xXCurrently enrolled or planning to enroll in a weight loss program (e.g., Innergy, Weight Watchers, Jenny Craig, Nutrisystem, and Medifast); participants also agree not to enroll in such a program for the duration of study participation (regardless of randomization)Xx_NEWLINE_xXParticipants must have received =< 12 months of prior chemotherapy for this disease without evidence of progressive disease with treatment; participants may have received prior radiotherapy provided approval has been obtained from the principal investigator (PI); participants with a history of radiation who have a platelet count < 150,000 due to radiation (disease, chemo, and other factors have been ruled out) will be excluded from this studyXx_NEWLINE_xXParticipants must not have life-threatening co-morbiditiesXx_NEWLINE_xXParticipants may not be receiving any other investigational or commercial agents or therapies other than those described in this protocol to treat their malignancyXx_NEWLINE_xXSignificant co-morbidity that could affect the safety or evaluability of participants as assessed by the treating physician and or principal investigatorXx_NEWLINE_xXHistologically- or cytologically-confirmed stage IV non-squamous, NSCLC who have progressed after at least one prior line of treatment; in the expansion phase, participants are only eligible if their molecular category has not been fully enrolled (10 participants with epidermal growth factor receptor (EGFR) mutations, 5 participants with anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangement, 5 participants with wild type v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), EGFR and ALK)Xx_NEWLINE_xXParticipants must have achieved a complete or partial response per disease-appropriate imaging technique (to be determined by the study principal investigator) within 4 weeks of study entry following administration of chemotherapyXx_NEWLINE_xXParticipants must have baseline echocardiogram and pulmonary function tests within 3 months prior to study entryXx_NEWLINE_xXParticipants must have histologically intermediate- or high-grade soft tissue sarcomaXx_NEWLINE_xXParticipants who will have a central access catheter or a peripheral intravascular central catheter (PICC) should schedule this procedure at least 10 days prior to the start date of study drugXx_NEWLINE_xXParticipants who have previously received doxorubicin, any other anthracycline chemotherapy or bevacizumabXx_NEWLINE_xXParticipants who have undergone allogenic stem cell transplant are ineligible unless they meet the following criteria, a) participants who are off all immunosuppressive therapy, b) participants who have no signs and/or symptoms of acute or chronic graft versus host disease, or c) participants must have appropriate hematology countsXx_NEWLINE_xXFor Cohort 1 and 2, participants must have documented pathological diagnosis of a WHO grade II astrocytoma or oligoastrocytomaXx_NEWLINE_xXFor Cohort 3, participants must have WHO grade II astrocytoma, oligoastrocytoma or oligodendroglioma that is histologically confirmed either by the previous biopsy or resection, or at the time of re-operation (re-operation before entry to the current study is allowed; however participants must be off post-surgery dexamethasone for at least 4 weeks before administration of the first vaccine)Xx_NEWLINE_xXParticipants with known addiction to any drugsXx_NEWLINE_xXNo prior treatment with bortezomib for cGVHD; participants may have received bortezomib for other reasons besides cGVHD (such as leukemia or solid tumor); any other previous treatments for cGVHD are allowedXx_NEWLINE_xXParticipants may not have received any prior camptothecin, including but not limited to: topotecan, irinotecanXx_NEWLINE_xXParticipants with gross hematuria are not eligible; patients with microscopic hematuria are eligibleXx_NEWLINE_xXParticipants with gross hematuria are ineligibleXx_NEWLINE_xXFemale research participants of childbearing age or males research participants of child fathering potential must agree to use safe contraceptive methods for the duration of the study and for 3 months thereafterXx_NEWLINE_xXUse of enzyme-inducing anticonvulsants (EIACs); a minimum interval of 10 days between the last dose of EIAC and start of this therapy will be required for research participants who were previously receiving such medicationsXx_NEWLINE_xXParticipants with cardiovascular conditions specified in protocolsXx_NEWLINE_xXParticipants with relapsed and/or refractory multiple myeloma (RRMM) who had received 1 to 3 prior therapies. NOTE: population included the following 3 categories of participants:Xx_NEWLINE_xXParticipants who were refractory to all lines of previous treatment(s) (ie, participants who had never responded to any therapies received).Xx_NEWLINE_xXParticipants who received prior allogenic transplant must have had no active graft-versus-host disease.Xx_NEWLINE_xXMust have also adhered to the guidelines of the RevAssist program (US participants), RevAid program (Canadian participants), iAccess program (Australian participants), RevMate program (Japanese participants) or The Lenalidomide Pregnancy Risk Minimisation Plan as outlined in the study Manual (all other participants who were not using commercial supplies)Xx_NEWLINE_xXAll prospective participants must have an Ommaya reservoir (or equivalent ventricular access device) inserted as part of their standard clinical care prior to initiation of study treatmentXx_NEWLINE_xXAny prior treatment with capecitabine for patients enrolled to cohorts 3a/3b and prior lapatinib for participants on cohort 3aXx_NEWLINE_xXParticipants may have received prior hydroxyurea but may not be currently being treated with hydroxyurea at the time of study initiationXx_NEWLINE_xXParticipants may not be receiving any other study agentXx_NEWLINE_xXParticipants with metastasesXx_NEWLINE_xXFor participants with follicular lymphoma: requirement for treatment according to Groupe d'Etude des Lymphomes Folliculaires (GELF) criteriaXx_NEWLINE_xXParticipants may not be receiving any other study agents during the study or within 4 weeks of the start of the trialXx_NEWLINE_xXEXPANSION COHORT ONLY: Participants may not be receiving any other study agents during the study or within 4 weeks of the start of the studyXx_NEWLINE_xXOngoing monthly gonadotrophin releasing hormone (GNRH) agonist is required in pre-menopausal women or male participants for at least 4 weeks prior to study entryXx_NEWLINE_xXMales and female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 12 months after the last dose of study treatment for participants who have received cyclophosphamide, and 6 months after the last dose of study treatment for participants who did not.Xx_NEWLINE_xXRefractory to any previous regimen containing rituximab (defined by participants who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen)Xx_NEWLINE_xXParticipants with a history of confirmed progressive multifocal leukoencephalopathy (PML)Xx_NEWLINE_xXParticipants with chronic hepatitis B or seropositive occult (HBV) infectionXx_NEWLINE_xXParticipants must have available archival or fresh tumor tissue or both to submit to a central laboratory for CD38 assay. Expression of CD38 is measured by immunohistochemistry on fresh or archived tumor sample by central assessment using a CD38 investigational IHC assay under development: a) Stage 1: participants whose tumors are more than or equal to (>=) 50 percent (%) positive for CD38, b) Stage 2: participant has less than (<) 50% CD38+ or greater than (>) 50% CD38+ depending on the distribution of CD 38 expression of enrolled participants during Stage 2. The sponsor will advise on which eligibility criterion is permitted during the enrollment periodXx_NEWLINE_xXParticipant has known chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1 second (FEV1) less than (<) 50% predicted normal. Note that FEV1 testing is required for participants suspected of having COPD and participants must be excluded if FEV1 <50% b) Participant has known moderate or severe persistent asthma within 2 years (see Attachment 4: NHLBI table of asthma severity), or currently has uncontrolled asthma of any classification. (Note that participants who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study)Xx_NEWLINE_xXParticipants in the Dose Escalation portion must have one of the following advanced or recurrent malignancies: gastrointestinal (colorectal or gastric); ovarian; melanoma; non-small cell lung adenocarcinoma; or bladder.Xx_NEWLINE_xX? 2 weeks elapsed from the completion of previous treatment regimen and participants must have recovered or be at a new stable baseline from any related toxicities.Xx_NEWLINE_xXThe participant has a solid tumor. Parts 2 and 3 are limited to participants with non-small cell lung cancer. Part 4 is limited to participants with small cell lung, head and neck, pancreatic, colorectal, and cervical cancersXx_NEWLINE_xXParticipants who have an indwelling draining IP catheter (to be drained only under medical supervision)Xx_NEWLINE_xXFor Phase 1b of the study: Participants who have experienced failure of multiple lines of prior chemotherapy are eligible.Xx_NEWLINE_xXFemale participants must agree to not donate eggs (ova) during the course of this study and for 30 days after receiving their last dose of TAK-117 and, for docetaxel, for as long as is mandated by local labeling.Xx_NEWLINE_xXMale participants must agree to not donate sperm during the course of the study and for 120 days after receiving their last dose of TAK-117 and, for docetaxel, for as long as is mandated by local labeling.Xx_NEWLINE_xXMale participants who intend to donate sperm during the course of this study or 120 days after receiving their last dose of TAK-117 and, for docetaxel, for as long as is mandated by local labeling.Xx_NEWLINE_xXInclusion Criteria -\n\n          1. Between the ages of greater or equal to (?) 6 months and less than (<) 18 years of age\n\n          2. Must have histologically proven B-cell acute lymphoblastic leukemia (ALL) or B-cell\n             lymphoblastic lymphoma with marrow involvement\n\n          3. All participants (both ALL and participants with lymphoblastic lymphoma) must have M2\n             or M3 bone marrow classification\n\n          4. Disease status: a) Participants must have relapsed or refractory disease b) In the\n             event of relapse after prior allogeneic hematopoietic stem cell transplant (HSCT),\n             participants must be at least 3 months post-transplant and have no evidence of active\n             graft-vs-host disease, and must have been off immunosuppression for at least 4 weeks,\n             c) Must have resolution of the acute toxic effects to less than or equal to (?) Grade\n             2 from prior chemotherapy before entry, in the opinion of the investigator\n\n          5. Participants with the following central nervous system (CNS) 1 or 2 status are\n             eligible only in the absence of neurologic symptoms\n\n          6. Female participants of childbearing potential and post-pubertal male participants must\n             use an approved method of contraception for the study.\n\n        Exclusion Criteria\n\n          1. Concurrent enrollment in another clinical study for cancer treatment, unless the\n             subject is in the follow-up period from a previous study.\n\n          2. Isolated testicular or CNS ALL\n\n          3. Participants with mixed-lineage leukemia (MLL) gene rearrangement\n\n          4. Inadequate Hepatic function\n\n          5. Inadequate Renal function\n\n          6. Radiologically-detected CNS lymphoma\n\n          7. Participants with clear laboratory or clinical evidence of disseminated intravascular\n             coagulation (DIC)\n\n          8. Hyperleukocytosis or rapidly progressive disease that would compromise ability to\n             complete study therapy\n\n          9. QT interval corrected using Fridericia's formula (QTcF) greater than or equal to a\n             Grade 2, confirmed by 2 additional seperate electrocardiographs (ECG's) within 28 days\n             prior to starting study drug. The initial screening ECG need not be repeated for\n             confirmation if the QTcF interval is <481 milliseconds.\n\n         10. Pregnant or breast-feeding females\n\n         11. Prior treatment with CAT-3888 (BL22), moxetumomab pasudotox, or any\n             pseudomonas-exotoxin-containing compound\n\n         12. Prior treatment with any anticancer biologic therapy within 2 weeks prior to starting\n             study drug, including but not limited to therapeutic monoclonal antibodies or\n             antibody-drug conjugates\n\n         13. Systemic chemotherapy ? 2 weeks (6 weeks for nitrosoureas) and radiation therapy ? 3\n             weeks prior to starting study drug\n\n         14. Clinically significant ophthalmologic findings (evidence of retinal damage or injury)\n             during the screening\n\n         15. Presence of a second invasive malignancy\n\n         16. Uncontrolled pulmonary infection, presence of pulmonary edema\n\n         17. Serum albumin < 2 gram per deciliter (g/dL). Albumin infusions for correction of\n             hypoalbuminemia are allowed, but cannot have administered within 7 days prior to start\n             of study drug\n\n         18. Radioimmunotherapy within 2 years prior to study start of study drug\n\n         19. Participants with prior history of thrombotic microangiopathy or hemolytic uremic\n             syndrome (HUS)\n\n         20. T-cell ALL or T-cell lymphoblastic lymphoma\n\n         21. Participants currently receiving high-dose estrogen therapy defined as >0.625\n             milligram per day (mg/day) of an estrogen compound or within 2 weeks prior to starting\n             study drug.Xx_NEWLINE_xXParticipants must have cutaneous lesion(s) amenable to four total biopsies (either four lesions > 4 mm or one large lesion measuring 20 mm that can undergo serial biopsy) and at least five additional lesions measurable for assessment with no improvement over the four weeks prior to enrollmentXx_NEWLINE_xXParticipants for whom front-line cytotoxic therapy is indicated (i.e., symptomatic visceral or pulmonary KS or symptomatic KS impairing functional status); all participants must have a chest X-ray to rule out pulmonary KS within 28 days of study enrollmentXx_NEWLINE_xXParticipants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications, when clinically indicated and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 8 weeks following study entry; as study-specific (antiretroviral-based) strata fill, however, only participants who are receiving the therapies eligible for the remaining open strata will be accruedXx_NEWLINE_xXParticipants who received prior treatment with erlotinib or other EGFR-targeted agentsXx_NEWLINE_xXParticipants who take medications that are not recommended for concomitant use with their current antiretroviral regimenXx_NEWLINE_xX? 2 weeks elapsed from the completion of previous treatment regimen and participants must have recovered or be at a new stable baseline from any related toxicities.Xx_NEWLINE_xXParticipants with treated brain metastases are eligible for study participation; participants may not receive ongoing treatment with steroids at screening, anticonvulsants (at stable dose) are allowedXx_NEWLINE_xXPediatric participants, 12 to 17 years of age inclusiveXx_NEWLINE_xXBecause there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with bevacizumab, cobimetinib, and vemurafenib, female participants who are breastfeeding must agree to discontinue nursing prior to Day 1 of the study.Xx_NEWLINE_xXParticipants must have biopsy-proven KS involving skin with or without visceral involvementXx_NEWLINE_xXIf participant is HIV positive, participants must be on a stable antiretroviral regimen for at least 12 weeks prior to study enrollmentXx_NEWLINE_xXParticipants for whom front-line cytotoxic therapy is indicated (i.e. symptomatic visceral or pulmonary KS or symptomatic KS impairing functional status)Xx_NEWLINE_xXFor BCG-unresponsive and BCG-relapsing NMIBC, participants must have received an adequate course of BCGXx_NEWLINE_xXParticipants with cT4 or cN3 stage breast tumorsXx_NEWLINE_xXHighly effective contraception as defined by the protocol Participants with Ovarian CancerXx_NEWLINE_xXParticipants with a history of gross hemoptysis within 2 months prior to study treatmentXx_NEWLINE_xXInclusion Criteria:\n\n        General:\n\n          -  Participants with solid tumors must have one or more metastatic tumors evaluable or\n             measurable on radiographic imaging\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (or 2 upon\n             approval by the medical monitor)\n\n          -  Life expectancy of greater than or equal to (>/=) 3 months\n\n          -  Disease-free of active second/secondary or prior malignancies >/= 2 years with the\n             exception of currently treated basal cell, squamous cell carcinoma of the skin, or\n             carcinoma \in-situ\ of the cervix or breast\n\n          -  Adequate hematological, renal, hepatic and coagulation laboratory test results\n\n          -  Women of child bearing potential and men must agree to use adequate contraception\n             during the study and for 4 months after the last dose of study drug\n\n        Advanced Solid Malignancies:\n\n          -  Participants with previously treated, histologically confirmed advanced solid\n             malignancy with progressive disease requiring therapy\n\n          -  Participants must be refractory or intolerant to standard therapy\n\n        NUT-midline carcinoma:\n\n          -  Participants with histologically confirmed newly diagnosed or relapsed/refractory NMC\n             with PD requiring therapy\n\n          -  Diagnosis of one of the following is required:\n\n               1. NUT Midline Carcinoma based on ectopic expression of NUT protein as determined by\n                  Immunohistochemistry (IHC) and/or;\n\n               2. Detection of NUT gene translocation as determined by Fluorescence In-Situ\n                  Hybridization (FISH) Advanced Aggressive DLBCL\n\n          -  Histologically confirmed advanced aggressive B-cell lymphoma with abnormal MYC\n             expression with persistent disease requiring treatment\n\n          -  Participants must have relapsed or progressed after at least 2 lines of prior therapy\n             and not eligible for any curative treatment\n\n          -  Participants must have measurable disease\n\n        Exclusion Criteria:\n\n          -  Participants with hematologic malignancies\n\n          -  New York Heart Association Class III or IV, cardiac disease, myocardial infarction\n             within the past 6 months, unstable arrhythmia\n\n          -  Have Fridericia-corrected QT interval (QTcF) greater than (>) 470 milliseconds (msec)\n             (female) or > 450 (male), or history of congenital long QT syndrome\n\n          -  Active, uncontrolled bacterial, viral, or fungal infections\n\n          -  Known clinically important respiratory impairment\n\n          -  Positive for human immunodeficiency virus (HIV), hepatitis B surface antigen, or\n             hepatitis C antibodies\n\n          -  History of major organ transplant\n\n          -  History of an autologous or allogeneic bone marrow transplant. For DLBCL participants\n             only: DLBCL participants may have had a previous autologous transplant but not within\n             90 days of study entry\n\n          -  Symptomatic central nervous system malignancy or metastasis\n\n          -  Pregnant or nursing\n\n          -  Treatment with surgery or chemotherapy within 28 days prior to study entry\n\n          -  Prior treatment with small molecule (BET) family inhibitor\n\n          -  Radiation for symptomatic lesions within 14 days of study enrollmentXx_NEWLINE_xXParticipants with cT4 or cN3 stage breast tumorsXx_NEWLINE_xXParticipants requiring any daily supplemental oxygenXx_NEWLINE_xXParticipants must have recurrent or refractory disease after receiving at least one prior platinum-containing chemotherapy regimen, or standard therapy is refused or not suitable. For participants in Canada: participants should also not be suitable for treatment with topotecan hydrochlorideXx_NEWLINE_xXParticipants medicated with anti-depressants reported to have lysine-specific histone demethylase 1A (KDM1A)/lysine (K)-specific demethylase 1A (LSD1) inhibitory activity (such as tranylcypromine or phenelzine) within 28 days of treatment startXx_NEWLINE_xXParticipants with untreated central nervous system metastases, or history of previously treated disease. Participants must have stable hematological parameters, satisfying eligibility, platelet count must be stable for >=2 weeks prior to study drug administrationXx_NEWLINE_xXParticipants who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the studyXx_NEWLINE_xXParticipants with evidence of electrolyte imbalanceXx_NEWLINE_xXParticipants who refuse to potentially receive blood products and/or have a hypersensitivity to blood productsXx_NEWLINE_xXParticipants with abnormal hepatic functionXx_NEWLINE_xXParticipants who have failed at least one line of systemic therapy for advanced stage HCC or participants who are ineligible or unable to tolerate the standard of care treatment.Xx_NEWLINE_xXParticipants who need to take therapeutic anti-coagulation or anti-platelet therapy.Xx_NEWLINE_xXParticipants With AML: treatment naive or relapsed for whom experimental therapy is appropriate (as assessed by their treating physician) For Part B:Xx_NEWLINE_xXParticipants who received prior treatment with a hypomethylating agentXx_NEWLINE_xXParticipant’s age is 1 to 39 years, inclusive; (St. Jude participants must be aged 1 to 25 years)Xx_NEWLINE_xXParticipants must have histologically confirmed intrahepatic cholangiocarcinoma (IHC) without evidence of extrahepatic metastasis within 3 months prior to study registrationXx_NEWLINE_xXMale participants, even if surgically sterilized (ie, status postvasectomy), who:Xx_NEWLINE_xXParticipants with biliary obstruction for which a stent had been placed are eligible provided that the stent has been in place for more than 14 days before the first dose of alisertib and liver function has stabilized.Xx_NEWLINE_xXParticipants of North/East Asian ethnicity (ie, Japanese, Chinese, Korean) will be excluded.Xx_NEWLINE_xXGeneral eligibility criteria:\n\n          -  ECOG performance status 0 or 1.Patients with multiple myeloma who have an ECOG\n             performance status of 2 based on peripheral neuropathy from prior therapies are\n             eligible.\n\n          -  Ability to understand and the willingness to sign a written informed consent document.\n\n          -  Pathological confirmation of AML, MDS-RAEB or Multiple myeloma.\n\n          -  Agree to use adequate contraception prior to the study, for the duration of study\n             participation, and 4 months after completion of CM-CS1 CART-cell administration.\n\n          -  Ability to adhere with the study visit schedule and other protocol procedures.\n\n          -  Willingness to remain within a 50 mile radius of Brigham Women's Hospital during the\n             initial 10 days following CM-CS1 infusion\n\n        Disease specific eligibility criteria for patients with AML, MDS-RAEB:\n\n          -  Pathological confirmation of AML, MDS-RAEB according to WHO classification (CMML is\n             excluded) that is not in remission (defined as >5% blasts in bone marrow or peripheral\n             blood) and for which there are no reasonable standard treatment options.\n\n          -  No known or suspected CNS disease. A neurologic exam is required and signs or symptoms\n             suggestive of potential CNS disease require CNS imaging.\n\n          -  Disease status deemed not to require additional therapy for at least 4 weeks from\n             enrollment.\n\n          -  Life expectancy of greater than 4 weeks.\n\n          -  Participants must have satisfactory organ function as defined below:\n\n               1. Total bilirubin ?2.0 × institutional upper limit of normal (Except for subjects\n                  with known Gilbert's syndrome)\n\n               2. AST(SGOT)/ALT(SGPT) ?3 × institutional upper limit of normal\n\n               3. Creatinine ? 2.0 mg/dL\n\n        Disease specific eligibility criteria for patients with multiple myeloma:\n\n          -  Diagnosis of active multiple myeloma according to the International Myeloma Working\n             Group diagnostic criteria.\n\n          -  Relapsed or relapsed/refractory multiple myeloma with progressive disease\n\n          -  Presence of measurable disease as defined as one or more of the following:\n\n               1. Serum M-protein >0.5g/dl\n\n               2. Urine M-protein > 200mg/24hr\n\n               3. Serum FLC assay: involved FLC level > 10mg/dl with abnormal serum FLC ratio\n\n               4. Measurable plasmocytoma in non-secretory patients.\n\n          -  Previous treatment with both an immunomodulator and a proteosome inhibitor therapy\n\n          -  Life expectancy of greater than 12 weeks\n\n          -  No known or suspected CNS involvement. A neurologic exam is required and signs or\n             symptoms of potential CNS involvement require CNS imaging. Peripheral neuropathy is\n             acceptable.\n\n          -  Participants must have satisfactory organ and marrow function as defined below:\n\n               1. Absolute neutrophil count > 500/mcL. Screening ANC should be independent of G-CSF\n                  and GM-CSF support for at least 1 week and of pegylated G-CSF for at least 2\n                  weeks\n\n               2. Platelets >20,000/mcL. Subjects may receive platelet transfusions, if clinically\n                  indicated, in accordance with institutional guidelines.\n\n               3. Total bilirubin ?2.0 × institutional upper limit of normal. (Except patients with\n                  known Gilbert's syndrome)\n\n               4. AST(SGOT)/ALT(SGPT) ?3 × institutional upper limit of normal\n\n               5. Creatinine ? 2.0 mg/dL\n\n        Exclusion Criteria:\n\n          -  Participants who have received chemotherapy or radiotherapy within 3 weeks prior to\n             entering the study or those who have not recovered from adverse events due to agents\n             administered more than 3 weeks earlier.\n\n          -  Concurrent systemic steroid or other immunosuppressive therapy.\n\n          -  Participants who are concurrently receiving any other investigational agents, or have\n             received another investigational agent within 3 weeks before enrollment.\n\n          -  Participants who have received prior allogeneic stem cell transplantation, gene\n             therapy, or adoptive T-cell therapy.\n\n          -  Active infections necessitating use of treatment antibiotics/antivirals during the\n             screening period (prophylaxis is acceptable) or evidence of an active communicable\n             infectious disease.\n\n          -  Participants who underwent major surgery within 4 weeks before day 0 of planned CM-CS1\n             T-cell infusion (this does not include placement of vascular access device or tumor\n             biopsies).\n\n          -  Participants with any known history of primary immunodeficiency.\n\n          -  History of allergic reactions or hypersensitivity attributed to Human serum albumin or\n             Plasma-lyte A.\n\n          -  Uncontrolled intercurrent illness or serious uncontrolled medical disorder\n\n          -  Pregnancy or breastfeeding\n\n          -  Known HIV-positive participants are ineligible because the effect of transducing\n             HIV-infected lymphocytes with the chimeric NKG2D- transgene on the disease course is\n             unknown.\n\n          -  Clinically relevant active infection including active hepatitis B or C or any other\n             concurrent disease which in the judgment of the Investigator would make the subject\n             inappropriate for enrollment on this study.\n\n          -  Active autoimmune disease\n\n          -  History of a malignancy other than one of the malignancies in this study with\n             exception of the following circumstances:\n\n               1. Patients with a history of malignancy who have been adequately treated and have\n                  been disease-free for at least 2 years are not excluded.\n\n               2. Patients with adequately treated active non-invasive cancers (such as\n                  non-melanomatous skin cancer or in-situ bladder, cervical and breast cancers) are\n                  not excluded.\n\n          -  Unwillingness to use an effective contraceptive method during the study and at least 4\n             months after administration of CM-CS1 T-cells unless subject is naturally infertile.Xx_NEWLINE_xXParticipants must have received at least one prior therapy for FLXx_NEWLINE_xXFor participants potentially receiving chemotherapy: if the participant has received prior bendamustine, response duration must have been greater than (>) 1 yearXx_NEWLINE_xXParticipants with occult or prior hepatitis B virus (HBV) infection may be included if HBV deoxyribonucleic acid (DNA) is undetectable at screening. These participants must be willing to undergo monthly HBV DNA test until at least 12 months after the last treatment cycleXx_NEWLINE_xXParticipants with newly detected enhancement are eligible, with bevacizumab treatment hoped to prevent symptomsXx_NEWLINE_xXParticipants with stable enhancement/edema are eligible if they require corticosteroids to control symptomsXx_NEWLINE_xXMale participants, even if surgically sterilized (that is, status postvasectomy), who:Xx_NEWLINE_xXParticipants who are willing to refrain from donating blood for at least 90 days after their final dose of MLN4924 and (for male participants) willing to refrain from donating semen for at least 4 months after their final dose of MLN4924.Xx_NEWLINE_xXParticipants with a cardiac pacer whose heart rate is set at a fixed rate and participants on concomitant medication that may limit increase in heart rate in response to hypotension (example, high-dose beta blocker).Xx_NEWLINE_xXDonor-specific antibodies (DSA) will be assessed by the local laboratory 30 days or less prior to transplant using solid phase micro particle technology (by Luminex phenotype panel or Luminex single antigen bead test); the following criteria apply:\r\n* Participants without detectable DSA will be deemed eligible if they meet other entry criteria\r\n* Participants with detectable DSA and a positive flow cytometric crossmatch may undergo de-sensitization per standard of care if they are cytotoxic crossmatch negative; such participants must demonstrate a negative flow cytometric crossmatch by day -9 in order to receive the first dose of study therapy (ATG); participants who do not demonstrate an acceptable response to de-sensitization by day -9 will be considered screen failures and will be terminated from the study\r\n* Participants with a positive cytotoxicity crossmatch will be excludedXx_NEWLINE_xXAll participants must demonstrate a negative QuantiFERON (QFT) assay result within 52 weeks of transplant regardless of purified protein derivative (PPD) status; participants with a positive QFT assay must complete treatment for latent tuberculosis (TB) and have a negative chest x-ray; QFT testing done within 52 weeks before transplant is acceptable as long as there is documentation of the results; prior recipients of a bacillus calmette-guerin (BCG) vaccination are not exemptXx_NEWLINE_xXFor participants with lung cancer, centrally confirmed high expression of a sodium-dependent phosphate transporter (NaPi2b) by immunohistochemistry (IHC) is required (i.e., IHC 2+ or 3+).Xx_NEWLINE_xXParticipants with unknown primary SCCHN presumed to be of head and neck mucosal origin are eligible if they meet all other entry criteriaXx_NEWLINE_xXParticipants must have relapsed or progressed after at least 1 prior course of anti-lymphoma therapyXx_NEWLINE_xXParticipants may not be receiving any other study agents at the time of first treatmentXx_NEWLINE_xXPART I: Participants who smoke tobacco products will not be allowed to participateXx_NEWLINE_xXPART II: The oncology participants must have study approved by oncologist responsible for management of care or follow upXx_NEWLINE_xXPART II: Oncology participants must be unwilling or ineligible for further radiation or chemotherapy at the time of enrollment into studyXx_NEWLINE_xXPART II: Participants must be without evidence of active spinal cord compressionXx_NEWLINE_xXParticipants with multiple basal cell carcinomas, including participants with Gorlin syndrome, with at least 6 clinically evident basal cell carcinomas at the time of randomization, of which 3 measure 5 mm or more in diameter and are considered target lesions. All other lesions are considered to be non-target lesionsXx_NEWLINE_xXParticipants must have histologically documented metastatic or locally inoperable advanced urothelial carcinoma (bladder, urethra, ureter and renal pelvis) (T4b, N2, N3, or M1 disease. NOTE: Aberrant differentiation such as squamous, glandular (adenocarcinoma), and micropapillary are eligible unless the tumor is considered a pure histological variant according to the pathology report. Participants with small cell histology are not eligible.Xx_NEWLINE_xXParticipants receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within 14 days of first receipt of study drug, with the exception of hydroxyurea as defined in protocolXx_NEWLINE_xXParticipants with severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the studyXx_NEWLINE_xXParticipants who refuse to potentially receive blood products and/or have a hypersensitivity to blood productsXx_NEWLINE_xXInclusion criteria:\n\n        Phase 1 Part (dose escalation): Participants with a histologically confirmed solid tumor\n        including tumors of the central nervous system that was recurrent or refractory and for\n        which no further effective standard treatment was available. All participants must had\n        measurable disease. Participants with diffuse pontine glioma were eligible without a biopsy\n        after evidence of progressive disease post radiation therapy.\n\n        Phase 2 Part (safety and activity): Participants with recurrent or refractory high grade\n        glioma or diffuse intrinsic pontine glioma for whom no further effective therapy was\n        available. All participants must had measurable disease. Participants with diffuse pontine\n        glioma were eligible without a biopsy after evidence of progressive disease post radiation\n        therapy. Participants with a grade III or grade IV glioma must had pathologic confirmation\n        either at the time of initial diagnosis or at the time of recurrence.\n\n        Participants aged ?2 years and ?18 years\n\n        Participants met the body surface area (BSA) requirements to be eligible:\n\n          1. Minimal BSA requirements for a particular dose level;\n\n          2. During the Phase 1 part participants must had a BSA <2.1 m² at the time of enrollment\n\n          3. During the Phase 2 part participants with a BSA ?2.1 m² were eligible, however the\n             actual dose of cabazitaxel for these participants were adjusted to a maximum dose\n             calculated with (capped at) the BSA of 2.1 m²\n\n        Performance status by:\n\n          1. Lansky score ?60 (participants ?10 years of age)\n\n          2. Karnofsky score ?60% (participants >10 years of age) Participants who were unable to\n             walk because of paralysis, but who were mobile in a wheelchair, were considered\n             ambulatory for the purpose of assessing the performance score.\n\n        Participants must had adequate liver, renal and marrow function as defined below:\n\n          1. Total bilirubin ?1.0 x the upper limit of normal (ULN) for age\n\n          2. AST (SGOT) and ALT (SGPT) ?2.5 x ULN\n\n          3. Serum creatinine ?1.5 x ULN for age or creatinine clearance ?60 mL/min/1.73 m²\n\n          4. Absolute neutrophil count ?1.0x10^9 /L\n\n          5. Platelets ?75x10^9/L (transfusion independent)\n\n          6. Hemoglobin ?8.0 g/dL (could be transfused)\n\n        Female participants of child-bearing potential must had a negative pregnancy test ?7 days\n        before starting cabazitaxel treatment.\n\n        Male and female participants of reproductive potential must agreed to use adequate\n        contraception prior to study entry, for the duration of study participation and for 6\n        months following the last dose of cabazitaxel.\n\n        Written informed consent/assent prior to any study-specific procedures. Consent must be\n        obtained from the participant and/or parent(s) or legal guardian(s) and the signature of at\n        least one parent or guardian was required. Investigators also obtained assent of\n        participants according to local, regional or national guidelines.\n\n        Participants must have recovered from the acute toxic effects of all prior therapy to ?\n        grade 1 before entering the study.\n\n        Exclusion criteria:\n\n        Prior treatment within the following timeframes:\n\n          1. Systemic anti-cancer treatment within 3 weeks (6 weeks for nitrosourea, mitomycin and\n             monoclonal antibodies including bevacizumab)\n\n          2. Surgery or smaller field radiation therapy within 4 weeks\n\n          3. Treatment with an investigational agent within 4 weeks or within 5 half-lives of the\n             agent, whichever was longer Craniospinal or other large field radiation therapy\n             (defined as >25% of bone marrow irradiated) within 6 months prior to the first dose.\n\n        Prior systemic radioisotope therapy (this did not include diagnostic imaging or\n        radioimmunoconjugates lacking myelosuppressive properties) or total body irradiation.\n\n        Prior bone marrow or stem cell transplant\n\n        Participants with any clinically significant illness that, in the investigator's opinion,\n        could not be adequately controlled with appropriate therapy, would compromise a\n        participant's ability to tolerate cabazitaxel or result in inability to assess toxicity.\n        This included, but was not limited to uncontrolled intercurrent illness including ongoing\n        or active infection, cardiac disease, renal impairment, planned surgery or psychiatric\n        illness/social situations that would limit compliance with study requirements.\n\n        Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency-syndrome\n        (AIDS)-related disease Known history of hepatitis C or known active hepatitis B infection.\n        Pregnant or breast feeding women Treatment with strong inhibitors or strong inducers of\n        CYP3A4 or enzyme inducing anti-epileptic drugs (EIAED) within 14 days prior to first dose\n        of cabazitaxel and for the duration of study. Non-EIAEDs were permitted.\n\n        Known history of hypersensitivity to taxanes or polysorbate 80 or G-CSF. Participation in\n        another interventional clinical trial and/or concurrent treatment with any investigational\n        drug.\n\n        Participants not able to comply with scheduled visits, treatment plans, laboratory tests,\n        and other study procedures.\n\n        The above information was not intended to contain all considerations relevant to a\n        participant's potential participation in a clinical trial.Xx_NEWLINE_xXParticipants with GBM can be enrolled 2 weeks after last treatmentXx_NEWLINE_xXParticipants taking medications known to have a significant risk of causing QTc prolongation and Torsades de PointesXx_NEWLINE_xXParticipants must have completed one of the following clinical study protocols and have been determined to have clinical benefit on treatment at the conclusion of required study analyses as defined in the respective parent protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296)Xx_NEWLINE_xXParticipants who developed disease progression/ requiring other anti-tumor therapy while in the parent protocolXx_NEWLINE_xXParticipants who have stopped study drug dosing for greater than 56 daysXx_NEWLINE_xXParticipants continuing to require dose modificationsXx_NEWLINE_xXParticipants with worsening adverse eventsXx_NEWLINE_xXParticipants with unrelated adverse events, medical illnesses, or changes in performance status that, per investigator discretion, put them at high risk for continuing participation in the clinical studyXx_NEWLINE_xXIf the participant has received prior bendamustine, response duration must have been greater than (>) 1 year (for participants who have relapse disease after a prior regimen)Xx_NEWLINE_xXParticipants with HR+/HER2- breast cancer for whom endocrine-based therapy is considered an appropriate option per local clinical guidelines (i.e. participants should not be considered eligible for endocrine-based treatment)Xx_NEWLINE_xXParticipants with measurable disease per RECIST v1.1 Additional Inclusion Criteria for Participants Who Backfill Cleared Cohorts of Phase 1a and Phase 1b:Xx_NEWLINE_xXBackfill cohort enrollment may be limited to participants whose tumors have PD-L1 (programmed death-ligand 1) and/or different levels of cluster of differentiation 8 (CD8) expression, as defined by the SponsorXx_NEWLINE_xXParticipants must have relapsed or refractory cancer.Xx_NEWLINE_xXFor the fifth cohort during Part 2 Cohort Expansion, participants with solid tumors must have evidence of BCL-2 expression.Xx_NEWLINE_xXParticipants who have received any of the following within the listed time frame, prior to the first dose of study drugXx_NEWLINE_xXParticipants who are less than 6 weeks post-131 I-metaiodobenzylguanidine (mIBG) therapy.Xx_NEWLINE_xXParticipants who have received the following within 7 days prior to the first dose of study drug:Xx_NEWLINE_xXParticipants with malabsorption syndrome or any other condition that precludes enteral administration.Xx_NEWLINE_xXParticipants must have histological or cytological confirmed melanoma that is metastatic or unresectable and clearly progressiveXx_NEWLINE_xXParticipants who have undergone hysterectomyXx_NEWLINE_xXParticipants with carcinoma of the cervical stumpXx_NEWLINE_xXSerious uncontrolled concomitant disease that would contraindicate the use of any of the investigational drugs used in this study or would put the participants at high risk for treatment-related complicationsXx_NEWLINE_xXParticipants may not be receiving any other study agents or other types of cancer therapy while on this protocol except for disease progressionXx_NEWLINE_xXPart II: Postmenopausal women with locally ABC or MBC whose disease has progressed during or after treatment with an AI. Participants who discontinued the AI for toxicity rather than completion of regimen or for disease progression are not eligibleXx_NEWLINE_xXParticipants requiring anti-hyperglycemic therapyXx_NEWLINE_xXFor participants in the second NSCLC cohort expansion, not more than two prior regimens in the metastatic settingXx_NEWLINE_xXEstimated life expectancy that will permit the participants to complete 8 weeks of treatment.Xx_NEWLINE_xXPart B Expansion Cohort 6 (LY2875358 plus trametinib in participants with uveal melanoma with liver metastasis): Contra-indications for trametinibXx_NEWLINE_xXPart E - Diagnosed with cholangiocarcinoma, either intrahepatic or extrahepatic, that is unresectable, recurrent, or metastatic. Participants must not have received prior systemic front line therapy for metastatic or resectable disease (i.e. participants may have received adjuvant gemcitabine but have not yet received gemcitabine/cisplatin for recurrent metastatic disease). Participants must be, in the opinion of the investigator, an appropriate candidate for experimental therapy. Participants should be evaluated for the need to undergo biliary drainage by stent placement prior to study participation. Participants should have adequate biliary drainage with no unresolved biliary obstruction.Xx_NEWLINE_xXParticipants who received prior chemotherapy that included cisplatin, carboplatin, or oxaliplatinXx_NEWLINE_xXParticipants who are clearly disease-free after transurethral resection of bladder tumor (TURBT)Xx_NEWLINE_xXParticipants in whom the required program of oral (PO) and IV fluid hydration is contraindicatedXx_NEWLINE_xXParticipants who have squamous histology.Xx_NEWLINE_xXParticipants who have received prior Pemetrexed treatment.Xx_NEWLINE_xXParticipants must be < 31 years of age at the time of study entry\r\n* Participants currently on therapy at St. Jude, or within 3 years of completing therapy at St. Jude must be =< 24 years of age\r\n* Other participants must be =< 21 years of ageXx_NEWLINE_xXParticipants who have relapsed while on sorafenib therapyXx_NEWLINE_xXParticipants must not receive concomitant medications known to inhibit platelet function or known to selectively inhibit cyclooxygenase-2 (COX-2) activity (i.e., all antipyretic and anti-inflammatory medications except acetaminophen)Xx_NEWLINE_xXImmunocompromised participants with primary or secondary immunodeficiencyXx_NEWLINE_xXPatient participants must also be a current smoker, defined as anyone who responds “every day” or “some days” to the question: “Do you smoke cigarettes every day, some days, or not at all?” (Behavioral Risk Factor Surveillance System [BRFSS])Xx_NEWLINE_xXHearing loss that would preclude participating in interventions; adequate hearing to participate will be determined via: (1) response of “no” to the question [“Do you have a hearing problem now?”]; participants with hearing aids will be allowed to enroll as long as their hearing is adequate to hear the sounds on the study devices; if necessary, potential study participants will receive a brief test trial with the RESPeRATE device; if they indicate inability to hear the guiding tones, they will not be enrolled in the studyXx_NEWLINE_xXCORTISOL EXCLUSION: Participants with endocrine disorders (e.g., diabetes and thyroid disorders) or on steroid-based medications are excluded from the cortisol portion of the study (with the exception of topical hydrocortisone that is permitted)Xx_NEWLINE_xXParticipants with bilateral synchronous or metachronous disease (DCIS, LCIS, ADH, ALH) are eligibleXx_NEWLINE_xXParticipants may not be receiving any other study agents within 21 days prior to entry on the studyXx_NEWLINE_xXParticipants with evidence of active thromboembolic disease or a history of thromboembolism within the preceding 6 months (excluding thrombosis of a central line)Xx_NEWLINE_xXPatient participants will have an appointment in the Thoracic Oncology Program at the Brigham and Women’s HospitalXx_NEWLINE_xXInclusion Criteria:\n\n        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please\n        visit www.BMSStudyConnect.com\n\n          -  Kidney tumor has been completely resected 4 to 12 weeks prior to randomization\n\n          -  Pathologic TNM staging meeting one of the following: pT2a, G3 or G4, N0 M0; pT2b, G\n             any, N0 M0; pT3, G any, N0 M0; pT4, G any, N0 M0; pT any, G any, N1 M0\n\n          -  Post-nephrectomy tumor shows RCC with a predominantly clear cell histology, including\n             participants with sarcomatoid features\n\n        Exclusion Criteria:\n\n          -  Participants with an active known or suspected autoimmune disease\n\n          -  Known history of positive test for human immunodeficiency virus (HIV) or known\n             acquired immunodeficiency syndrome (AIDS)\n\n          -  Any severe or serious, acute or chronic medical or psychiatric condition, or\n             laboratory abnormality that may increase the risk associated with study participation\n\n          -  Participants with a condition requiring systemic treatment with corticosteroids\n\n        Other protocol defined inclusion/exclusion criteria could applyXx_NEWLINE_xXGlycosylated hemoglobin is <=6.5% hyperglycemic participants permitted if glucose is well controlled by hypoglycemic medication).Xx_NEWLINE_xXParticipants with certain cardiovascular conditions are excluded.Xx_NEWLINE_xXParticipants with another malignancy within 2 years of study start. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection and are considered disease-free at the time of study entry.Xx_NEWLINE_xXParticipants with accessible disease must be willing to undergo a research biopsy before beginning crossover therapyXx_NEWLINE_xXHas a pathologically proven new diagnosis of oropharyngeal p16 positive, oropharyngeal p16 negative, or larynx/hypopharynx/oral cavity (independent of p16) squamous cell carcinoma. Participants with oral cavity tumors need to have unresectable disease. Participants with multiple synchronous tumors are not eligible for the study.Xx_NEWLINE_xXParticipants with prior exposure to a pyrrolobenzodiazepine or indolinobenzodiazepine based drug. Additional Exclusion Criteria for the SC-006 and ABBV-181 Combination Treatment Regimen:Xx_NEWLINE_xXParticipants with any of the following cardiovascular conditions are excluded:Xx_NEWLINE_xXFor participants in all combination arms (Cohorts A-E), use or consumption of any of the following substances:Xx_NEWLINE_xXAdditionally, for participants in the ibrutinib combination arm (Cohort E), use or consumption of any of the following substances:Xx_NEWLINE_xXParticipants with another malignancy within 2 years of study start. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection and are considered disease-free at the time of study entry.Xx_NEWLINE_xXParticipants with histologically confirmed non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease. Participants must have one of the following subtypes of nccRCC: papillary, chromophobe, collecting duct carcinoma (CDC), renal medullary carcinoma (RMC), or unclassified.Xx_NEWLINE_xXPregnant participants will not be entered on this studyXx_NEWLINE_xXParticipants must be candidates for RP and considered surgically resectable by urologic evaluationXx_NEWLINE_xXAre unable to walk or to complete the 6-minute walk test\r\n* According to our current standard of care, those participants will be referred to physical therapy for evaluation and treatment and will be excluded from the study as unsupervised exercise would not be safeXx_NEWLINE_xXALL PARTICIPANTSXx_NEWLINE_xXParticipants must live within 35 miles of the University of Washington, Seattle, WA to receive the in-person version of the interventionXx_NEWLINE_xXMust agree to take progestin agents (i.e., oral agents or MIRENA intrauterine device [IUD] which are accepted treatments for low grade uterine malignancies to control their disease while the intervention is ongoing)\r\n* Note: potential participants WILL NOT be asked to delay surgery to participate in this pilot studyXx_NEWLINE_xXParticipants who develop treatment complications or disease recurrence after being enrolled in the study may continue to participate if they are able to do soXx_NEWLINE_xXOther conditions may exclude participants from the study (e.g. intractable nausea/emesis, allergic reaction to shake, patient decides not to have surgery, any medical condition that prevents patient from having surgery)Xx_NEWLINE_xXParticipants must self-identify as female; thus only women with breast cancer will be invited to participate in this studyXx_NEWLINE_xXParticipants must self-identify as Hispanic/LatinaXx_NEWLINE_xXParticipants must be willing and able to attend four 4-hour in-person sessionsXx_NEWLINE_xXParticipants must consume < 5 servings of fruits and vegetables per day and/or engages in < 150 weekly minutes of moderate to vigorous physical activityXx_NEWLINE_xXParticipants with untreated depression or anxiety as assessed by self-report and review of medical historyXx_NEWLINE_xXAs per self-report participants with pacemakers, intracranial electrodes, implanted defibrillators or any other prosthesisXx_NEWLINE_xXNote: additional contraindications for individual nicotine replacement therapies and drugs (bupropion, or varenicline) are embedded within each study component to further screen participants when smoking cessation options are being consideredXx_NEWLINE_xXParticipants must have documentation of a plexiform neurofibroma (PN), based on either clinical exam or imagingXx_NEWLINE_xXParticipants have not received intravenous or oral chemotherapy on the same day and prior to scheduled exercise sessionXx_NEWLINE_xXParticipants have received intravenous or oral chemotherapy on the same day and prior to scheduled exercise sessionXx_NEWLINE_xXCAREGIVER PARTICIPANTS:Xx_NEWLINE_xXPATIENT PARTICIPANTS:Xx_NEWLINE_xXInsurance information will be reviewed to ensure geriatric referral is covered for all potential participantsXx_NEWLINE_xXParticipants may be enrolled on other treatment-based clinical trials but may not be enrolled on any other weight loss trialsXx_NEWLINE_xXSUBJECT: History of medical non-compliance or difficulty completing previous required study tasks or visits that suggest the participants would not follow through with the home study procedures.Xx_NEWLINE_xXParticipants must be oriented to person, place, and timeXx_NEWLINE_xXParticipants must have a body mass index (BMI) of 24.45 or higher as assessed in the medical recordXx_NEWLINE_xXPresence or recent history of other concurrent cancers, with the following exceptions: \r\n* Participants with completely treated basal or squamous skin cancers can be included in the study if their physicians deem that they are medically stable\r\n* Participants with completely treated in situ carcinoma of the breast or cervix may be included in the study if they have not had chemotherapy within the past month and their physicians deem that they are medically stable\r\n* Participants with pre-cancerous lesions in the colon can be included in the study if they have not had chemotherapy within the past month and their physicians deem that they are medically stableXx_NEWLINE_xXParticipants are also required to have access to internet; either through their cell phone, home, or secondary locationXx_NEWLINE_xXResearch participants having any uncontrolled illness including ongoing or active infection; research participants with known active hepatitis B or C infection; research participants who are human immunodeficiency virus (HIV) seropositive based on testing performed within 4 weeks of enrollment; research participants with any signs or symptoms of active infection, positive blood cultures, or radiological evidence of infectionsXx_NEWLINE_xXParticipants enrolled in a radiation de-intensification protocolXx_NEWLINE_xXStage I participants are ineligibleXx_NEWLINE_xXParticipants who are receiving any other investigational agents; participants who are receiving standard of care induction therapy on a clinical trial may be eligible after discussion with the overall principal investigatorXx_NEWLINE_xXParticipants receiving any medications or antibiotics to treat Clostridium difficile infection prior to the initiation of the study will be ineligible for this studyXx_NEWLINE_xXIlliterate participantsXx_NEWLINE_xXDeaf participantsXx_NEWLINE_xXCAREGIVER PARTICIPANTS:Xx_NEWLINE_xXPATIENT PARTICIPANTS:Xx_NEWLINE_xXParticipants with a second cancer diagnosis at the time of enrollment will be excludedXx_NEWLINE_xXResearch participants who have no computer and internet access and/or do not use a computer even if one is present in the householdXx_NEWLINE_xXParticipants must not be actively receiving physical therapy in a relevant area (e.g. leg strengthening, balance and gait training), at time of enrollment, or participating in intensive (30 min per day) aerobic program three times per weekXx_NEWLINE_xXParticipants may be on anti-depressants and/or anxiolytics as long as the dosing has remained stable over the preceding 4 weeksXx_NEWLINE_xXWomen who self-report to be pregnant\r\n* As this is an observational study, we will not be performing a pregnancy test, participants will be asked if they are or are not pregnantXx_NEWLINE_xXParent- or self-reported (for participants 18+ years old) physician diagnosis of sarcomaXx_NEWLINE_xXParticipants with acute, active gastrointestinal infection (e.g., typhlitis, diverticulitis, appendicitis)Xx_NEWLINE_xXParticipants who develop treatment complications or disease recurrence after being enrolled in the study may continue to participate if they are able to do soXx_NEWLINE_xXThere will be no restrictions on time since diagnosis for participantsXx_NEWLINE_xXPATIENT: Participants must be under the care of an oncologist (who does not practice as a palliative care physician for that patient), but their current plan may or may not include chemotherapy or other forms of tumor-directed therapiesXx_NEWLINE_xXParticipants with a diagnosis of diabetes, unless they are able to provide a letter from a physician who will continue to monitor the participant during the research studyXx_NEWLINE_xXRCT: Participants will include ovarian cancer patients who are considered by their primary oncologist to be candidates for IP/IV chemotherapyXx_NEWLINE_xXRCT: Participants will come from urban and rural regions of the countryXx_NEWLINE_xXNot willing or able to follow procedures specified by the study and/or instructions of the researcher; prior to randomization, participants must provide a signed authorization and medical clearance from their personal physician or our nurse practitionerXx_NEWLINE_xXParticipants are able to give consentXx_NEWLINE_xXParticipants are eligible if they are able to give consentXx_NEWLINE_xXNo prior line of systemic therapy (includes participants who are sorafenib-naïve)Xx_NEWLINE_xXFor expansion stage: age at study entry to be >= 6 months (>=6 years if suspension is not available) to < 30 years. Participants >= 6 months to < 1 year of age may not be enrolled until >= 6 participants >= 1 year to < 18 years of age have received at least one cycle of therapy with suspension in the dose-escalation phase and until safety and pharmacokinetic assessment of these participants have been conducted.Xx_NEWLINE_xXPrior to Segment B enrollment, participants on combination anti-retroviral therapy (cART) will be required to have a minimum CD4 count of >= 200 and participants not on cART will be required to have a minimum CD4 count of >= 350 to be eligible for the study; participants not currently on cART who have a CD4 count >= 200 and who agree to start cART immediately will be eligible for participation; laboratory data should be obtained within 16 weeks prior to Segment B enrollmentXx_NEWLINE_xXParticipants must have organ and marrow function within the following parameters within 16 weeks before Segment B enrollment:Xx_NEWLINE_xXConcurrent malignancy. Participants with carcinoma in situ of any origin and participants with prior malignancies in remission may be eligible with sponsor approval.Xx_NEWLINE_xXRight handed (quantitative EEG [qEEG] database comparison is specific to handedness; by requiring all participants be right handed, we will be consistent across EEG analysis)Xx_NEWLINE_xXPILOT PARTICIPANTS AND HEALTHY CONTROLS ONLY: Women with no history of cancerXx_NEWLINE_xXPILOT PARTICIPANTS AND HEALTHY CONTROLS ONLY: No history of prior chemotherapyXx_NEWLINE_xXPILOT PARTICIPANTS AND HEALTHY CONTROLS ONLY: Willing to come to MDACC and HIAE for the assessment sessionXx_NEWLINE_xXPILOT PARTICIPANTS AND HEALTHY CONTROLS ONLY: Right handedXx_NEWLINE_xXPILOT PARTICIPANTS AND HEALTHY CONTROLS ONLY: Mini-Mental State Examination score of 23 or belowXx_NEWLINE_xXPILOT PARTICIPANTS AND HEALTHY CONTROLS ONLY: Undergoing chemotherapyXx_NEWLINE_xXPILOT PARTICIPANTS AND HEALTHY CONTROLS ONLY: Primary caretaker of a cancer patientXx_NEWLINE_xXPILOT PARTICIPANTS AND HEALTHY CONTROLS ONLY: Patients who have regularly practiced meditation (greater than once per week) in the year prior to study enrollmentXx_NEWLINE_xXPhase 2: The same four groups of stakeholders from Phase 1 will become involved as research collaborators/consultants for Phase 2 of the study and will not be considered study participants (i.e., will not be registered with Quality Assurance Office for Clinical Trials [QACT])Xx_NEWLINE_xXParticipants may have had prior breast surgery and/or chemotherapyXx_NEWLINE_xXParticipants who are receiving any other investigational agents that might interact with study medication or influence the measurement of study outcomesXx_NEWLINE_xXParticipants using other contraindicated medications (thioridazine, yohimbine)Xx_NEWLINE_xXParticipants with serious or unstable illness, as determined by study physicians and clinicians, may be deemed unfit to participateXx_NEWLINE_xXParticipants who have recently started or changed doses of psychoactive medication which might affect psychological outcome measures in the judgment of the study PI; allowable time frames are medication-specific and will be determined by the study PIXx_NEWLINE_xXParticipants may not enroll in this study if they are receiving a study agent at the time of enrollment; a participant who chooses to enroll in a medication trial AFTER initial enrollment in our study will be allowed to stay in the study at the discretion of the study PIXx_NEWLINE_xXParticipants must be at least 100 days after HCTXx_NEWLINE_xXFor local participants undergoing bioelectrical impedance measurements: pregnancy, metal implants, and defibrillator implantsXx_NEWLINE_xXPATIENT PARTICIPANTSXx_NEWLINE_xXParticipants will be diagnosed with breast cancer; the participants will be scheduled for a lumpectomy or a mastectomy at UH GMC Seidman Cancer CenterXx_NEWLINE_xXPatients included in the study will have a hematologic malignancy (any stage or grade) for which they are undergoing preparation for allogeneic HSCT; participants in the study will be restricted to those undergoing HSCT under reduced-intensity protocols 9924 and 9907Xx_NEWLINE_xXCHILD PARTICIPANTS:Xx_NEWLINE_xXADULT PARTICIPANTS:Xx_NEWLINE_xXParticipants must have been in their spousal relationship for at least the past 1 yearXx_NEWLINE_xXIf participants are unable to access a computer they will be excludedXx_NEWLINE_xXPATIENT PARTICIPANTS:Xx_NEWLINE_xXParticipants must be at least 100 days after HCTXx_NEWLINE_xXParticipants must be diagnosed with cancerXx_NEWLINE_xXParticipants must have been informed of their eligibility for a specific phase II or III therapeutic clinical trial open for enrollment at the participating National Cancer Institute (NCI) Community Oncology Research Program (NCORP) siteXx_NEWLINE_xXParticipants must not have documented or observable visual, auditory, psychiatric, or neurological disorders that would interfere with study participation (e.g., blindness, deafness, psychosis, or dementia)Xx_NEWLINE_xXParticipants must not be eligible only for phase I trialXx_NEWLINE_xXHas received treatment for a recurrent or 2nd cancer that required > surgical excision in the past 2 years or did not have a hematologic malignancy or myelodysplasia diagnosis or did not receive a first transplant between 2-10 years before approach for the study; (these participants will be ineligible for randomization, but will have intervention site access if they complete baseline PRO assessment)Xx_NEWLINE_xXParticipants taking illegal drugsXx_NEWLINE_xXParticipants answering ‘Yes’ to one or more of the questions on the physical activity readiness questionnaire (PAR-Q) will need to obtain approval from a physician before they can participate in the interventionXx_NEWLINE_xXAll at-risk relatives of the participants found to have LSXx_NEWLINE_xXFirst-degree relatives (parents, siblings and adult children >= 25 years of age) of the CRC participants who do not have LSXx_NEWLINE_xXParticipants who have received endocrine therapy within 1 year prior to screening breast MRIXx_NEWLINE_xXParticipants who had a percutaneous breast biopsy (to include stereotactic, tomosynthesis, or ultrasound guided) that revealed ADH.Xx_NEWLINE_xXParticipants will be undergoing surgical excision to remove the ADH.Xx_NEWLINE_xXParticipants with a core biopsy diagnosis of atypia with associated malignancy (in the same quadrant) will be excluded.Xx_NEWLINE_xXParticipants who have a known severe allergic response to one or more allergens, as defined by anaphylaxis.Xx_NEWLINE_xXParticipants with persistent asthma as defined by the National Heart, Lung, and Blood Institute.Xx_NEWLINE_xXParticipants who are breastfeeding are excluded because there is an unknown but potential risk for adverse events in nursing infants secondary to contrast administration in the mother.Xx_NEWLINE_xXParticipants who have a known severe allergic response to one or more allergens, defined as anaphylaxisXx_NEWLINE_xXParticipants with persistent asthma as defined by the National Heart, Lung, and Blood InstituteXx_NEWLINE_xXParticipants who are pregnantXx_NEWLINE_xXParticipants who are breastfeeding are excludedXx_NEWLINE_xXParticipants who have a pacemaker, pacer wires, implantable defibrillator, or implanted monitoring deviceXx_NEWLINE_xXParticipants with intracranial clips, metal implants or external clips within 10 mm of the headXx_NEWLINE_xXParticipants who have had a metal injury to the eyeXx_NEWLINE_xXParticipants from Franklin County or from Appalachia Ohio (depending on program location)Xx_NEWLINE_xXStudy participants are expected to be generally healthy and non-symptomatic for cervical diseaseXx_NEWLINE_xXPhase II: Participants must be asymptomatic, not at increased risk due to family history or personal high risk syndromesXx_NEWLINE_xXParticipants in other ongoing clinical trials are eligible for this studyXx_NEWLINE_xXParticipants who only have a single HSIL lesion that is likely to be removed entirely with the initial screening biopsyXx_NEWLINE_xXParticipants may not be concurrently receiving any other study agentsXx_NEWLINE_xXParticipants who cannot have their warfarin, Lovenox, Plavix, or other comparable medications held for percutaneous or transjugular liver biopsy and surgery if so indicatedXx_NEWLINE_xXParticipants must be pre- or post-menopausalXx_NEWLINE_xXParticipants must have a diagnosis of DCIS made by core needle biopsyXx_NEWLINE_xXParticipants must be human leukocyte antigen (HLA)-A2 positiveXx_NEWLINE_xXWHITE, NON-HISPANIC: Participants reporting sun-sensitive phenotypes.Xx_NEWLINE_xXWHITE, NON-HISPANIC: Participants having had a skin examination within the past year.Xx_NEWLINE_xXH/L: Participants having had a skin examination within the past year.Xx_NEWLINE_xXH/L: Participants with a personal history of melanoma and/or more personal history of more than one SCC and/or BCC.Xx_NEWLINE_xXParticipants must not have evidence of active/recurrent malignant disease for a minimum of 6 months.Xx_NEWLINE_xXParticipants must have endoscopically accessible distal colon and/or rectal mucosa (i.e. participants must have at least part of the descending/sigmoid colon and/or rectum intact).Xx_NEWLINE_xXParticipants must consent to two standard of care lower gastro-intestinal GI endoscopy (flexible sigmoidoscopy or colonoscopy) with biopsies that will be 12 months (+/-21 days) apart.Xx_NEWLINE_xXParticipants that are unable to provide a mailing address within the mainland United States or Puerto Rico, or are unable to provide a mailing address (i.e., do not have one), will be excluded from participating in the studyXx_NEWLINE_xXParticipants will be excluded from participation in future stagesXx_NEWLINE_xXEligible participants for focus groups include current or former smokers who are between 55-80 with a 30 pack­-year historyXx_NEWLINE_xXPatients with major psychiatric illnesses who may not be able to fully participate in the brief telephone counseling (i.e. participants with schizophrenia)Xx_NEWLINE_xXParticipants must have a smoking history of 20 pack-years or greaterXx_NEWLINE_xXParticipants must have the ability to safely undergo bronchoscopy in the judgment of the investigatorsXx_NEWLINE_xXParticipants must not have used any tobacco product in the past yearXx_NEWLINE_xXParticipants must not have been treated with iloprost at any time; Note: participants on the placebo arm of previous iloprost trials are eligible, but participants on the placebo arm of cohort A of this study may not be enrolled in cohort BXx_NEWLINE_xXParticipants must not have used any other investigation agent within the last six monthsXx_NEWLINE_xXParticipants must not have received either chemotherapy or radiotherapy within the previous 6 months; Note: participants receiving long-term adjuvant hormonal therapy (such as tamoxifen or aromatase inhibitors for breast cancer) are allowedXx_NEWLINE_xXAll participants must also report an intention to quit smoking within the next month and a desire to receive behavioral and medication treatment.Xx_NEWLINE_xXParticipants must have a dental examination within 6 months of enrolling in the studyXx_NEWLINE_xXOnly participants found to express high levels (immunohistochemistry [IHC] score 3 and above) of gamma-OHPdG (gamma-OHPdG-high hepatocellular carcinoma [HCC]) in baseline liver biopsy will be enrolled to receive Polyphenon E treatmentXx_NEWLINE_xXParticipant has confirmed HCC by CT/MRI; participants who have previously had HCC but have been treated and have been recurrence free for 5 years are eligibleXx_NEWLINE_xXParticipants take supplements or foods that are labelled as containing green tea for 8 weeks before start of treatmentXx_NEWLINE_xXParticipants with a calcium intake >= 700 mg/day measuring with 24 hour dietary recallsXx_NEWLINE_xXParticipants with a calcium intake < 2000 mg/day measuring with 24 hour dietary recallsXx_NEWLINE_xXParticipants with known genotype for Thr1482Ile polymorphism in TRPM7Xx_NEWLINE_xXParticipants who have had any immunomodulatory treatment in the past 3 months will be excludedXx_NEWLINE_xXParticipants with oral leukoplakia or erythroplakia with mild, moderate, or severe histologic dysplasia, or hyperplasia not associated with mechanical factors such as ill-fitted denturesXx_NEWLINE_xXThe number of participants from the same street address will be limited to 1Xx_NEWLINE_xXParticipants who exhibit severe psychological distress that prohibits them from participating in our intervention or long-term research programXx_NEWLINE_xXParticipants must be willing to forego foods, beverages and supplements containing pomegranate for the duration of the studyXx_NEWLINE_xXParticipants cannot be taking 5-alpha-reductase inhibitors while on study or within 6 months of the baseline study visitXx_NEWLINE_xXParticipants may not be taking carbamazepine (tegretol)Xx_NEWLINE_xXParticipants must not have evidence of active/recurrent malignant disease for 6 monthsXx_NEWLINE_xXParticipants must have endoscopically accessible distal colon and/or rectal mucosa (i.e. participants must have at least part of the descending/sigmoid colon and/or rectum intact)Xx_NEWLINE_xXParticipants must consent to refrain from using aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase (COX)-inhibitors for the duration of the trialXx_NEWLINE_xXLGBT SUB-STUDY: Participants who complete the screener, are willing to participate in a longitudinal study for one year, and who self-identify as lesbian, gay, bisexual or transgender will be eligible to participate in the cohort studyXx_NEWLINE_xXParticipants may not be using metformin, cimetidine (Tagamet), furosemide (Lasix), nifedipine (Cardizem), or any other drug contraindicated for use with metforminXx_NEWLINE_xXParticipants planning to undergo elective radiologic studies involving intravascular administration of iodinated contrast materialsXx_NEWLINE_xXParticipants in the control group must be disease free, never-smokers and otherwise healthyXx_NEWLINE_xXParticipants with hyperplasia, in absence of dysplasia or carcinoma in situ, will be excludedXx_NEWLINE_xXParticipants with acute intercurrent illness or those who had surgery within the preceding 4 weeks unless they have fully recoveredXx_NEWLINE_xXParticipants who were taking EGFR tyrosine kinase inhibitors within 3 months of study entryXx_NEWLINE_xXAll participants must be nonsmokers at the time of the study (i.e., have not used any tobacco product); have not smoked an entire cigarette, cigar, or hookah session beforeXx_NEWLINE_xXAll participants must score 3 out of 5 or above on the place attachment scale (i.e., measuring adolescents’ feeling of attachment to their after-school program)Xx_NEWLINE_xXPotential participants must be underactive (defined as participating in moderate or vigorous PA two days per week or less for 30 minutes or less each day)Xx_NEWLINE_xXParticipants must have access to a telephoneXx_NEWLINE_xXParticipants who are already enrolled in, or planning to enroll in another research study where weight loss is targeted will be excludedXx_NEWLINE_xXParticipants who plan to relocate outside of their provider’s service area or who plan to leave their primary care clinic in the next two years will be excludedXx_NEWLINE_xXDiagnosis of nonalcoholic steatohepatitis (NASH) and a NAFLD (nonalcoholic fatty liver disease) activity score (NAS) >= 5; NOTES and EXCEPTIONS: NAS is based on findings from a liver biopsy; participants with NAS of =< 2 are eligible for enrollment; participants with NAS of 3-4 must be discussed with the principal investigator and Division of Cancer Prevention (DCP) before enrollment to consider other risk factors (i.e., obesity, alcohol intake); participants with a prior diagnosis of NASH and no available NAS must be discussed with the principal investigator and DCP before enrollment to considered risk factors (i.e., obesity, alcohol intake)Xx_NEWLINE_xXParticipants who have previously enrolled and received study drugs on arm 1 of this study cannot re-enroll onto arm 1 after being removed from this study, but if they were removed from arm 1 for disease progression, they are eligible to re-register onto this study in order to enroll onto arm 2 of this study if they otherwise meet all of the eligibility criteria for this study; all participants who received an investigational product on a clinical trial, including arm 1 of this study, must wait 21 days prior to course 1 day 1 (C1D1) of this studyXx_NEWLINE_xXParticipants must have a body mass index (BMI) >= 25, defined as (weight in kilograms/[height in meters]^2)Xx_NEWLINE_xXParticipants with known genotype for rs174535 in fatty acid desaturase 1 (FADS1)Xx_NEWLINE_xXParticipants who were eligible for the main trial with the exception of not meeting BMI criteria for obesityXx_NEWLINE_xXParticipants must have an echocardiogram within normal limits within the last yearXx_NEWLINE_xXParticipants must not have pneumonia or acute bronchitis for at least 2 weeks prior to enrollmentXx_NEWLINE_xXParticipants must be able and willing to undergo a bronchoscopy before and after treatment for 6 monthsXx_NEWLINE_xXPARTICIPANTS: Self-identified as Filipino, Hmong, or Korean AmericansXx_NEWLINE_xXPARTICIPANTS: live in relevant area and intend to stay there for at least 12 monthsXx_NEWLINE_xXPARTICIPANTS: Are willing to participate in a study about health behaviors involving nutrition or CRC screeningXx_NEWLINE_xXParticipants must agree to discontinue all vitamin supplements while taking study medication and for thirty days past the last dose of study medicationXx_NEWLINE_xXParticipants may not be taking medications that might interact with 9cUAB30Xx_NEWLINE_xXParticipants may not be taking lipid lowering agentsXx_NEWLINE_xXParticipants may not receive any other investigational agents within 30 days of enrollment nor during study participationXx_NEWLINE_xXParticipants must be candidates for neoadjuvant therapy (NAT) upfrontXx_NEWLINE_xXParticipants with a known BRCA 1 or 2 mutationXx_NEWLINE_xXParticipants with a known Li-Fraumeni or Cowden’s diseaseXx_NEWLINE_xXParticipants with prior mantle radiationXx_NEWLINE_xXParticipants who are pregnantXx_NEWLINE_xXParticipants who are already enrolled in a conflicting investigational trialXx_NEWLINE_xXParticipants with known active collagen vascular diseaseXx_NEWLINE_xXParticipants who exceed the weight limit for the operative surgical table, 350 lbs or who will not fit into the 60 cm diameter bore of the MRI scannerXx_NEWLINE_xXParticipants must have a pre-operative standard mammogram with or without ultrasound; these may be performed at outside institutionsXx_NEWLINE_xXParticipants with known Li-Fraumeni or Cowden’s diseaseXx_NEWLINE_xXParticipants with prior mantle radiationXx_NEWLINE_xXParticipants who are pregnantXx_NEWLINE_xXParticipants who enroll in a preoperative therapy trial or who have been treated with neoadjuvant chemotherapyXx_NEWLINE_xXParticipants with known active collagen vascular diseaseXx_NEWLINE_xXParticipants with prior history of ipsilateral breast carcinomaXx_NEWLINE_xXFemale participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiationXx_NEWLINE_xXParticipants will be drawn from the pool of patients who have suspicious lesions identified on CT and who are already scheduled for a lung biopsy procedure with Dr. Hennemeyer or one of his colleaguesXx_NEWLINE_xXParticipants who have already received anti-VEGF or investigational anti-angiogenic therapy for glioblastomaXx_NEWLINE_xXParticipants must present with a gadolinium-enhancing brain lesion (or lesions) that are thought by the neuroradiologist and the neurosurgeon to be consistent with high-grade glioma; these may be newly diagnosed lesions or recurrent tumorsXx_NEWLINE_xXParticipants/volunteers with a pacemaker, aneurysm clip, or any other condition that would warrant avoidance of a strong magnetic fieldXx_NEWLINE_xXParticipants/volunteers from the vulnerable population, as defined by 45 Code of Federal Regulations (CFR) 46Xx_NEWLINE_xXParticipants at higher risk due to age, frailty, or the emergent nature of their conditionXx_NEWLINE_xXParticipants who have a known severe allergic response to one or more allergensXx_NEWLINE_xXParticipants with persistent asthma as defined by the National Heart, Lung, and Blood InstituteXx_NEWLINE_xXParticipants who are pregnantXx_NEWLINE_xXParticipants who are breastfeeding are excludedXx_NEWLINE_xXParticipants with actively treated thyroid disease who still have a portion or all of their thyroid glandXx_NEWLINE_xXParticipants who are taking a beta blocker at the time of the investigational exam are excludedXx_NEWLINE_xXParticipants who are taking metformin at the time of the exam are excludedXx_NEWLINE_xXParticipants with severe claustrophobia not relieved by oral anxiolytic medication or patients weighing > 136 kg (weight limit for scanner table)Xx_NEWLINE_xXThe study population may include illiterate persons and University Hospital (UH)/Case employees if they meet other inclusion criteria; the consent process for these potential participants will be conducted according to Institutional Review Board (IRB) guidelinesXx_NEWLINE_xXGROUPS 1, 2, AND 3: \All participants” described aboveXx_NEWLINE_xXParticipants with concurrent clinical diagnosis, evidence of suspected hemochromatosis, or other diseases of iron metabolism (i.e., iron overload)Xx_NEWLINE_xXParticipants with any contraindications to gadolinium-based contrast agentsXx_NEWLINE_xXParticipants must have clinical characteristics consistent with IBC, characterized by a rapid onset of clinical findings exemplified as diffuse edema and erythema of the breast, often without a palpable massXx_NEWLINE_xXParticipants must be eligible for preoperative chemotherapy for IBC as determined by the treating physicianXx_NEWLINE_xXParticipants unwilling to complete the protocol (24 month duration)Xx_NEWLINE_xXAll participants under the care of St. Jude physicians with known or suspected neoplastic disease are eligible for participationXx_NEWLINE_xXINCLUSION CRITERIA FOR OPEN-ACCESS: All participants under the care of St. Jude physicians with known or suspected neoplastic disease are eligible for participationXx_NEWLINE_xXParticipants who do not have residual calcifications present on mammogram following biopsyXx_NEWLINE_xXGroup III: Participants with well-controlled vascular risk factors, such as treated hypertension, treated hyperlipidemia or well-controlled type II diabetes (glucose levels < 250) may be includedXx_NEWLINE_xXOVARIAN CANCER PARTICIPANTS: Patient is able to remain still for duration of each imaging procedureXx_NEWLINE_xXOVARIAN CANCER PARTICIPANTS: Patients participating in other research imaging protocols will be excluded from this studyXx_NEWLINE_xXWomen matched to age with our 16 post-cancer treatment participantsXx_NEWLINE_xXPreviously untreated participants must have a measureable lesion on an imaging studyXx_NEWLINE_xXAfter entry into the study, participants agree to be followed for up to 6 weeks after the final infusion of ferumoxytolXx_NEWLINE_xXBaseline MRI studies for participants receiving ferumoxytol must be performed within 16 weeks of study entryXx_NEWLINE_xXParticipants with known allergic or hypersensitivity reactions to parenteral iron, parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide preparations, are not eligible; participants with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator’s discretionXx_NEWLINE_xXParticipants with known hepatic insufficiency or cirrhosisXx_NEWLINE_xXParticipants that have a known or suspected iron overload (genetic hemochromatosis or history of multiple transfusions)Xx_NEWLINE_xXParticipants who have received trastuzumab within the prior 36 daysXx_NEWLINE_xXParticipants who are not considered candidates for ado-trastuzumab-emtansineXx_NEWLINE_xXParticipants with any extent of resection are eligibleXx_NEWLINE_xXParticipants enrolled in other therapeutic protocols are eligible, except protocols involving a VEGF-receptor (R) inhibitor or radiation therapy outside the standard of careXx_NEWLINE_xXParticipants with multifocal or recurrent glioblastomaXx_NEWLINE_xXParticipants with glioblastoma involving the brainstem or posterior fossa, cerebrospinal fluid disseminationXx_NEWLINE_xXParticipants with prior exposure to a pyrrolobenzodiazepine or indolinobenzodiazepine based drug.Xx_NEWLINE_xXParticipants with a clinical diagnosis of neurofibromatosis type 2 (NF2) (either by National Institutes of Health [NIH] or Manchester criteria) or with a molecular diagnosis of NF2Xx_NEWLINE_xXParticipants who received biopsy only or have received more than 2 prior courses of radiation for meningiomaXx_NEWLINE_xXParticipants with severe claustrophobia unresponsive to oral anxiolyticsXx_NEWLINE_xXPatients will be identified as possible participants in the Radiology Imaging suites and Breast Surgery ClinicsXx_NEWLINE_xXParticipants will be excluded if they have a recurrence that requires anti-cancer treatmentXx_NEWLINE_xXParticipants who have had chemotherapy, radiofrequency ablation, microwave ablation, chemo-embolization, or radiotherapy within 4 weeks prior to entering the studyXx_NEWLINE_xXParticipants with AML must either refuse or not be considered candidates for intensive induction chemotherapy. Previously treated participants should have evidence of persistent or recurrent AML in the peripheral blood and/or bone marrow. Participants must have white blood cell (WBC) < 15 x 10^9cells/L.Xx_NEWLINE_xXFor IPSS intermediate-1 or low-risk MDS, participants must be transfusion dependent for red blood cells or platelets (as determined by instructional practices or local standard of care). Participants who are red blood cell transfusion dependent must also have failed erythropoiesis stimulating agents (primary resistance or relapse after a response) or have serum erythropoietin (EPO) levels > 500 U/L.Xx_NEWLINE_xXFor CMML, participants must have been treated with at least one prior therapy (hydroxyurea or an hypomethylating agent [HMA]).Xx_NEWLINE_xXParticipants with HCC must have received prior sorafenib therapy. ICC participants must have received prior platinum (cisplatin or oxaliplatin) based therapy unless contraindicated.Xx_NEWLINE_xXNon-nodal lesion that measures ?1.0 cm in the longest diameter ii.Participants with ICC:Xx_NEWLINE_xXParticipants with genetic diseases of the liver that may complicate review of safety dataXx_NEWLINE_xXParticipants taking any drug that is a strong inhibitor or inducer of the CYP3A4 enzyme within at least 2 weeks before the start of study drug and during the conduct of the study unless there is an emergent or life-threatening medical condition that requires itXx_NEWLINE_xXParticipants taking any drug known to prolong QTc interval within at least 2 weeks before the start of the study drug and during the conduct of the studyXx_NEWLINE_xXPrevious treatment with a selective FGF19-FGFR4 targeted therapy and/or selective pan-FGFR inhibitor 14. Use of any vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of study therapy 15. Presence of gastric or esophageal varices requiring active treatment 16. A clinically significant ECG abnormality, including a marked baseline prolonged QTc interval (eg, a repeated demonstration of a QTc interval >500 ms) 17. Significant cardiovascular impairment or any other major illness, medical condition 19. Males who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria 20. Hypersensitivity to the study drug or to any of the excipients 21. Intolerance or hypersensitivity to both CT and MRI contrast material that would preclude the ability to acquire the triphasic liver imaging required by the protocol 22. Participants with inorganic phosphorus > upper limit of normal for the institution 23. Participants with total or ionized serum calcium > upper limit of normal for the institution 24. Participants with endocrine changes that may result in increases in calcium or phosphate, including but not limited to hyperparathyroidism and tumoral calcinosis 25. Participants with past medical history and/or current evidence of tumoral calcinosis or tissue calcification 26. Participants who take calcium, vitamin D or systemic corticosteroidsXx_NEWLINE_xXParticipants not capable of keeping moderately still for the imaging portion of the study session (~1 hour for imaging)Xx_NEWLINE_xXParticipants must have a mammographic breast composition category (density) of c or dXx_NEWLINE_xXParticipants must be willing to discontinue any use of nonsteroidal antiinflammatory drugs (NSAIDs) like aspirin or ibuprofen until the tumor is removedXx_NEWLINE_xXParticipants with type 2 diabetes, documented stomach ulcers and pulmonary embolismXx_NEWLINE_xXParticipants who are currently pregnantXx_NEWLINE_xXParticipants whose girth exceeds the bore of the MRI scannerXx_NEWLINE_xXParticipants requiring conscious sedation for magnetic resonance (MR) imagingXx_NEWLINE_xXIf is neither a citizen of the United State nor a Permanent Resident Alien (Green Card holder) (to facilitate compensation of participants)Xx_NEWLINE_xXParticipants who are already on treatment with metformin, except when metformin can be held for 4 weeks prior to the start of the studyXx_NEWLINE_xXMale participants are required to use a condom during the entire study period with RO6958688 and up to 90 days after last administration of RO6958688. Male participants should not donate sperm for 90 days after the last dose of RO6958688.Xx_NEWLINE_xXParticipants with non-colorectal, non-gastric, or non-pancreatic cancer should have confirmed CEA expression in tumor tissue. CEA expression should be centrally confirmed. For colorectal cancer (CRC) participants, CEA assessment should be performed but the result is not required for participant selection.Xx_NEWLINE_xXParticipants with paraspinal, paratracheal, and mediastinal pathological lesions larger than 2 centimeters (cm) unless they are previously irradiatedXx_NEWLINE_xXAIM 2: Will consider participants from phase 1 of this study ineligible for this phase of the studyXx_NEWLINE_xXAIM 2: Will not re-screen participants who were considered ineligible for phase 1 of this study, as determined from study recordsXx_NEWLINE_xXFor clinical provider participants: Clinical provider at a Houston Area Location of MD Anderson assigned to the interventionXx_NEWLINE_xXAll participants will be recruited from patients receiving care at the HFHSXx_NEWLINE_xXParticipants not willing to complete interviews or survey instruments (usability test and RCT)Xx_NEWLINE_xXHalf of the participants will be overdue for CRC screening and the remaining half will be current on their screening, as defined by national published guidelinesXx_NEWLINE_xXTreatment with QT-prolonging drugs with a risk of causing torsades de pointes (TdP. Participants taking drugs with a possible or conditional risk of QT prolongation or drugs that are to be avoided by participants with congenital long QT syndrome may be considered if on a stable dose, pending discussion and agreement between the investigator and the sponsor.Xx_NEWLINE_xXAdmission or evidence of illicit drug use, drug abuse, or alcohol abuse. Entry Criteria for Continuation to Optional Part B: After completing Part A of the study, participants may choose to enter the optional Part B of the study. To be eligible for the optional Part B, participants must have completed Part A and be reassessed to determine if they meet the entry criteria for optional Part B. Only participants who meet the following criteria may enter into Part B:Xx_NEWLINE_xXFor Part B only, participants must have advanced or metastatic CRC expressing either low or high levels of GCC, for whom standard treatment is no longer effective or does not offer curative or life-prolonging benefit. A portion of participants should have tumors amenable for serial biopsy and a willingness to provide consent for pharmacodynamic assessment.Xx_NEWLINE_xXFor participants enrolled in the expansion cohorts in which tumor biopsies are obtained:Xx_NEWLINE_xXParticipants who are relapsed after or refractory to regimens containing venetoclax or other BCL2 inhibitors.Xx_NEWLINE_xXTo be enrolled in the TNBC expansion cohort, participants must have:Xx_NEWLINE_xXSafely accessible tumor lesions (based on investigator's assessment) for serial pre treatment and post treatment biopsies are required for participants receiving TAK-659 monotherapy run-in treatment for 2 weeks followed by TAK-659 plus nivolumab combination treatment [ approximately 10/30 response-evaluable participants]; adequate, newly obtained, core or excisional biopsy of a metastatic tumor lesion not previously irradiated is required. Mandatory biopsies will be taken before TAK-659 monotherapy, after the 2 weeks of TAK-659 monotherapy, and after 6 weeks of TAK-659 plus nivolumab combination therapy. An optional biopsy may be taken at PD with additional consent from the participants.Xx_NEWLINE_xXTo be enrolled in the NSCLC expansion cohort, participants must have:Xx_NEWLINE_xXSafely accessible tumor lesions (based on investigator's assessment) for serial pretreatment and posttreatment biopsies are required for participants receiving TAK-659 monotherapy run-in treatment for 2 weeks followed by TAK-659 plus nivolumab combination treatment (approximately10/30 response-evaluable participants); adequate, newly obtained, core or excisional biopsy of a metastatic tumor lesion not previously irradiated is required. Mandatory biopsies will be taken before TAK-659 monotherapy, after the 2 weeks of TAK-659 monotherapy, and after 6 weeks of TAK-659 plus nivolumab combination therapy. An optional biopsy may be taken at progression with additional consent from the participants.Xx_NEWLINE_xXTo be enrolled in the HNSCC expansion cohort, participants must have:Xx_NEWLINE_xXHistologically confirmed recurrent or metastatic carcinoma of the nasopharynx is allowed, but these participants will not be included as response-evaluable participants for efficacy analysis of HNSCC.Xx_NEWLINE_xXSafely accessible tumor lesions (based on investigator's assessment) for serial pretreatment and posttreatment biopsies are required for participants receiving TAK-659 monotherapy run-in treatment for 2 weeks followed by TAK-659 plus nivolumab combination treatment (approximately 10/30 response-evaluable participants); adequate, newly obtained, core or excisional biopsy of a metastatic tumor lesion not previously irradiated is required. Mandatory biopsies will be taken before TAK-659 monotherapy, after the 2 weeks of TAK-659 monotherapy, and TAK-659 after 6 weeks of TAK-659 plus nivolumab combination therapy. An optional biopsy may be taken at progression with additional consent from the participants.Xx_NEWLINE_xXParticipants with another malignancy within 2 years of study start. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection and are considered disease-free at the time of study entry.Xx_NEWLINE_xXFor dose expansion participants who will have tumor biopsies collected:Xx_NEWLINE_xXParticipants must possess at least two of the following clinical characteristics which enrich for EGFR mutations:\r\n* Smoked less than 10 pack years\r\n* Asian race\r\n* Adenocarcinoma (including adenosquamous carcinoma) on histology or cytologyXx_NEWLINE_xXParticipants must not have had chemotherapy within the past 10 daysXx_NEWLINE_xXParticipants must be Iodine-131 refractory/resistant as defined by at least one of the following:Xx_NEWLINE_xXFemale participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days (for participants receiving pembrolizumab) or 180 days (for participants receiving BV) after the last dose of study drug.Xx_NEWLINE_xX